

WEST Search History

[Hide Items](#) | [Restore](#) | [Clear](#) | [Cancel](#)

DATE: Friday, April 22, 2005

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L12	= 2001	519
<input type="checkbox"/>	L11	L10 AND L8	937
<input type="checkbox"/>	L10	coronary artery disease	9074
<input type="checkbox"/>	L9	L7 AND L8	158
<input type="checkbox"/>	L8	FGF-1 OR aFGF OR FGF-2 OR bFGF OR VEGF	14483
<input type="checkbox"/>	L7	L6 AND coronary artery disease	467
<input type="checkbox"/>	L6	514/2,8,12,14.CCLS.	15126
<input type="checkbox"/>	L5	Franco.IN.	6857
<input type="checkbox"/>	L4	Franco-W.IN.	4
<input type="checkbox"/>	L3	Franco-Wayne.IN.	0
<input type="checkbox"/>	L2	Franco-W-P.IN.	3
<input type="checkbox"/>	L1	(Franco-Wayne-P.IN.)	7

END OF SEARCH HISTORY



National
Library
of Medicine



My NC
[Sign In] [Regis]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for Save Search

Limits Preview/Index History Clipboard Details

Display Show Sort by

All: 38 Review: 7

Items 1 - 38 of 38

One page.

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS.](#) Related Articles, Links

Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support.
Circulation. 2004 Jun 22;109(24):2986-92. Epub 2004 Jun 7.
PMID: 15184289 [PubMed - indexed for MEDLINE]

2: [van Royen N, Voskuil M, Hoefer I, Jost M, de Graaf S, Hedwig F, Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST.](#) Related Articles, Links

CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization.
Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15.
PMID: 15023889 [PubMed - indexed for MEDLINE]

3: [Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R.](#) Related Articles, Links

Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
PMID: 14988094 [PubMed - indexed for MEDLINE]

4: [Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato L, Smith ML, Landolfo C, Lowe JE, Annex BH, Landolfo KP.](#) Related Articles, Links

Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study.
J Thorac Cardiovasc Surg. 2004 Jan;127(1):34-43.
PMID: 14752410 [PubMed - indexed for MEDLINE]

5: [Aviles RJ, Annex BH, Lederman RJ.](#) Related Articles, Links

Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).
Br J Pharmacol. 2003 Oct;140(4):637-46.
PMID: 14534147 [PubMed - indexed for MEDLINE]

6: [Ruel M, Sellke FW.](#) Related Articles, Links

Angiogenic protein therapy.
Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.
PMID: 12973700 [PubMed - indexed for MEDLINE]

7: [Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham RJ, Sellke FW.](#) Related Articles, Links

-  Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model.
Circulation. 2003 Sep 9;108 Suppl 1:II335-40.
PMID: 12970256 [PubMed - indexed for MEDLINE]
- 8: [Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.](#) Related Articles, Links
-  Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.
PMID: 12907464 [PubMed - indexed for MEDLINE]
- 9: [Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M.](#) Related Articles, Links
-  Toward surgical angiogenesis using slow-released basic fibroblast growth factor.
Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.
PMID: 12853053 [PubMed - indexed for MEDLINE]
- 10: [Sellke FW, Ruel M.](#) Related Articles, Links
-  Vascular growth factors and angiogenesis in cardiac surgery.
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]
- 11: [Zhang C, Yang J, Feng J, Jennings LK.](#) Related Articles, Links
-  Short-term administration of basic fibroblast growth factor enhances coronary collateral development without exacerbating atherosclerosis and balloon injury-induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction.
J Lab Clin Med. 2002 Aug;140(2):119-25.
PMID: 12228768 [PubMed - indexed for MEDLINE]
- 12: [Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P.](#) Related Articles, Links
-  Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina.
Int J Cardiol. 2002 Aug;84(2-3):195-9.
PMID: 12127372 [PubMed - indexed for MEDLINE]
- 13: [Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M.](#) Related Articles, Links
-  The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis.
Clin Cardiol. 2002 Jun;25(6):271-8.
PMID: 12058790 [PubMed - indexed for MEDLINE]
- 14: [Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P.](#) Related Articles, Links
-  Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?
Eur J Med Res. 2002 Mar 28;7(3):93-7.
PMID: 11953278 [PubMed - indexed for MEDLINE]
- 15: [Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA.](#) Related Articles, Links

-  Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.
Circulation. 2002 Feb 19;105(7):788-93.
PMID: 11854116 [PubMed - indexed for MEDLINE]
- 16: [Wilke NM, Zenovich AG, Jerosch-Herold M, Henry TD.](#) [Related Articles](#), [Links](#)
-  Cardiac Magnetic Resonance Imaging for the Assessment of Myocardial Angiogenesis.
Curr Interv Cardiol Rep. 2001 Aug;3(3):205-212.
PMID: 11485690 [PubMed - as supplied by publisher]
- 17: [Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA.](#) [Related Articles](#), [Links](#)
-  Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease.
J Clin Pharmacol. 2001 Apr;41(4):378-85.
PMID: 11304894 [PubMed - indexed for MEDLINE]
- 18: [Rosengart TK, Hillebrand K.](#) [Related Articles](#), [Links](#)
-  Gene therapy for coronary artery disease.
Adv Card Surg. 2001;13:107-20. Review. No abstract available.
PMID: 11209652 [PubMed - indexed for MEDLINE]
- 19: [Lambiase P, Edwards R, Bucknall CA, Marber MS.](#) [Related Articles](#), [Links](#)
-  Physiologically assessed collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Circulation. 2001 Jan 30;103(4):E22. No abstract available.
PMID: 11157734 [PubMed - indexed for MEDLINE]
- 20: [Schumacher B, Hannekum A, Pecher P.](#) [Related Articles](#), [Links](#)
-  [Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]
Z Kardiol. 2000;89 Suppl 7:23-30. German.
PMID: 11098556 [PubMed - indexed for MEDLINE]
- 21: [Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M.](#) [Related Articles](#), [Links](#)
-  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease.
Circulation. 2000 Oct 3;102(14):1605-10.
PMID: 11015335 [PubMed - indexed for MEDLINE]
- 22: [Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA.](#) [Related Articles](#), [Links](#)
-  Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.
Am J Cardiol. 2000 Jun 15;85(12):1414-9.
PMID: 10856385 [PubMed - indexed for MEDLINE]
- 23: [Lucassen AM, de Waal RM, Verheugt FW.](#) [Related Articles](#), [Links](#)
-  [Therapeutic angiogenesis as a new experimental treatment for vascular disease]
Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dutch.

PMID: 10774292 [PubMed - indexed for MEDLINE]

- 24: [Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA.](#) Related Articles, Links

 Expression and function of PPARgamma in rat and human vascular smooth muscle cells.
Circulation. 2000 Mar 21;101(11):1311-8.
PMID: 10725292 [PubMed - indexed for MEDLINE]

- 25: [Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C.](#) Related Articles, Links

 Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Circulation. 1999 Nov 9;100(19):1945-50.
PMID: 10556219 [PubMed - indexed for MEDLINE]

- 26: [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#) Related Articles, Links

 Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.
Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]

- 27: [Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S.](#) Related Articles, Links

 Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.
PMID: 10082659 [PubMed - indexed for MEDLINE]

- 28: [Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW.](#) Related Articles, Links

 Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation.
J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8.
PMID: 9832695 [PubMed - indexed for MEDLINE]

- 29: [Iwakura A, Komeda M, Fujita M.](#) Related Articles, Links

 [Coronary stenosis and mechanisms of collateral vessel growth]
Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.
PMID: 9796310 [PubMed - indexed for MEDLINE]

- 30: [Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.](#) Related Articles, Links

 Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.
Ann Thorac Surg. 1998 Jun;65(6):1540-4.
PMID: 9647055 [PubMed - indexed for MEDLINE]

- 31: [Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, Scheinowitz M.](#) Related Articles, Links

 Serum basic fibroblast growth factor levels in patients with ischemic heart disease.
Int J Cardiol. 1997 Apr 18;59(2):133-8.
PMID: 9158164 [PubMed - indexed for MEDLINE]

- 32: [Ito A, Shimokawa H, Fukumoto Y, Kadokami T, Nakaike R, Takayanagi T, Egashira K, Sueishi K, Takeshita A.](#) [Related Articles](#), [Links](#)
-  The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo. *Cardiovasc Res.* 1996 Sep;32(3):570-9.
PMID: 8881517 [PubMed - indexed for MEDLINE]
- 33: [Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R.](#) [Related Articles](#), [Links](#)
-  Proliferative activity in coronary atherectomy tissue. Clinical, histopathologic, and immunohistochemical correlates. *Chest.* 1995 Sep;108(3):815-20.
PMID: 7656639 [PubMed - indexed for MEDLINE]
- 34: [Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ.](#) [Related Articles](#), [Links](#)
-  Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? *Circulation.* 1994 Apr;89(4):1511-7.
PMID: 7908609 [PubMed - indexed for MEDLINE]
- 35: [Wilcox JN.](#) [Related Articles](#), [Links](#)
-  Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. *Am J Cardiol.* 1993 Oct 18;72(13):88E-95E. Review.
PMID: 8213576 [PubMed - indexed for MEDLINE]
- 36: [Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK.](#) [Related Articles](#), [Links](#)
-  A cascade model for restenosis. A special case of atherosclerosis progression. *Circulation.* 1992 Dec;86(6 Suppl):III47-52. Review.
PMID: 1424051 [PubMed - indexed for MEDLINE]
- 37: [Gordon D.](#) [Related Articles](#), [Links](#)
-  Growth factors and cell proliferation in human transplant arteriosclerosis. *J Heart Lung Transplant.* 1992 May-Jun;11(3 Pt 2):S7. No abstract available.
PMID: 1623005 [PubMed - indexed for MEDLINE]
- 38: [Heidemann P, Hofling B, Heimerl J, Emberger C, Meyer G, Kandolf R, Bauriedel G.](#) [Related Articles](#), [Links](#)
-  [Proliferative response of smooth muscle cells from human arteriosclerosis lesions to PDGF, bFGF and EGF] *Vasa Suppl.* 1992;35:137-9. German. No abstract available.
PMID: 1481019 [PubMed - indexed for MEDLINE]

Display [Summary](#) Show 500 Sort by Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine



My NC

[Sign In] [Regis]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search **PubMed**



for **coronary artery disease AND FGF-1**



Save Search

Limits Preview/Index History Clipboard Details

Display **Summary**



Show

500



Sort by



Send to



All: 7

Review: 1

Items 1 - 7 of 7

One page.

1: [Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.](#)

Related Articles, Links

Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.
PMID: 12907464 [PubMed - indexed for MEDLINE]

2: [Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.](#)

Related Articles, Links

Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.
PMID: 12692004 [PubMed - indexed for MEDLINE]

3: [Sellke FW, Ruel M.](#)

Related Articles, Links

Vascular growth factors and angiogenesis in cardiac surgery.

Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]

4: [Schumacher B, Hannekum A, Pecher P.](#)

Related Articles, Links

Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease

Z Kardiol. 2000;89 Suppl 7:23-30. German.
PMID: 11098556 [PubMed - indexed for MEDLINE]

5: [Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC.](#)

Related Articles, Links

Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.

Microvasc Res. 1999 Nov;58(3):238-49.
PMID: 10527767 [PubMed - indexed for MEDLINE]

6: [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#)

Related Articles, Links

Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]

7: [Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.](#)

Related Articles, Links

Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Surgery. 1996 Aug;120(2):182-8.

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

PMID: 8751581 [PubMed - indexed for MEDLINE]

Display Summary Show 500 Sort by Send to [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12



National
Library
of Medicine



My NC
[Sign In] [Regis]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search for

Limits Preview/Index History Clipboard Details

Display Summary Show Sort by Send to

All: 113 Review: 38

Items 1 - 113 of 113

One page.

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Matsunaga T, Chilian WM, March K.](#)

Related Articles, Links

[Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease.](#)

Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2042-6.
PMID: 15840902 [PubMed - in process]

2: [Urbich C, Dimmeler S.](#)

Related Articles, Links

[Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.](#)

Kidney Int. 2005 May;67(5):1672-6.
PMID: 15840010 [PubMed - in process]

3: [Urbich C, Knau A, Fichtlscherer S, Walter DH, Bruhl T, Potente M, Hofmann WK, de Vos S, Zeiher AM, Dimmeler S.](#)

Related Articles, Links

[FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells.](#)

FASEB J. 2005 Apr 11; [Epub ahead of print]
PMID: 15824087 [PubMed - as supplied by publisher]

4: [Gupta K, Zhang J.](#)

Related Articles, Links

[Angiogenesis: a curse or cure?](#)

Postgrad Med J. 2005 Apr;81(954):236-42.
PMID: 15811887 [PubMed - in process]

5: [Gounis MJ, Spiga MG, Graham RM, Wilson A, Haliko S, Lieber BB, Wakhloo AK, Webster KA.](#)

Related Articles, Links

[Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle.](#)

Gene Ther. 2005 May;12(9):762-71.
PMID: 15772688 [PubMed - in process]

6: [Panutsopoulos D, Papalambros E, Sigala F, Zafiroopoulos A, Arvanitis DL, Spandidos DA.](#)

Related Articles, Links

[Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions.](#)

Int J Mol Med. 2005 Apr;15(4):603-10.
PMID: 15754021 [PubMed - in process]

7: [Alber HF, Frick M, Dulak J, Dorler J, Zwick RH, Dichtl W, Pachinger O, Weidinger F.](#)

Related Articles, Links

[Vascular endothelial growth factor \(VEGF\) plasma concentrations in coronary artery disease.](#)

Heart. 2005 Mar;91(3):365-6. No abstract available.
PMID: 15710722 [PubMed - indexed for MEDLINE]

- 8: [Czekalski S.](#) [Related Articles](#), [Links](#)
 [What is new in the treatment of diabetes?--The importance of nephro- and cardioprotective management]
Pol Arch Med Wewn. 2004 Oct;112 Spec No:65-9. Polish.
PMID: 15669203 [PubMed - indexed for MEDLINE]
- 9: [Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM; CAPTURE Study Investigators](#) [Related Articles](#), [Links](#)
 Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis.
J Am Coll Cardiol. 2005 Jan 18;45(2):229-37.
PMID: 15653020 [PubMed - indexed for MEDLINE]
- 10: [Yoon YS, Johnson IA, Park JS, Diaz L, Losordo DW.](#) [Related Articles](#), [Links](#)
 Therapeutic myocardial angiogenesis with vascular endothelial growth factors.
Mol Cell Biochem. 2004 Sep;264(1-2):63-74. Review.
PMID: 15544036 [PubMed - indexed for MEDLINE]
- 11: [Maulik N.](#) [Related Articles](#), [Links](#)
 Angiogenic signal during cardiac repair.
Mol Cell Biochem. 2004 Sep;264(1-2):13-23. Review.
PMID: 15544031 [PubMed - indexed for MEDLINE]
- 12: [Pawlak J, Klim B, Szkudlarek M, Dzieciol J.](#) [Related Articles](#), [Links](#)
 [The formation of new blood vessels in coronary artery disease: where we are now]
Postepy Hig Med Dosw (Online). 2004 Oct 6;58:358-63. Polish.
PMID: 15536393 [PubMed - in process]
- 13: [Suzuki A, Miyagawa-Tomita S, Komatsu K, Nakazawa M, Fukaya T, Baba K, Yutani C.](#) [Related Articles](#), [Links](#)
 Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease.
Pediatr Int. 2004 Oct;46(5):590-6.
PMID: 15491390 [PubMed - indexed for MEDLINE]
- 14: [Crawford SE, Mavroudis C, Backer CL, Huang X, Mu Y, Volpert OV, Stellmach V, Pahl E, Huang L.](#) [Related Articles](#), [Links](#)
 Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels.
J Heart Lung Transplant. 2004 Jun;23(6):666-73.
PMID: 15366425 [PubMed - indexed for MEDLINE]
- 15: [Celec P, Yonemitsu Y.](#) [Related Articles](#), [Links](#)
 Vascular endothelial growth factor - basic science and its clinical implications.
Pathophysiology. 2004 Oct;11(2):69-75.
PMID: 15364116 [PubMed - as supplied by publisher]
- 16: [Tio RA, Tan ES, Jessurun GA, Veeger N, Jager PL, Slart RH, de Jong RM, Pruijm J, Hospers GA, Willemse AT, de Jongste MJ,](#) [Related Articles](#), [Links](#)

- van Boven AJ, van Veldhuisen DJ, Zijlstra F.
- PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.
J Nucl Med. 2004 Sep;45(9):1437-43.
PMID: 15347709 [PubMed - indexed for MEDLINE]
- 17: Kolsut P, Malecki M, Firek B, Teresinska A, Janik P, Religa Z. Related Articles, Links
- [Gene therapy with phVEGF165 plasmid--preliminary report]
Kardiol Pol. 2004 Feb;60 Suppl 1:I-82-9. Polish. No abstract available.
PMID: 15247953 [PubMed - indexed for MEDLINE]
- 18: Depre C, Kim SJ, John AS, Huang Y, Rimoldi OE, Pepper JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG, Vatner SF. Related Articles, Links
- Program of cell survival underlying human and experimental hibernating myocardium.
Circ Res. 2004 Aug 20;95(4):433-40. Epub 2004 Jul 8.
PMID: 15242971 [PubMed - indexed for MEDLINE]
- 19: Nakajima K, Tabata S, Yamashita T, Kusuvara M, Arakawa K, Ohmori R, Yonemura A, Higashi K, Ayaori M, Nakamura H, Ohsuzu F. Related Articles, Links
- Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease.
Clin Cardiol. 2004 May;27(5):281-6.
PMID: 15188944 [PubMed - indexed for MEDLINE]
- 20: Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Related Articles, Links
- Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support.
Circulation. 2004 Jun 22;109(24):2986-92. Epub 2004 Jun 7.
PMID: 15184289 [PubMed - indexed for MEDLINE]
- 21: Lemstrom KB, Nykanen AI, Tikkanen JM, Krebs R, Sihvola RK, Kallio EA, Olivier R, Koskinen PK. Related Articles, Links
- Role of angiogenic growth factors in transplant coronary artery disease.
Ann Med. 2004;36(3):184-93. Review.
PMID: 15181974 [PubMed - indexed for MEDLINE]
- 22: Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL. Related Articles, Links
- Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease.
J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7.
PMID: 15093871 [PubMed - indexed for MEDLINE]
- 23: Gouni-Berthold I, Sachinidis A. Related Articles, Links
- Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases.
Curr Pharm Des. 2004;10(11):1261-71. Review.
PMID: 15078140 [PubMed - indexed for MEDLINE]
- 24: Perrin LA, June JE, Rosebury W, Robertson A, Kovacs I, Bruder JT, Kessler PD, Keiser JA, Gordon D. Related Articles, Links

-  Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).
Gene Ther. 2004 Mar;11(6):512-21.
PMID: 14999223 [PubMed - indexed for MEDLINE]
- 25: [Syed IS, Sanborn TA, Rosengart TK.](#) Related Articles, Links
-  Therapeutic angiogenesis: a biologic bypass.
Cardiology. 2004;101(1-3):131-43. Review.
PMID: 14988635 [PubMed - indexed for MEDLINE]
- 26: [Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R.](#) Related Articles, Links
-  Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
PMID: 14988094 [PubMed - indexed for MEDLINE]
- 27: [Chong AY, Caine GJ, Lip GY.](#) Related Articles, Links
-  Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?
Eur J Clin Invest. 2004 Jan;34(1):9-13.
PMID: 14984432 [PubMed - indexed for MEDLINE]
- 28: [Schalch P, Rahman GF, Patejunas G, Goldschmidt RA, Carbray J, Retuerto MA, Kim D, Esser K, Crystal RG, Rosengart TK.](#) Related Articles, Links
-  Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.
J Thorac Cardiovasc Surg. 2004 Feb;127(2):535-40.
PMID: 14762365 [PubMed - indexed for MEDLINE]
- 29: [Symes JF.](#) Related Articles, Links
-  Gene therapy for ischemic heart disease: therapeutic potential.
Am J Cardiovasc Drugs. 2001;1(3):159-66. Review.
PMID: 14728030 [PubMed - indexed for MEDLINE]
- 30: [Calvi C, Dentelli P, Pagano M, Rosso A, Pegoraro M, Giunti S, Garbarino G, Camussi G, Pegoraro L, Brizzi MF.](#) Related Articles, Links
-  Angiopoietin 2 induces cell cycle arrest in endothelial cells: a possible mechanism involved in advanced plaque neovascularization.
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):511-8. Epub 2004 Jan 15.
PMID: 14726409 [PubMed - indexed for MEDLINE]
- 31: [Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G.](#) Related Articles, Links
-  Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis.
Circulation. 2004 Jan 20;109(2):220-6. Epub 2003 Dec 22.
PMID: 14691039 [PubMed - indexed for MEDLINE]
- 32: [Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A.](#) Related Articles, Links
-  Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting.
J Am Coll Cardiol. 2003 Dec 17;42(12):2073-80.
PMID: 14680729 [PubMed - indexed for MEDLINE]

- 33: [Kolsut P, Malecki M, Zelazny P, Teresinska A, Firek B, Janik P, Religa Z.](#) Related Articles, Links
 Gene therapy of coronary artery disease with phvegf165--early outcome.
Kardiol Pol. 2003 Nov;59(11):373-84. English, Polish.
PMID: 14668888 [PubMed - indexed for MEDLINE]
- 34: [Baklanov D, Simons M.](#) Related Articles, Links
 Arteriogenesis: lessons learned from clinical trials.
Endothelium. 2003;10(4-5):217-23. Review.
PMID: 14660081 [PubMed - indexed for MEDLINE]
- 35: [Roguin A, Resar JR.](#) Related Articles, Links
 Genetics and susceptibility of coronary collateral formation.
Circulation. 2003 Nov 25;108(21):e149; author reply e149. No abstract available.
PMID: 14638531 [PubMed - indexed for MEDLINE]
- 36: [Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY.](#) Related Articles, Links
 Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease.
Heart. 2003 Dec;89(12):1411-5.
PMID: 14617549 [PubMed - indexed for MEDLINE]
- 37: [Panoutsopoulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA.](#) Related Articles, Links
 Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression.
J Transl Med. 2003 Oct 6;1(1):6.
PMID: 14585103 [PubMed - as supplied by publisher]
- 38: [Juan-Babot JO, Martinez-Gonzalez J, Berrozpe M, Badimon L.](#) Related Articles, Links
 [Neovascularization in human coronary arteries with lesions of different severity]
Rev Esp Cardiol. 2003 Oct;56(10):978-86. Spanish.
PMID: 14563292 [PubMed - indexed for MEDLINE]
- 39: [Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y, Imayoshi M, Ishii E, Tasaki H, Hamasaki Y.](#) Related Articles, Links
 A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease.
J Pediatr. 2003 Sep;143(3):357-62.
PMID: 14517520 [PubMed - indexed for MEDLINE]
- 40: [Fujita M, Ikemoto M, Tanaka T, Tamaki S, Yamazato A, Sawamura T, Hasegawa K, Kihara Y, Nohara R, Sasayama S.](#) Related Articles, Links
 Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
Angiogenesis. 1998;2(1):105-8.
PMID: 14517380 [PubMed]
- 41: [Crottogini A, Meckert PC, Vera Janavel G, Lascano E, Negroni J, Del Valle H, Dulbecco E, Werba P, Cuniberti L, Martinez V, De Lorenzi A, Telayna J, Mele A, Fernandez JL, Marangunich L, Criscuolo M, Capogrossi MC, Laguens R.](#) Related Articles, Links

- 41: [Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs.](#) [Hum Gene Ther.](#) 2003 Sep 20;14(14):1307-18.
PMID: 14503966 [PubMed - indexed for MEDLINE]
- 42: [Ruel M, Sellke FW.](#) [Related Articles, Links](#)
- 43: [Angiogenic protein therapy.](#) [Semin Thorac Cardiovasc Surg.](#) 2003 Jul;15(3):222-35. Review.
PMID: 12973700 [PubMed - indexed for MEDLINE]
- 44: [Hedman M, Yla-Herttula S.](#) [Related Articles, Links](#)
- 45: [Gene therapy for the treatment of peripheral vascular disease and coronary artery disease.](#) [Drugs Today \(Barc\).](#) 2000 Sep;36(9):609-17.
PMID: 12847566 [PubMed]
- 46: [Chung NA, Makin AJ, Lip GY.](#) [Related Articles, Links](#)
- 47: [Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.](#) [Eur J Clin Invest.](#) 2003 Jul;33(7):529-35.
PMID: 12814387 [PubMed - indexed for MEDLINE]
- 48: [Kastrup J.](#) [Related Articles, Links](#)
- 49: [Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?](#) [Curr Gene Ther.](#) 2003 Jun;3(3):197-206. Review.
PMID: 12762479 [PubMed - indexed for MEDLINE]
- 50: [Rasmussen HS, Rasmussen CS, Macko J.](#) [Related Articles, Links](#)
- 51: [VEGF gene therapy for coronary artery disease and peripheral vascular disease.](#) [Cardiovasc Radiat Med.](#) 2002 Apr-Jun;3(2):114-7. Review.
PMID: 12699842 [PubMed - indexed for MEDLINE]
- 52: [Kusumanto YH, Hospers GA, Mulder NH, Tio RA.](#) [Related Articles, Links](#)
- 53: [Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review.](#) [Int J Cardiovasc Intervent.](#) 2003;5(1):27-34. Review.
PMID: 12623562 [PubMed - indexed for MEDLINE]
- 54: [Sellke FW, Ruel M.](#) [Related Articles, Links](#)
- 55: [Vascular growth factors and angiogenesis in cardiac surgery.](#) [Ann Thorac Surg.](#) 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]
- 56: [Khan TA, Sellke FW, Laham RJ.](#) [Related Articles, Links](#)
- 57: [Therapeutic angiogenesis: protein-based therapy for coronary artery disease.](#) [Expert Opin Pharmacother.](#) 2003 Feb;4(2):219-26. Review.
PMID: 12562312 [PubMed - indexed for MEDLINE]
- 58: [Sim EK, Zhang L, Shim WS, Lim YL, Ge R.](#) [Related Articles, Links](#)
- 59: [Therapeutic angiogenesis for coronary artery disease.](#) [J Card Surg.](#) 2002 Jul-Aug;17(4):350-4. Review.

PMID: 12546086 [PubMed - indexed for MEDLINE]

- 51: [Kutryk MJ, Stewart DJ.](#) [Related Articles](#), [Links](#)
 Angiogenesis of the heart.
Microsc Res Tech. 2003 Feb 1;60(2):138-58. Review.
PMID: 12539168 [PubMed - indexed for MEDLINE]
- 52: [Lenihan DJ, Osman A, Sriram V, Aitsebaomo J, Patterson C.](#) [Related Articles](#), [Links](#)
 Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease.
Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1507-12. Epub 2003 Jan 9.
PMID: 12521946 [PubMed - indexed for MEDLINE]
- 53: [Lee CH, Smits PC.](#) [Related Articles](#), [Links](#)
 Vascular growth factors for coronary angiogenesis.
J Interv Cardiol. 2002 Dec;15(6):511-8. Review.
PMID: 12476656 [PubMed - indexed for MEDLINE]
- 54: [Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G.](#) [Related Articles](#), [Links](#)
 Angiogenic gene therapy strategies for the treatment of cardiovascular disease.
Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review.
PMID: 12435049 [PubMed - indexed for MEDLINE]
- 55: [Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG.](#) [Related Articles](#), [Links](#)
 Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Mol Ther. 2002 Aug;6(2):287-97.
PMID: 12349828 [PubMed - indexed for MEDLINE]
- 56: [Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM.](#) [Related Articles](#), [Links](#)
 Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA.
Hum Gene Ther. 2002 Sep 1;13(13):1595-603.
PMID: 12228014 [PubMed - indexed for MEDLINE]
- 57: [Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY.](#) [Related Articles](#), [Links](#)
 Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?
Stroke. 2002 Sep;33(9):2187-91.
PMID: 12215585 [PubMed - indexed for MEDLINE]
- 58: [Eppeler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF.](#) [Related Articles](#), [Links](#)
 A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
Clin Pharmacol Ther. 2002 Jul;72(1):20-32.
PMID: 12152001 [PubMed - indexed for MEDLINE]
- 59: [Alber HF, Dulak J, Frick M, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F.](#) [Related Articles](#), [Links](#)

-  Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease.
J Am Coll Cardiol. 2002 Jun 19;39(12):1951-5.
PMID: 12084593 [PubMed - indexed for MEDLINE]
- 60: [Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF, Erusalimsky JD.](#) [Related Articles](#), [Links](#)
-  Acute rise of circulating vascular endothelial growth factor-A in patients with coronary artery disease following cardiothoracic surgery.
Eur Heart J. 2002 Jun;23(12):953-9.
PMID: 12069450 [PubMed - indexed for MEDLINE]
- 61: [Vale PR, Isner JM, Rosenfield K.](#) [Related Articles](#), [Links](#)
-  Therapeutic angiogenesis in critical limb and myocardial ischemia.
J Interv Cardiol. 2001 Oct;14(5):511-28. Review.
PMID: 12053643 [PubMed - indexed for MEDLINE]
- 62: [Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE.](#) [Related Articles](#), [Links](#)
-  Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo.
Blood. 2002 Jun 15;99(12):4434-42.
PMID: 12036873 [PubMed - indexed for MEDLINE]
- 63: [Herrmann J, Best PJ, Ritman EL, Holmes DR, Lerman LO, Lerman A.](#) [Related Articles](#), [Links](#)
-  Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia.
J Am Coll Cardiol. 2002 May 1;39(9):1555-61.
PMID: 11985922 [PubMed - indexed for MEDLINE]
- 64: [Rosen LS.](#) [Related Articles](#), [Links](#)
-  Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44. Review.
PMID: 11965229 [PubMed - indexed for MEDLINE]
- 65: [Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM, Barsness K, Harken AH.](#) [Related Articles](#), [Links](#)
-  Clinical applications of cardiovascular angiogenesis.
J Card Surg. 2001 Nov-Dec;16(6):490-7. Review.
PMID: 11925031 [PubMed - indexed for MEDLINE]
- 66: [Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C.](#) [Related Articles](#), [Links](#)
-  Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.
J Intern Med. 2001 Nov;250(5):373-81.
PMID: 11887971 [PubMed - indexed for MEDLINE]
- 67: [Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY.](#) [Related Articles](#), [Links](#)
-  Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of

patients with coronary or peripheral atherosclerosis, or Type II diabetes.
Clin Sci (Lond). 2002 Feb;102(2):187-94.
PMID: 11834138 [PubMed - indexed for MEDLINE]

- 68: [Sarkar N, Blomberg P, Wardell E, Eskandarpour M, Sylven C, Drvota V, Islam KB.](#) Related Articles, Links
[J Cardiovasc Pharmacol. 2002 Feb;39\(2\):215-24.](#)
PMID: 11791007 [PubMed - indexed for MEDLINE]

-  Nonsurgical direct delivery of plasmid DNA into rat heart: time course, dose response, and the influence of different promoters on gene expression.
[J Cardiovasc Pharmacol. 2002 Feb;39\(2\):215-24.](#)
PMID: 11791007 [PubMed - indexed for MEDLINE]

- 69: [Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C.](#) Related Articles, Links
[Hum Gene Ther. 2002 Jan 1;13\(1\):65-100.](#)
PMID: 11779413 [PubMed - indexed for MEDLINE]

-  Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.
[Hum Gene Ther. 2002 Jan 1;13\(1\):65-100.](#)
PMID: 11779413 [PubMed - indexed for MEDLINE]

- 70: [Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.](#) Related Articles, Links
[Hum Gene Ther. 2002 Jan 1;13\(1\):15-63.](#)
PMID: 11779412 [PubMed - indexed for MEDLINE]

-  Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
[Hum Gene Ther. 2002 Jan 1;13\(1\):15-63.](#)
PMID: 11779412 [PubMed - indexed for MEDLINE]

- 71: [Freedman SB, Isner JM.](#) Related Articles, Links
 Therapeutic angiogenesis for coronary artery disease.
[Ann Intern Med. 2002 Jan 1;136\(1\):54-71. Review.](#)
PMID: 11777364 [PubMed - indexed for MEDLINE]

- 72: [Dulak J, Jozkowicz A, Frick M, Alber HF, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F.](#) Related Articles, Links
[J Am Coll Cardiol. 2001 Dec;38\(7\):2137-8. No abstract available.](#)
PMID: 11738334 [PubMed - indexed for MEDLINE]

- 73: [Huwer H, Welter C, Ozbek C, Seifert M, Straub U, Greilach P, Kalweit G, Isringhaus H.](#) Related Articles, Links
 Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease.
[Eur J Cardiothorac Surg. 2001 Dec;20\(6\):1128-34.](#)
PMID: 11717016 [PubMed - indexed for MEDLINE]

- 74: [Davda J, Labhsetwar V.](#) Related Articles, Links
 An update on angiogenesis therapy.
[Crit Rev Eukaryot Gene Expr. 2001;11\(1-3\):1-21. Review.](#)
PMID: 11693956 [PubMed - indexed for MEDLINE]

- 75: [Henry TD, Rocha-Singh K, Isner JM, Kerejakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER.](#) Related Articles, Links
[Intracoronary administration of recombinant human vascular endothelial](#)

-  growth factor to patients with coronary artery disease.
Am Heart J. 2001 Nov;142(5):872-80.
PMID: 11685177 [PubMed - indexed for MEDLINE]
- [76: Choukroun G.](#) Related Articles, Links
-  [Prevention and treatment of type 1 diabetes]
Presse Med. 2001 Sep 1;30(24 Pt 2):21-3. French.
PMID: 11577580 [PubMed - indexed for MEDLINE]
- [77: Basara N.](#) Related Articles, Links
-  AdGVVEGF121.10 (GenVec).
Curr Opin Investig Drugs. 2001 Jun;2(6):792-5. Review.
PMID: 11572658 [PubMed - indexed for MEDLINE]
- [78: Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM.](#) Related Articles, Links
-  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
J Clin Invest. 2001 Aug;108(3):391-7.
PMID: 11489932 [PubMed - indexed for MEDLINE]
- [79: Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N.](#) Related Articles, Links
-  Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease.
Heart Vessels. 2000;15(3):105-11.
PMID: 11289497 [PubMed - indexed for MEDLINE]
- [80: Ray S, Panja M.](#) Related Articles, Links
-  Current understanding of pathogenesis of coronary artery disease and its future implications.
J Indian Med Assoc. 2000 Nov;98(11):710-1, 714, 718.
PMID: 11265801 [PubMed - indexed for MEDLINE]
- [81: Brizzi MF, Formato L, Bonamini R.](#) Related Articles, Links
-  The molecular mechanisms of angiogenesis: a new approach to cardiovascular diseases.
 Ital Heart J. 2001 Feb;2(2):81-92. Review.
PMID: 11256548 [PubMed - indexed for MEDLINE]
- [82: Morse MA.](#) Related Articles, Links
-  Technology evaluation: VEGF165 gene therapy, Valentis Inc.
Curr Opin Mol Ther. 2001 Feb;3(1):97-101. Review.
PMID: 11249737 [PubMed - indexed for MEDLINE]
- [83: Rosengart TK, Hillebrand K.](#) Related Articles, Links
-  Gene therapy for coronary artery disease.
Adv Card Surg. 2001;13:107-20. Review. No abstract available.
PMID: 11209652 [PubMed - indexed for MEDLINE]
- [84: Freedman SB, Isner JM.](#) Related Articles, Links
-  Therapeutic angiogenesis for ischemic cardiovascular disease.
J Mol Cell Cardiol. 2001 Mar;33(3):379-93. Review.
PMID: 11181008 [PubMed - indexed for MEDLINE]

- 85: [Durairaj A, Mehra A, Singh RP, Faxon DP.](#) [Related Articles](#), [Links](#)
 Therapeutic angiogenesis.
Cardiol Rev. 2000 Sep-Oct;8(5):279-87. Review.
PMID: 11174906 [PubMed - indexed for MEDLINE]
- 86: [Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla-Herttuala S.](#) [Related Articles](#), [Links](#)
 Clinical applications of vascular gene therapy.
Curr Cardiol Rep. 2001 Jan;3(1):29-36. Review.
PMID: 11139796 [PubMed - indexed for MEDLINE]
- 87: [Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM.](#) [Related Articles](#), [Links](#)
 Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.
Anesth Analg. 2001 Jan;92(1):19-25.
PMID: 11133594 [PubMed - indexed for MEDLINE]
- 88: [Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM.](#) [Related Articles](#), [Links](#)
 Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.
Circulation. 2000 Aug 29;102(9):965-74.
PMID: 10961959 [PubMed - indexed for MEDLINE]
- 89: [Mukherjee D, Ellis SG.](#) [Related Articles](#), [Links](#)
 New options for untreatable coronary artery disease: angiogenesis and laser revascularization.
Cleve Clin J Med. 2000 Aug;67(8):577-83.
PMID: 10946453 [PubMed - indexed for MEDLINE]
- 90: [O'Brien T, Simari RD.](#) [Related Articles](#), [Links](#)
 Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution.
Mayo Clin Proc. 2000 Aug;75(8):831-4. Review.
PMID: 10943238 [PubMed - indexed for MEDLINE]
- 91: [Lucassen AM, de Waal RM, Verheugt FW.](#) [Related Articles](#), [Links](#)
 [Therapeutic angiogenesis as a new experimental treatment for vascular disease]
Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dutch.
PMID: 10774292 [PubMed - indexed for MEDLINE]
- 92: [Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF.](#) [Related Articles](#), [Links](#)
 Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.
Cardiovasc Res. 1999 Nov;44(2):294-302.
PMID: 10690306 [PubMed - indexed for MEDLINE]
- 93: [Chawla PS, Keelan MH, Kipshidze N.](#) [Related Articles](#), [Links](#)
 Angiogenesis for the treatment of vascular diseases.
Int Angiol. 1999 Sep;18(3):185-92. Review.
PMID: 10688416 [PubMed - indexed for MEDLINE]

- 94:** [Moussa I, Moses JW.](#) [Related Articles](#), [Links](#)
-  Angiogenesis for treatment of ischemic heart disease: should we worry about progression of atherosclerosis?
Circulation. 1999 Nov 30;100(22):e109. No abstract available.
PMID: 10578010 [PubMed - indexed for MEDLINE]
- 95:** [Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C.](#) [Related Articles](#), [Links](#)
-  Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Circulation. 1999 Nov 9;100(19):1945-50.
PMID: 10556219 [PubMed - indexed for MEDLINE]
- 96:** [Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG.](#) [Related Articles](#), [Links](#)
-  Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.
Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.
PMID: 10522716 [PubMed - indexed for MEDLINE]
- 97:** [Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM.](#) [Related Articles](#), [Links](#)
-  Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7.
PMID: 10509970 [PubMed - indexed for MEDLINE]
- 98:** [Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP.](#) [Related Articles](#), [Links](#)
-  Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation.
Circulation. 1999 Aug 3;100(5):547-52.
PMID: 10430770 [PubMed - indexed for MEDLINE]
- 99:** [Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG.](#) [Related Articles](#), [Links](#)
-  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
Circulation. 1999 Aug 3;100(5):468-74.
PMID: 10430759 [PubMed - indexed for MEDLINE]
- 100:** [Losordo DW, Vale PR, Isner JM.](#) [Related Articles](#), [Links](#)
-  Gene therapy for myocardial angiogenesis.
Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review.
PMID: 10426872 [PubMed - indexed for MEDLINE]
- 101:** [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#) [Related Articles](#), [Links](#)
-  Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]

102: Patterson C, Runge MS.

[Related Articles](#), [Links](#)



Therapeutic angiogenesis: the new electrophysiology?
Circulation. 1999 May 25;99(20):2614-6. Review. No abstract available.
PMID: 10338451 [PubMed - indexed for MEDLINE]

103: Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S.

[Related Articles](#), [Links](#)



Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.
PMID: 10082659 [PubMed - indexed for MEDLINE]

104: Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K.

[Related Articles](#), [Links](#)



Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries.
Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):131-9.
PMID: 9888875 [PubMed - indexed for MEDLINE]

105: Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM.

[Related Articles](#), [Links](#)



Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.
Circulation. 1998 Dec 22-29;98(25):2800-4.
PMID: 9860779 [PubMed - indexed for MEDLINE]

106: Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K.

[Related Articles](#), [Links](#)



Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.
Circulation. 1998 Nov 17;98(20):2108-16.
PMID: 9815864 [PubMed - indexed for MEDLINE]

107: Iwakura A, Komeda M, Fujita M.

[Related Articles](#), [Links](#)



[Coronary stenosis and mechanisms of collateral vessel growth]
Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.
PMID: 9796310 [PubMed - indexed for MEDLINE]

108: Komatsu R, Ueda M.

[Related Articles](#), [Links](#)



[Plaque progression and destabilization in human coronary arteries]
Nippon Rinsho. 1998 Oct;56(10):2477-82. Review. Japanese.
PMID: 9796305 [PubMed - indexed for MEDLINE]

109: Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, Carel K, Scott S, Nadler J, Sowers JR, Draznin B.

[Related Articles](#), [Links](#)



Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells.
Endocrinology. 1998 Oct;139(10):4067-72.
PMID: 9751484 [PubMed - indexed for MEDLINE]

- 110: [Metais C, Li J, Li J, Simons M, Sellke FW.](#) [Related Articles](#), [Links](#)
 Effects of coronary artery disease on expression and microvascular response to VEGF.
Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8.
PMID: 9746492 [PubMed - indexed for MEDLINE]
- 111: [Brilla CG, Rybinski L, Gehrke D, Rupp H.](#) [Related Articles](#), [Links](#)
 [Transmyocardial laser revascularization--an innovative pathophysiologic concept]
Herz. 1997 Aug;22(4):183-9. Review. German.
PMID: 9378452 [PubMed - indexed for MEDLINE]
- 112: [Labarrere CA, Faulk WP.](#) [Related Articles](#), [Links](#)
 Antithrombin determinants of coronary artery disease in transplanted human hearts.
Semin Hematol. 1995 Oct;32(4 Suppl 2):61-6. Review. No abstract available.
PMID: 8821212 [PubMed - indexed for MEDLINE]
- 113: [Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA.](#) [Related Articles](#), [Links](#)
 Regulation of vascular endothelial growth factor in cardiac myocytes.
Circ Res. 1995 May;76(5):758-66.
PMID: 7728992 [PubMed - indexed for MEDLINE]

Display [Summary](#)  Show [500](#)  Sort by  Send to 

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12



National
Library
of Medicine



My NC
[Sign In] [Regis]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search **PubMed**for **coronary artery disease AND aFGF**

Save Search

Limits ▾ Preview/Index ▾ History ▾ Clipboard ▾ Details ▾

Display **Summary**

Show

500



Sort by



Send to



About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

All: 8 Review: 1

Items 1 - 8 of 8

One page.

- 1: [Pawlak J, Klim B, Szkudlarek M, Dzieciol J.](#) Related Articles, Links
 [The formation of new blood vessels in coronary artery disease: where we are now]
Postepy Hig Med Dosw (Online). 2004 Oct 6;58:358-63. Polish.
 PMID: 15536393 [PubMed - in process]
- 2: [Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.](#) Related Articles, Links
 Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.
 PMID: 12907464 [PubMed - indexed for MEDLINE]
- 3: [Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.](#) Related Articles, Links
 Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.
 PMID: 12692004 [PubMed - indexed for MEDLINE]
- 4: [Sellke FW, Ruel M.](#) Related Articles, Links
 Vascular growth factors and angiogenesis in cardiac surgery.
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
 PMID: 12607713 [PubMed - indexed for MEDLINE]
- 5: [Schumacher B, Hannekum A, Pecher P.](#) Related Articles, Links
 Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]
Z Kardiol. 2000;89 Suppl 7:23-30. German.
 PMID: 11098556 [PubMed - indexed for MEDLINE]
- 6: [Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC.](#) Related Articles, Links
 Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.
Microvasc Res. 1999 Nov;58(3):238-49.
 PMID: 10527767 [PubMed - indexed for MEDLINE]
- 7: [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#) Related Articles, Links
 Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.
Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

8: [Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.](#) Related Articles, Links

 Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

u [Surgery. 1996 Aug;120\(2\):182-8.](#)

PMID: 8751581 [PubMed - indexed for MEDLINE]

Display [Summary](#)



Show

500



Sort by



Send to



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12



National
Library
of Medicine



My NC
[Sign In] [Regis]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search **PubMed**for **coronary artery disease AND acidic FGF**

Save Sea

Limits ▾ Preview/Index ▾ History ▾ Clipboard ▾ Details ▾

Display **Summary**Show **500**

Sort by



Send to



All: 2 Review: 0

Items 1 - 2 of 2

One page.

1: [Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.](#) Related Articles, Links

Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.
PMID: 12692004 [PubMed - indexed for MEDLINE]

2: [Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.](#) Related Articles, Links

Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Surgery. 1996 Aug;120(2):182-8.
PMID: 8751581 [PubMed - indexed for MEDLINE]

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12



National
Library
of Medicine



My NC
[Sign In] [Regis]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search **PubMed**for **coronary artery disease AND basic FGF**

Save Search

Limits ▾ Preview/Index ▾ History ▾ Clipboard ▾ Details ▾

Display **Summary**Show **500**

All: 4 Review: 0

Items 1 - 4 of 4

One page.

1: [Aviles RJ, Annex BH, Lederman RJ.](#) Related Articles, Links

[Testing clinical therapeutic angiogenesis using basic fibroblast growth factor \(FGF-2\).](#)

Br J Pharmacol. 2003 Oct;140(4):637-46.

PMID: 14534147 [PubMed - indexed for MEDLINE]

2: [Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M.](#) Related Articles, Links

[Toward surgical angiogenesis using slow-released basic fibroblast growth factor.](#)

Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.

PMID: 12853053 [PubMed - indexed for MEDLINE]

3: [Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P.](#) Related Articles, Links

[Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?](#)

Eur J Med Res. 2002 Mar 28;7(3):93-7.

PMID: 11953278 [PubMed - indexed for MEDLINE]

4: [Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ.](#) Related Articles, Links

[Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?](#)

Circulation. 1994 Apr;89(4):1511-7.

PMID: 7908609 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Welcome to STN International! Enter x:x

* * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:09:39 ON 22 APR 2005

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'ANABSTR' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:09:47 ON 22 APR 2005

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'CONFSCI' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DRUGB' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'KOSMET' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'NIOSHTIC' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:09:47 ON 22 APR 2005

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 15:09:47 ON 22 APR 2005

Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:09:47 ON 22 APR 2005

Any reproduction or dissemination in part or in full, ...

by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 WIPO

FILE 'PHAR' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'VETB' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 15:09:47 ON 22 APR 2005

COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s coronary artery disease OR acute coronary artery disease OR chronic coronary

11 FILES SEARCHED...

12 FILES SEARCHED...

22 FILES SEARCHED...

25 FILES SEARCHED...

32 FILES SEARCHED...

45 FILES SEARCHED...

53 FILES SEARCHED...

65 FILES SEARCHED...

L1 323642 CORONARY ARTERY DISEASE OR ACUTE CORONARY ARTERY DISEASE OR
CHRONIC CORONARY ARTERY DISEASE

=> S FGF-1 OR FGF-2 OR aFGF OR bFGF OR VEGF

14 FILES SEARCHED...

29 FILES SEARCHED...

40 FILES SEARCHED...

53 FILES SEARCHED...

67 FILES SEARCHED...

65 FILES SEARCHED...

71 FILES SEARCHED...

L5 549 L4 AND PY<=2000

=> D L5 1-549

L5 ANSWER 1 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on
STN

AN 2000:14563 ADISCTI

DN 800836302

TI Effects of a single intracoronary injection of basic fibroblast growth
factor in stable angina pectoris.

ADIS TITLE: Fibroblast growth factor: therapeutic use.

Angina pectoris

Intracoronary administration in patients with ***coronary***
artery ***disease*** .

AU Unger E F; Goncalves L; Epstein S E; Chew E Y; Trapnell C B; et al.

CS National Heart, Lung, and Blood Institute, Rockville, Maryland, USA.

SO American Journal of Cardiology (Jun 15, 2000), Vol. 85, pp. 1414-1419

DT Study

RE Ischaemic Heart Disease

FS Summary

LA English

WC 663

L5 ANSWER 2 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on
STN

AN 2000:3823 ADISCTI

DN 800813542

TI Effect of intracoronary recombinant human vascular endothelial growth
factor on myocardial perfusion: evidence for a dose-dependent effect.

ADIS TITLE: Vascular endothelial growth factor: pharmacodynamics.

Effect on myocardial perfusion

In patients with ***coronary*** ***artery*** ***disease*** .

AU Hendel R C; Henry T D; Rocha Singh K; Isner J M; Kereiakes D J; et al.

CS Northwestern University Medical School, Chicago, Illinois, USA.

Coronary disorders

In patients refractory to conventional therapies.

AU Losordo D W; Vale P R; Isner J M.

CS St. Elizabeth's Medical Center, Boston, Massachusetts, USA.

SO American Heart Journal (Aug 1, 1999), Vol. 138, pp. 132-141

DT Study

RE Ischaemic Heart Disease

FS Summary

LA English

WC 450

L5 ANSWER 5 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on
STN

AN 1999:11635 ADISCTI

DN 800742050

TI The stimulation of neoangiogenesis in the ischemic human heart by the
growth factor FGF: first clinical results.

ADIS TITLE: Fibroblast growth factor: pharmacodynamics.

Stimulation of neoangiogenesis

In patients undergoing coronary artery bypass graft surgery.

AU Schumacher B; Stegmann Th; Pecher P.

CS University of Ulm, Ulm, Germany.

SO Journal of Cardiovascular Surgery (Dec 1, 1998), Vol. 39, pp. 783-789

DT Study

RE Ischaemic Heart Disease

FS Summary

LA English

WC 518

L5 ANSWER 6 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on
STN

AN 1999:2247 ADISCTI

DN 800734037

TI Gene therapy for myocardial angiogenesis: initial clinical results with
direct myocardial injection of phVEGF165 as sole therapy for myocardial
ischemia.

SOURCE: INPHARMA ***21 Sep 2000*** ISSN: 1173-8324
DOCUMENT TYPE: (MIX)
WORD COUNT: 344

L5 ANSWER 9 OF 549 ADISNEWS COPYRIGHT (C) 2005 Adis Data Information BV on
STN

ACCESSION NUMBER: 2000:197 ED: 8 Aug 2001 UP: 8 Aug 2001

DOCUMENT NUMBER: 11738324-800763516

TITLE: Symposia: News from the 49th Annual Scientific Session of
the American College of Cardiology.

SOURCE: INPHARMA ***20 Apr 2000*** ISSN: 1173-8324

DOCUMENT TYPE: (MIX)

WORD COUNT: 1210

L5 ANSWER 10 OF 549 ADISNEWS COPYRIGHT (C) 2005 Adis Data Information BV on
STN

ACCESSION NUMBER: 1999:2132 ED: 8 Aug 2001 UP: 8 Aug 2001

DOCUMENT NUMBER: 11738324-800786553

TITLE: Product news: Gene therapy shows promise in CAD.

SOURCE: INPHARMA ***20 Aug 1999*** ISSN: 1173-8324

DOCUMENT TYPE: (MIX)

WORD COUNT: 283

L5 ANSWER 11 OF 549 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.
on STN

AN 1998:31898 BIOBUSINESS

DN 0983721

TI ***FGF*** - ***1*** promotes neoangiogenesis in the ischaemic heart.

AU Anon

SO European Biotechnology Newsletter, (***1998***) No.263, March 11,
p.10-11.

ISSN: 0765-2046.

DT ARTICLE

FS UNIQUE

LA English

L5 ANSWER 15 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0187890 BIOCOMMERCE FS Abstract
CO Valentis Inc (51189), USA
SO Valentis Press Release, 01 JUN 2000
TC (Company information)

L5 ANSWER 16 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0187333 BIOCOMMERCE FS Abstract
CO GenVec Inc (28772), USA
Scios Inc (25945), USA
SO GenVec Press Release, 26 APR 2000, vol. 2541, Page(s) 22.
Scrip, 19 MAY 2000
TC (Company information)

L5 ANSWER 17 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0186685 BIOCOMMERCE FS Abstract
CO Vascular Genetics Inc (VGI) (44457), USA
Food and Drug Administration (FDA) (815), USA
Johnson & Johnson (1565), USA
SO Clinica, 20 MAR 2000, vol. 900, Page(s) 15.
TC (Company information)

L5 ANSWER 18 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0186500 BIOCOMMERCE FS Abstract
CO Chiron Corp (1282), USA
SO Chiron Press Release, 12 MAR 2000, vol. 2523, Page(s) 10.
Scrip, 17 MAR 2000
TC (Company information)

L5 ANSWER 19 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0181030 BIOCOMMERCE FS Abstract
CO Vascular Genetics Inc (VGI) (44457), USA
Human Genome Sciences Inc (HGSI) (26897), USA
SO Human Genome Sciences Press Release, 17 JUN 1999, vol. 2626, Page(s) 28.
Marketletter, 28 JUN 1999
TC (Company information)

TC (Company information)

L5 ANSWER 24 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0161264 BIOCOMMERCE FS Abstract
CO GenVec Inc (28772), USA
Parke-Davis Co (3379), USA
SO Scrip, 16 SEP 1997, vol. 2267, Page(s) 9.
R&D Focus Drug News, 22 SEP 1997, vol. 637, Page(s) 10.
BioWorld Financial Watch, 29 SEP 1997, vol. 539, Page(s) 8.
Genetic Technology News, 24 SEP 1997, vol. 1719, Page(s) 3.
BioVenture View, OCT 1997, vol. 1210, Page(s) 24.
Scrip, 16 JAN 1998, vol. 2301, Page(s) 17.
Nature Biotechnology, OCT 1997, vol. 1510, Page(s) 930.
Genetic Engineering News, 01 OCT 1997, vol. 1717, Page(s) 27.
Genetic Engineering News, 15 OCT 1997, vol. 1718, Page(s) 45.
In Vivo, OCT 1997, vol. 159, Page(s) 74-75.
Business Week International, 24 NOV 1997, vol. 3538868, Page(s) 44.

TC (Company information)

L5 ANSWER 25 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 2001:257278 BIOSIS
DN PREV200100257278
TI Rat sponge implant model: A new system for evaluating angiogenic gene
transfer.
AU Wang, H. [Reprint author]; Gordon, D.; Olszewski, B.; Song, Y. L.;
Kovesdi, I.; Keiser, J. A.
CS Cardiovascular Therapeutics, Parke-Davis Pharmaceutical Research, 2800
Plymouth Road, Ann Arbor, MI, 48105, USA
he.wang@wl.com
SO International Journal of Molecular Medicine, (December, 2000) Vol. 6, No.
6, pp. 645-653. print.
ISSN: 1107-3756.
DT Article
LA English

2000.

CODEN: ZKRDAX. ISSN: 0300-5860.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 28 Mar 2001

Last Updated on STN: 15 Feb 2002

L5 ANSWER 28 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 2001:150039 BIOSIS

DN PREV200100150039

TI Role of circulating vascular endothelial growth factor and hepatocyte
growth factor in patients with ***coronary*** ***artery***
disease .

AU Soeki, Takeshi [Reprint author]; Tamura, Yoshiyuki; Shinohara, Hisanori;
Tanaka, Hideji; Bando, Kanji; Fukuda, Nobuo

CS Department of Cardiology and Clinical Research Institute, National
Zentsuji Hospital, 2-1-1 Senyu-cho, Zentsuji, Kagawa, 765-8507, Japan
tsoeki@jun.ncvc.go.jp

SO Heart and Vessels, (2000) Vol. 15, No. 3, pp. 105-111. print.

CODEN: HEVEEO. ISSN: 0910-8327.

DT Article

LA English

ED Entered STN: 28 Mar 2001

Last Updated on STN: 15 Feb 2002

L5 ANSWER 29 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 2001:112482 BIOSIS

DN PREV200100112482

TI Shock waves upregulate vascular endothelial growth factor M-RNA in human
umbilical vascular endothelial cells.

AU Gutersohn, Achim [Reprint author]; Caspari, Guido H. [Reprint author]

CS Univ of Essen, Essen, Germany

SO Circulation, (October 31, 2000) Vol. 102, No. 18 Supplement, pp. II.432.

AN 2001:14963 BIOSIS
DN PREV200100014963
TI Neoangiogenesis by local gene therapy: A new therapeutic approach in the treatment of ***coronary*** ***artery*** ***disease*** .
Original Title: Neoangiogenese durch lokale Gentherapie: Ein neues therapeutisches Konzept in der Behandlung der koronaren Herzkrankheit.
AU Schumacher, B. [Reprint author]; Hannekum, A.; Pecher, P.
CS Abt. Chirurgie IV, Herzchirurgie, Universitaetsklinik Ulm, Steinboevelstr. 9, D-89075, Ulm, Germany
SO Zeitschrift fuer Kardiologie, (2000) Vol. 89, No. Supplement 7, pp. VII.23-VII.30. print.
CODEN: ZKRDAX. ISSN: 0300-5860.
DT Article
LA German
ED Entered STN: 27 Dec 2000
Last Updated on STN: 27 Dec 2000

L5 ANSWER 32 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:526436 BIOSIS
DN PREV200000526436
TI Vascular endothelial growth factor (***VEGF***) and soluble Flt-1 (sFlt-1) in patients with atherosclerotic vascular disease.
AU Belgore, F. M. [Reprint author]; Lip, G. Y. H. [Reprint author]; McCollum, C. N. [Reprint author]; Blann, A. D. [Reprint author]
CS Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK
SO Clinical Science (London), (August, 2000) Vol. 99, No. 2, pp. 19P-20P. print.
Meeting Info.: Communications for the Spring Meeting of the Medical Research Society. London, England, UK. May 22, 2000.
CODEN: CSCIAE. ISSN: 0143-5221.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 6 Dec 2000

L5 ANSWER 35 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 2000:415902 BIOSIS

DN PREV200000415902

TI Vascular endothelial growth factor (***VEGF***) and its soluble receptor (sFlt-1) in peripheral and ***coronary*** ***artery*** ***disease*** .

AU Blann, A. D. [Reprint author]; Belgore, F. M. [Reprint author]; McCollum, C. N.; Lip, G. Y. H. [Reprint author]

CS University Department of Medicine, City Hospital, Birmingham, UK

SO Haemostasis, (May, 2000) Vol. 30, No. 1-2, pp. 60. print.
Meeting Info.: 1st North Sea Conference on Thrombosis and Haemostasis. Maastrich, Netherlands. June 12-14, 2000.
CODEN: HMTSB7. ISSN: 0301-0147.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 27 Sep 2000
Last Updated on STN: 8 Jan 2002

L5 ANSWER 36 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 2000:385286 BIOSIS

DN PREV200000385286

TI Alcohol and catechin increase ***VEGF*** expression in cultured human endothelial cells.

AU Benza, R. L. [Reprint author]; Grenett, H. E. [Reprint author]; Tabengwa, E. M. [Reprint author]; Barchuc, J. P. [Reprint author]; Wheeler, C. G. [Reprint author]; Booyse, F. M. [Reprint author]

CS University of Alabama at Birmingham, Birmingham, AL, 35294, USA

SO Alcoholism Clinical and Experimental Research, (May, 2000) Vol. 24, No. 5 Supplement, pp. 128A. print.
Meeting Info.: Scientific Meeting of the Research Society on Alcoholism. Santa Barbara, California, USA. June 24-29, 2000. Research Society on Alcoholism.
CODEN: ACRSDM. ISSN: 0145-6008.

-
Meeting Info.: Autumn Meeting of the British Society for Haemostasis and Thrombosis. Cambridge, England, UK. September 22-24, 1999. British Society for Haemostasis and Thrombosis.

CODEN: BLFIE7. ISSN: 0957-5235.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 19 Apr 2000

Last Updated on STN: 4 Jan 2002

L5 ANSWER 39 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2000:24118 BIOSIS

DN PREV200000024118

TI Adenoviral-mediated gene transfer induces sustained pericardial ***VEGF*** expression in dogs: Effect on myocardial angiogenesis.

AU Lazarous, Daisy F. [Reprint author]; Shou, Matie; Stiber, Jonathan A.; Hodge, Everett; Thirumurti, Venugopal; Goncalves, Lino; Unger, Ellis F.

CS Division of Cardiology, A1 East, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD, 21224, USA

SO Cardiovascular Research, (Nov., 1999) Vol. 44, No. 2, pp. 294-302. print.

CODEN: CVREAU. ISSN: 0008-6363.

DT Article

LA English

ED Entered STN: 29 Dec 1999

.. Last Updated on STN: 31 Dec 2001

L5 ANSWER 40 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2000:17089 BIOSIS

DN PREV200000017089

TI Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel ***coronary*** ***artery*** ***disease*** .

AU Fleisch, Martin; Billinger, Michael; Eberli, Franz R.; Garachemani, Ali

AU Laham, Roger J. [Reprint author]; Sellke, Frank W. [Reprint author]; Ware, J. Anthony [Reprint author]; Pearlman, Justin D. [Reprint author]; Edelman, Elazar R. [Reprint author]; Simons, Michael [Reprint author]
CS BIDMC/Harvard Medical School, Boston, MA, USA
SO Journal of the American College of Cardiology, (Feb., 1999) Vol. 33, No. 2 SUPPL. A, pp. 383A-384A. print.

Meeting Info.: 48th Annual Scientific Session of the American College of Cardiology. New Orleans, Louisiana, USA. March 7-10, 1999. American College of Cardiology.

CODEN: JACCDI. ISSN: 0735-1097.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 18 Oct 1999

Last Updated on STN: 18 Oct 1999

L5 ANSWER 43 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 1999:406399 BIOSIS

DN PREV199900406399

TI Interindividual heterogeneity in the hypoxic regulation of ***VEGF*** : Significance for the development of the coronary artery collateral circulation.

AU Schultz, Aylit; Lavie, Lena; Hochberg, Irit; Beyar, Rafael; Stone, Tzachi; Skorecki, Karl; Lavie, Peretz; Roguin, Ariel; Levy, Andrew P. [Reprint author]

CS Rappaport Faculty of Medicine, Bat Galim, Israel .

SO Circulation, (Aug. 3, 1999) Vol. 100, No. 5, pp. 547-552. print.

CODEN: CIRCAZ. ISSN: 0009-7322.

DT Article

LA English

ED Entered STN: 8 Oct 1999

Last Updated on STN: 8 Oct 1999

L5 ANSWER 44 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

L5 ANSWER 46 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1999:134228 BIOSIS

DN PREV199900134228

TI Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.

AU Okada, Masaharu; Matsumori, Akira [Reprint author]; Ono, Koh; Miyamoto, Tadashi; Takahashi, Mamoru; Sasayama, Shigetake

CS Dep. Cardiovasc. Med., Kyoto Univ., 54 Kawaracho Shogoin, Sakyo-ku, Kyoto 606-8397, Japan

SO Biochemical and Biophysical Research Communications, (Feb. 5, 1999) Vol. 255, No. 1, pp. 80-87. print.
CODEN: BBRCA9. ISSN: 0006-291X.

DT Article

LA English

ED Entered STN: 31 Mar 1999
Last Updated on STN: 31 Mar 1999

L5 ANSWER 47 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1999:3267 BIOSIS

DN PREV199900003267

TI Perspectives of gene therapy for the treatment of ***coronary***
artery ***disease*** .

AU Waltenberger, J. [Reprint author]

CS Abteilung Innere Med. II, Med. Klinik Poliklinik, Univ. Ulm,
Robert-Koch-Str. 8, 89081 Ulm, Germany

SO Zeitschrift fuer Kardiologie, (1998) Vol. 87, No. SUPPL. 2, pp. 152-156.
print.
CODEN: ZKRDAX. ISSN: 0300-5860.

DT Article

LA German

ED Entered STN: 11 Jan 1999
Last Updated on STN: 11 Jan 1999

STN

AN 1997:270129 BIOSIS

DN PREV199799561847

TI Serum basic fibroblast growth factor levels in patients with ischemic heart disease.

AU Hasdai, David; Barak, Vivian; Leibovitz, Eyal; Herz, Itzhak; Sclarovsky, Samuel; Eldar, Michael; Scheinowitz, Mickey [Reprint author]

CS Neufeld Cardiac Res. Inst., Sheba Med. Cent., Tel Hashomer 52621, Israel

SO International Journal of Cardiology, (1997) Vol. 59, No. 2, pp. 133-138.
CODEN: IJCDD5. ISSN: 0167-5273.

DT Article

LA English

ED Entered STN: 24 Jun 1997

Last Updated on STN: 24 Jun 1997

L5 ANSWER 51 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1996:321934 BIOSIS

DN PREV199699044290

TI Vascular endothelial growth factor administration in chronic myocardial ischemia.

AU Harada, Kazumasa; Friedman, Menachem; Lopez, John J.; Wang, Steven Y.; Li, Jian; Prasad, Pottumarthi V.; Pearlman, Justin D.; Edelman, Elazer R.; Sellke, Frank W.; Simons, Michael [Reprint author]

CS Cardiovasc. Div., Beth Israel Hosp., 330 Brookline Ave., Boston, MA 02115,
USA

SO American Journal of Physiology, (1996) Vol. 270, No. 5 PART 2, pp.
H1791-1802.

CODEN: AJPHAP. ISSN: 0002-9513.

DT Article

LA English

ED Entered STN: 11 Jul 1996

Last Updated on STN: 11 Jul 1996

L5 ANSWER 52 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

L5 ANSWER 54 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1995:263157 BIOSIS

DN PREV199598277457

TI Regulation of vascular endothelial growth factor in cardiac myocytes.

AU Levy, Andrew P.; Levy, Nina S.; Loscalzo, Joseph; Calderone, Angelino; Takahashi, Nobuyuki; Yeo, Kiang-Teck; Koren, Gideon; Colucci, Wilson S.; Goldberg, Mark A. [Reprint author]

CS Brigham and Women's Hosp., 221 Longwood Ave., Boston, MA 02115, USA

SO Circulation Research, (1995) Vol. 76, No. 5, pp. 758-766.

CODEN: CIRUAL. ISSN: 0009-7330.

DT Article

LA English

ED Entered STN: 26 Jun 1995

Last Updated on STN: 26 Jun 1995

L5 ANSWER 55 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1995:8448 BIOSIS

DN PREV199598022748

TI Angiogenic therapy of acute myocardial infarction (AMI) by intrapericardial injection of basic fibroblast growth factor (***bFGF***) and heparan sulfate (HS): An experimental study.

AU Uchida, Yasumi; Yanagisawa-Miwa, Atsuko; Ikuta, Makoto; Makamura, Fumitaka; Tomaru, Takanobu; Fujimori, Yoshiharu; Morita, Toshihiro

CS Second Dep. Internal Med., Univ. Tokyo, Tokyo, Japan

SO Circulation, (1994) Vol. 90, No. 4 PART 2, pp. I296.

Meeting Info.: 67th Scientific Sessions of the American Heart Association.
Dallas, Texas, USA. November 14-17, 1994.

CODEN: CIRCAZ. ISSN: 0009-7322.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 5 Jan 1995

Last Updated on STN: 23 Feb 1995

L5 ANSWER 58 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:32044206 BIOTECHNO
TI Gene therapy for ***coronary*** ***artery*** ***disease*** .
Perspectives and limitations of the therapeutic induction of a collateral circulation
GENTHERAPIE BEI KORONARER HERZKRANKHEIT: MOGLICHKEITEN UND GRENZEN EINER THERAPEUTISCHEN INDUKTION VON KOLLATERALEN
AU Waltenberger J.
CS Dr. J. Waltenberger, Universitätsklinikum Ulm, Robert-Koch-Strasse 8,
D-89081 Ulm, Germany.
E-mail: johannes.waltenberger@medizin.uni-ulm.de
SO Hamostaseologie, (***2000***), 20/4 (162-166), 24 reference(s)
CODEN: HAEMD2 ISSN: 0720-9355
DT Journal; Conference Article
CY Germany, Federal Republic of
LA German
SL English; German

L5 ANSWER 59 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:30812493 BIOTECHNO
TI Neoangiogenesis by local gene therapy: A new therapeutic approach in the treatment of ***coronary*** ***artery*** ***disease***
NEOANGIOGENESE DURCH LOKALE GENTHERAPIE: EIN NEUES THERAPEUTISCHES KONZEPT IN DER BEHANDLUNG DER KORONAREN HERZKRANKHEIT
AU Schumacher B.; Hannekum A.; Pecher P.
CS Dr. B. Schumacher, Universitätsklinik Ulm, Abt. Chirurgie IV,
Herzchirurgie, Steinhovelstr. 9, D-89075 Ulm, Germany.
SO Zeitschrift fur Kardiologie, (***2000***), 89/SUPPL. 7 (VII23-VII30), 29 reference(s)
CODEN: ZKRDAX ISSN: 0300-5860
DT Journal; Article
CY Germany, Federal Republic of
LA German
SL English; German

Symes J.F.

CS Dr. J.F. Symes, Division of Cardiothoracic Surgery, St. Elizabeth's Medical Center, MOB 306, 11 Nevins St, Boston, MA 02135, United States.
E-mail: jsymes@semc.org

SO Annals of Thoracic Surgery, (***2000***), 70/3 (829-834), 20 reference(s)

CODEN: ATHSAK ISSN: 0003-4975

PUI S0003497500016337

DT Journal; Article

CY United States

LA English

SL English

L5 ANSWER 63 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

AN 2000:30644583 BIOTECHNO

TI Gene therapy in cardiovascular diseases

GENTHERAPIE BEI KARDIOVASKULAREN ERKRANKUNGEN

AU Stegmann Th.J.; Hoppert Th.

CS Dr. Th.J. Stegmann, Klinik Thorax Herz-/Gefasschirurgie, Klinikum Fulda, Pacelliallee 4, D-36043 Fulda, Germany.

E-mail: heart.stegmann@klinikum-fulda.de

SO Journal fur Kardiologie, (***2000***), 7/7-8 (292-295), 30 reference(s)

CODEN: JKARFN ISSN: 1024-0098

DT Journal; (Short Survey)

CY Austria

LA German

SL English; German

L5 ANSWER 64 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

AN 2000:30210343 BIOTECHNO

TI Angiogenesis and arteriogenesis - Not yet for prescription

AU Helisch A.; Schaper W.

CS Dr. A. Helisch, Abt. fur Experimentelle Kardiologie, Max-Planck-Inst. fur Physiologische, Klinische Forschung, Benekestr. 2, D-61231 Bad Nauheim, Germany.

SO Microvascular Research, (***1999***), 58/3 (238-249), 28 reference(s)
CODEN: MIVRA6 ISSN: 0026-2862
DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 67 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29526847 BIOTECHNO
TI Gene therapy with vascular endothelial growth factor for inoperable
 coronary ***artery*** ***disease***
AU Symes J.F.; Losordo D.W.; Vale P.R.; Lathi K.G.; Esakof D.D.; Mayskiy M.;
Isner J.M.; Schaff H.V.; Atkinson A.W.; Vincent C.K.; Pham S.M.;
Stanbridge R.D.L.; Horowitz S.; Thomas N.J.
CS Dr. J.F. Symes, 11 Nevins St/306, Boston, MA 02135, United States.
E-mail: jsymes@semc.org
SO Annals of Thoracic Surgery, (***1999***), 68/3 (830-837), 21
reference(s)

CODEN: ATHSAK ISSN: 0003-4975

PUI S0003497599008073
DT Journal; Conference Article
CY United States
LA English
SL English

L5 ANSWER 68 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29411709 BIOTECHNO
TI Role of vascular endothelial growth factor in the regulation of
angiogenesis
AU Ferrara N.
CS Dr. N. Ferrara, Dept. of Cardiovascular Research, Genentech Inc., 1 DNA
Way, South San Francisco, CA 94080, United States.
E-mail: nf@gene.com
SO Kidney International, (***1999***), 56/3 (794-814), 285 reference(s)
CODEN: KDYIA5 ISSN: 0085-2538
DT Journal; General Review

gene therapy with adeno- ***VEGF***

AU Rivard A.; Silver M.; Chen D.; Kearney M.; Magner M.; Annex B.; Peters K.; Isner J.M.

CS Dr. J.M. Isner, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, United States.

E-mail: jisner@opal.tufts.edu

SO American Journal of Pathology, (***1999***), 154/2 (355-363), 50 reference(s)

CODEN: AJPAA4 ISSN: 0002-9440

DT Journal; Article

CY United States

LA English

SL English

L5 ANSWER 72 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1998:29003959 BIOTECHNO

TI Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF.sub.1.sub.6.sub.5 as sole therapy for myocardial ischemia

AU Losordo D.W.; Vale P.R.; Symes J.F.; Dunnington C.H.; Esakof D.D.; Maysky M.; Ashare A.B.; Lathi K.; Isner J.M.

CS Dr. J.M. Isner, St. Elizabeth's Medical Center, 736 Cambridge St., Boston, MA 02135, United States.

SO Circulation, *** (29 DEC 1998)*** , 98/25 (2800-2804), 19 reference(s)
CODEN: CIRCAZ ISSN: 0009-7322

DT Journal; Article

CY United States

LA English

SL English

L5 ANSWER 73 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1998:28510806 BIOTECHNO

TI Basic fibroblast growth factor: A potential therapeutic agent for the treatment of acute neurodegenerative disorders and vascular insufficiency

AU Moyer J.A.; Wood A.; Zaleska M.M.; Ay I.; Finklestein S.P.; Protter A.A.
CS J.A. Moyer, CNS Disorders Division, Wyeth-Ayerst Research, CN 8000,

CODEN: MIVRA6 ISSN: 0026-2862

DT Journal; Article

CY United States

LA English

L5 ANSWER 76 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

AN 1997:27418032 BIOTECHNO

TI Enhanced angiogenesis and unfavorable remodeling in injured porcine coronary artery lesions: Effects of local basic fibroblast growth factor delivery

AU Staab M.E.; Simari R.D.; Srivatsa S.S.; Hasdai D.; Pompili V.J.; Holmes D.R. Jr.; Schwartz R.S.

CS Dr. R.S. Schwartz, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, United States.

SO Angiology, (***1997***), 48/9 (753-760), 29 reference(s)
CODEN: ANGIAB ISSN: 0003-3197

DT Journal; Article

CY United States

LA English

SL English

L5 ANSWER 77 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

AN 1996:26349307 BIOTECHNO

TI Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model

AU Horrigan M.C.G.; MacIsaac A.I.; Nicolini F.A.; Vince D.G.; Lee P.; Ellis S.G.; Topol E.J.

CS Department of Cardiology (F-25), Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, United States.

SO Circulation, (***1996***), 94/8 (1927-1933)
CODEN: CIRCAZ ISSN: 0009-7322

DT Journal; Article

CY United States

LA English

SL English

DN 20550038 PubMed ID: 11098556
TI [Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease].
Neoangiogenese durch lokale Gentherapie: Ein neues therapeutisches Konzept in der Behandlung der koronaren Herzkrankheit.
AU Schumacher B; Hannekum A; Pecher P
CS Universitätsklinik Ulm, Abt. Chirurgie IV Herzchirurgie.
SO ZEITSCHRIFT FÜR KARDIOLOGIE, ***(2000)*** 89 Suppl 7 23-30.
Journal code: 0360430. ISSN: 0300-5860.
CY GERMANY: Germany, Federal Republic of
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA German
FS MEDLINE; Priority Journals
OS MEDLINE 2001057653
EM 200012
ED Entered STN: 20010423
Last Updated on STN: 20010423

L5 ANSWER 81 OF 549 CANCERLIT on STN
AN 2000151124 CANCERLIT
DN 20151124 PubMed ID: 10688416
TI Angiogenesis for the treatment of vascular diseases.
AU Chawla P S; Keelan M H; Kipshidze N
SO INTERNATIONAL ANGIOLOGY, *** (1999 Sep) *** 18 (3) 185-92. Ref: 66
Journal code: 8402693. ISSN: 0392-9590. ..
CY Italy
DT Editorial
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2000151124
EM 200004
ED Entered STN: 20000515

L5 ANSWER 84 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:175692 CAPLUS
 DN 132:227446
 TI Angiogenically effective unit dose of fibroblast growth factor-2 and method of use
 IN Whitehouse, Martha Jo
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|--------------|
| PI | WO 2000013701 | A2 | 20000316 | WO 1999-US19770 | 19990827 <-- |
| | WO 2000013701 | A3 | 20000803 | | |
| | W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 9960223 | A1 | 20000327 | AU 1999-60223 | 19990827 <-- |
| | EP 1121142 | A2 | 20010808 | EP 1999-968630 | 19990827 |
| | EP 1121142 | B1 | 20041020 | | |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| | JP 2002524420 | T2 | 20020806 | JP 2000-568509 | 19990827 |
| | AT 279937 | E | 20041115 | AT 1999-968630 | 19990827 |
| | US 2002165160 | A1 | 20021107 | US 2002-131965 | 20020425 |
| PRAI | US 1998-145743P | P | 19980903 | | |
| | US 1998-104102P | P | 19981013 | | |

AN 1999:641878 CAPLUS
DN 131:252631
TI Angiogenesis in cardiovascular disease: current status and therapeutic potential
AU Sellke, Frank W.; Simons, Michael
CS Beth Israel Deaconess Medical Center, Division of Cardiothoracic Surgery and Cardiovascular Division, Harvard Medical School, Boston, MA, USA
SO Drugs (***1999***), 58(3), 391-396
CODEN: DRUGAY; ISSN: 0012-6667
PB Adis International Ltd.
DT Journal; General Review
LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 88 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:48639 CAPLUS
DN 130:76613
TI Novel composition for treating, preventing and/or delaying ischemic cell death using proteins having the function of ***aFGF*** or activators of stress-activated protein kinases
IN Schaper, Wolfgang; Htun, Patrik
PA Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Germany
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|--|----------|-----------------|--------------|
| | ----- | --- | ----- | ----- | ----- |
| PI | WO 9901150 | A1 | 19990114 | WO 1998-EP4134 | 19980703 <-- |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

L5 ANSWER 91 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:804532 CAPLUS
DN 123:276007
TI Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF and ***VEGF***
IN Brown, Paul A.; Bursten, Stuart L.; Rice, Glenn C.; Singer, Jack W.
PA Cell Therapeutics, Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|--------------|
| PI | WO 9519171 | A1 | 19950720 | WO 1995-US520 | 19950113 <-- |
| | W: AU, CA, JP | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2192470 | AA | 19950720 | CA 1995-2192470 | 19950113 <-- |
| | AU 9518313 | A1 | 19950801 | AU 1995-18313 | 19950113 <-- |
| | EP 739203 | A1 | 19961030 | EP 1995-910088 | 19950113 <-- |
| | R: AT, DE, ES, FR, GB, IE, IT | | | | |
| | US 5795898 | A | 19980818 | US 1995-485325 | 19950607 <-- |
| | US 5859018 | A | 19990112 | US 1995-485322 | 19950607 <-- |
| | US 5929081 | A | 19990727 | US 1995-485320 | 19950607 <-- |
| PRAI | US 1994-181947 | A | 19940114 | | |
| | WO 1995-US520 | W | 19950113 | | |
| OS | MARPAT 123:276007 | | | | |

L5 ANSWER 92 OF 549 CEABA-VTB COPYRIGHT 2005 DECHEMA on STN
AN 1999(06):4967 CEABA-VTB FS B
DN CEABA: 1999:3174891
TI Blood vessel growth factor genes seen as aid for failing hearts
CS St Elizabeth's Medical Center, Cambridge, MA, USA
SO Biotechnol. Newswatch (***1999***), p.4
ISSN: 0275-3685

TI The bottleneck at Vascular Genetics
SO BioCentury, 6 Mar 2000 (20000306), 8(11), p. A8. ISSN: 1097-7201; CODEN:
BICEFS.
LA English

L5 ANSWER 98 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 29(3):2019K CIN
TI ACE inhibitor promotes angiogenesis in rabbits
SO Emerging Pharm., Aug 1999 (19990800), 8(8), p. 7. ISSN: 1061-6098; CODEN:
EMPHFR.
LA English

L5 ANSWER 99 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 28(34):34201J CIN
TI Clinical results
SO BioCentury, 9 Aug 1999 (19990809), 7(48, Pt. 2), p. B8. ISSN: 1097-7201;
CODEN: BICEFS.
LA English

L5 ANSWER 100 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 28(27):27212K CIN
TI Clinical status
SO BioCentury, 21 Jun 1999 (19990621), 7(37, Pt. 2), p. B14. ISSN:
1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 101 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 28(13):12771T CIN
TI Clinical results
SO BioCentury, 15 Mar 1999 (19990315), 7(18, Pt. 2), p. B7-B8. ISSN:
1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 102 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 28(10):9559Z CIN
TI Clinical results

CODEN: BICEFS.

LA English

L5 ANSWER 108 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 27(4):3316A CIN

TI Clinical status

SO BioCentury, 5 Jan 1998 (19980105), 6(1, Pt. 2), p. B7. CODEN: BICEFS.

LA English

L5 ANSWER 109 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 26(23):25804Q CIN

TI Companies aim novel therapeutic strategies at dual nature of angiogenesis

SO Genet. Eng. News, 1 May 1997 (970501), 17(9), p. 6, 33. ISSN: 0270-6377;
CODEN: GENNDX.

LA English

L5 ANSWER 110 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 26(15):17282C CIN

TI Angiogenic factors put to the test in bypassing blocked arteries

SO Biotechnol. News, 27 Mar 1997 (970327), 17(8), p. 7. ISSN: 0273-3226;
CODEN: BINWEY.

LA English

L5 ANSWER 111 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 25(51):55796K CIN

TI Scios/Wyeth-Ayerst sign fibblast deal

SO Biotechnol. Bus. News, 13 Nov 1996 (961113), 6(137), p. 9.. ISSN:
0965-9595; CODEN: BBUNER.

LA English

L5 ANSWER 112 OF 549 CIN COPYRIGHT 2005 ACS on STN

AN 25(28):30596G CIN

TI Scios to patent method of producing human basic fibroblast growth factor

SO Biotech Pat. News, May 1996 (960500), 10(5), p. 5-6. ISSN: 0898-2813;
CODEN: BPANEP.

LA English

LA English
OS 2001-025162 [03]
CR N-PSDB: AAC90481
DESC Human VEGF206.

L5 ANSWER 116 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50434 Protein DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR N-PSDB: AAC90480
DESC Human VEGF189.

L5 ANSWER 117 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50433 Protein DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]

L5 ANSWER 120 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50428 Protein DGENE
TI Vascular endothelial growth factor dimer, useful for treating essential hypertension, polycystic kidney diseases, microvascular angiopathy and ***coronary*** ***artery*** ***disease*** , comprising two monomeric subunits -
IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A; Baldwin P A; Pollitt N S
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071716 A2 20001130 61***
AI WO 2000-US13636 20000518
PRAI US 1999-135312 19990520
US 2000-177407 20000120
DT Patent
LA English
OS 2001-041064 [05]
CR N-PSDB: AAC90473
DESC Mature human vascular endothelial growth factor polypeptide.

L5 ANSWER 121 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50427 Protein DGENE
TI Vascular endothelial growth factor dimer, useful for treating essential hypertension, polycystic kidney diseases, microvascular angiopathy and ***coronary*** ***artery*** ***disease*** , comprising two monomeric subunits -
IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A; Baldwin P A; Pollitt N S
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071716 A2 20001130 61***
AI WO 2000-US13636 20000518
PRAI US 1999-135312 19990520
US 2000-177407 20000120
DT Patent
LA English
OS 2001-041064 [05]

DESC Recombinant bovine ***FGF*** - ***2*** protein sequence.

L5 ANSWER 124 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAY92777 Protein DGENE

TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis

IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYOT-N) UNIV OTAGO.

PI ***WO 2000025805 A1 20000511 76***

AI WO 1999-US25869 19991102

PRAI US 1998-106689 19981102

US 1998-106800 19981103

DT Patent

LA English

OS 2000-365394 [31]

DESC PDGF/ ***VEGF*** family characteristic motif.

L5 ANSWER 125 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAY92776 Protein DGENE

TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis

IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYOT-N) UNIV OTAGO.

PI ***WO 2000025805 A1 20000511 76***

AI WO 1999-US25869 19991102

PRAI US 1998-106689 19981102

US 1998-106800 19981103

DT Patent

LA English

OS 2000-365394 [31]

DESC Orf virus strain NZ10 vascular endothelial growth factor-like protein.

AN AAY87848 protein DGENE
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
CR N-PSDB: AAA39555
DESC Bovine ***FGF*** - ***2*** protein.

L5 ANSWER 129 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY87847 protein DGENE
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
DESC Human ***FGF*** - ***2*** protein.

L5 ANSWER 130 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY87846 protein DGENE

or intestinal disorders

IN Achen M G; Alitalo K; Stacker S A; Wilks A F

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYHE-N) UNIV HELSINKI LICENSING LTD.

PI ***WO 9807832 A1 19980226 101***

AI WO 1997-US14696 19970821

PRAI US 1997-51426 19970701

AU 1996-1825 19960823

US 1996-23751 19960823

AU 1996-3554 19961111

US 1996-31097 19961114

AU 1997-4954 19970205

US 1997-38814 19970210

AU 1997-7435 19970619

DT Patent

LA English

OS 1998-179057 [16]

DESC Homo sapiens vascular endothelial growth factor D (***VEGF*** -D)
peptide.

L5 ANSWER 133 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAW53243 Protein DGENE

TI New isolated vascular endothelial growth factor-D - used to develop
products for use in e.g. modifying angiogenesis or treating lung, heart
or intestinal disorders

IN Achen M G; Alitalo K; Stacker S A; Wilks A F

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYHE-N) UNIV HELSINKI LICENSING LTD.

PI ***WO 9807832 A1 19980226 101***

AI WO 1997-US14696 19970821

PRAI US 1997-51426 19970701

AU 1996-1825 19960823

US 1996-23751 19960823

AU 1996-3554 19961111

US 1996-31097 19961114

AU 1997-4954 19970205

or intestinal disorders

IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.

PI ***WO 9807832 A1 19980226 101***

AI WO 1997-US14696 19970821

PRAI US 1997-51426 19970701

AU 1996-1825 19960823

US 1996-23751 19960823

AU 1996-3554 19961111

US 1996-31097 19961114

AU 1997-4954 19970205

US 1997-38814 19970210

AU 1997-7435 19970619

DT Patent

LA English

OS 1998-179057 [16]

CR N-PSDB: AAV20807

DESC Homo sapiens vascular endothelial growth factor D (***VEGF*** -D).

L5 ANSWER 136 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAW53240 Protein DGENE

TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders

IN Achen M G; Alitalo K; Stacker S A; Wilks A F

PA (LUDW-N) LUDWIG INST CANCER RES.

(UYHE-N) UNIV HELSINKI LICENSING LTD.

PI ***WO 9807832 A1 19980226 101***

AI WO 1997-US14696 19970821

PRAI US 1997-51426 19970701

AU 1996-1825 19960823

US 1996-23751 19960823

AU 1996-3554 19961111

US 1996-31097 19961114

AU 1997-4954 19970205

LA English
OS 2001-025162 [03]
DESC Human VEGF121 gene mutagenic forward primer oligo 1612.

L5 ANSWER 139 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90481 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR P-PSDB: AAB50435
DESC Human VEGF206 DNA.

L5 ANSWER 140 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90480 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR P-PSDB: AAB50434

L5 ANSWER 143 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90477 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR P-PSDB: AAB50431
DESC Human VEGF121 DNA.

L5 ANSWER 144 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90473 cDNA DGENE
TI Vascular endothelial growth factor dimer, useful for treating essential hypertension, polycystic kidney diseases, microvascular angiopathy and ***coronary*** ***artery*** ***disease*** , comprising two monomeric subunits -
IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A; Baldwin P A; Pollitt N S
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071716 A2 20001130 61***
AI WO 2000-US13636 20000518
PRAI US 1999-135312 19990520
US 2000-177407 20000120
DT Patent
LA English
OS 2001-041064 [05]
CR P-PSDB: AAB50427; AAB50428
DESC Human vascular endothelial growth factor cDNA.

L5 ANSWER 147 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAA28493 DNA DGENE
TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis
IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYOT-N) UNIV OTAGO.
PI ***WO 2000025805 A1 20000511 76***
AI WO 1999-US25869 19991102
PRAI US 1998-106689 19981102
US 1998-106800 19981103
DT Patent
LA English
OS 2000-365394 [31]
CR P-PSDB: AAY92775
DESC ORFV2- ***VEGF*** coding sequence.

L5 ANSWER 148 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAA39555 DNA DGENE
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
CR P-PSDB: AAY87848
DESC Bovine ***FGF*** - ***2*** DNA fragment.

AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619

DT Patent
LA English
OS 1998-179057 [16]
DESC Homo sapiens ***VEGF*** -D gene PCR primer.

L5 ANSWER 151 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV20809 cDNA DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619

DT Patent
LA English
OS 1998-179057 [16]
CR P-PSDB: AAW53243
DESC Mus musculus vascular endothelial growth factor D2 (***VEGF*** -D2) gene.

L5 ANSWER 152 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

| | | |
|------|--|----------|
| US | 1996-23751 | 19960823 |
| AU | 1996-3554 | 19961111 |
| US | 1996-31097 | 19961114 |
| AU | 1997-4954 | 19970205 |
| US | 1997-38814 | 19970210 |
| AU | 1997-7435 | 19970619 |
| DT | Patent | |
| LA | English | |
| OS | 1998-179057 [16] | |
| CR | P-PSDB: AAW53241 | |
| DESC | Homo sapiens vascular endothelial growth factor D (***VEGF*** -D) gene. | |

| | | | |
|------|---|------------------------------|--|
| L5 | ANSWER 154 OF 549 | DGENE | COPYRIGHT 2005 The Thomson Corp on STN |
| AN | AAV20806 | cDNA | DGENE |
| TI | New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders | | |
| IN | Achen M G; Alitalo K; Stacker S A; Wilks A F | | |
| PA | (LUDW-N) | LUDWIG INST CANCER RES. | |
| | (UYHE-N) | UNIV HELSINKI LICENSING LTD. | |
| PI | ***WO 9807832 | A1 19980226 | 101*** |
| AI | WO 1997-US14696 | 19970821 | |
| PRAI | US 1997-51426 | 19970701 | |
| | AU 1996-1825 | 19960823 | |
| | US 1996-23751 | 19960823 | |
| | AU 1996-3554 | 19961111 | - |
| | US 1996-31097 | 19961114 | |
| | AU 1997-4954 | 19970205 | |
| | US 1997-38814 | 19970210 | |
| | AU 1997-7435 | 19970619 | |
| DT | Patent | | |
| LA | English | | |
| OS | 1998-179057 [16] | | |
| CR | P-PSDB: AAW53240 | | |
| DESC | Homo sapiens vascular endothelial growth factor D (***VEGF*** -D) | | |

of a patient

IN Hammond H K; Kelly T L

PA (REGC) UNIV CALIFORNIA.

PI ***WO 9850079 A2 19981112 87***

AI WO 1998-US8848 19980430

PRAI US 1997-852779 19970506

DT Patent

LA English

OS 1998-610127 [51]

DESC PCR primer for ***FGF*** - ***1*** coding sequence.

L5 ANSWER 158 OF 549 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-41526 DRUGU T P B

TI Atorvastatin therapy reduces vascular endothelial growth factor (***VEGF***) in patients with ***coronary*** ***artery*** ***disease*** .

AU Alber H; Dulak J; Schwarzacher S; Pachinger O; Weidinger F

CS Univ.Innsbruck; Univ.Jagiellonian

LO Innsbruck, Austria; Cracow, Pol.

SO Atherosclerosis (151, No. 1, 191, 2000)

CODEN: ATHSBL ISSN: 0021-9150

AV Department of Cardiology, University of Innsbruck, Austria.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L5 ANSWER 159 OF 549 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-32505 DRUGU T

TI Phase II, multicenter, double-blind, placebo-controlled, dose-finding study for safety, pharmacokinetics, and efficacy of recombinant fibroblast growth factor (rFGF-2) in subjects with ***coronary*** ***artery*** ***disease*** (CAD): ***FGF*** - ***2*** initiating revascularization support trial (FIRST) .

AU Simons M

LO Boston, Mass., USA

LA English
DT Journal
FA AB; LA; CT
FS Literature

L5 ANSWER 162 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2001350870 EMBASE
TI Fate of latissimus dorsi muscle flap in cardiomyoplasty and availability of omental flap.
AU Okada M.; Tsukube T.; Hariu T.; Ootaki Y.; Okita Y.
CS Dr. M. Okada, 1-1-39-103 Sumiyoshihonmachi, Higashinada-ku, Kobe 658-0051, Japan
SO Journal of Congestive Heart Failure and Circulatory Support, (2000) Vol. 1, No. 4, pp. 285-289.
Refs: 8
ISSN: 1468-3768 CODEN: JCHFAT
CY United Kingdom
DT Journal; Conference Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
029 Clinical Biochemistry
027 Biophysics, Bioengineering and Medical Instrumentation
LA English
SL English
ED Entered STN: 20011018
Last Updated on STN: 20011018

L5 ANSWER 163 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2001018068 EMBASE
TI [Clinical results of the treatment of ***coronary*** ***artery*** ***disease*** with growth factors].
KLINISCHE ERGEBNISSE DER BEHANDLUNG DER KORONAREN HERZKRANKHEIT MIT WACHSTUMSTAKTOREN.
AU Hoppert Th.; Ibing R.; Schneider A.; Popp M.; Stegmann Th.J.
CS Dr. Th. Hoppert, Klin. fur Thorax-, Herz/Gefasschir., Klinikum Fulda,

L5 ANSWER 165 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN

AN 1999285095 EMBASE

TI Mechanical endothelial damage results in basic fibroblast growth factor-mediated activation of extracellular signal-regulated kinases.

AU Pintucci G.; Steinberg B.M.; Seghezzi G.; Yun J.; Apazidis A.; Baumann F.G.; Grossi E.A.; Colvin S.B.; Mignatti P.; Galloway A.C.

CS Dr. B.M. Steinberg, NYU Medical Center, 530 First Ave, New York, NY 10016, United States

SO Surgery, (1999) Vol. 126, No. 2, pp. 422-427.

Refs: 21

ISSN: 0039-6060 CODEN: SURGAZ

CY United States

DT Journal; Article

FS 018 Cardiovascular Diseases and Cardiovascular Surgery
026 Immunology, Serology and Transplantation

LA English

SL English

ED Entered STN: 19990826

Last Updated on STN: 19990826

L5 ANSWER 166 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN

AN 1999282282 EMBASE

TI Gene therapy for myocardial angiogenesis.

AU Losordo D.W.; Vale P.R.; Isner J.M.

CS Dr. D.W. Losordo, Department of Medicine, Division of Cardiovascular Research, St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135, United States

SO American Heart Journal, (1999) Vol. 138, No. 2 II, pp. S132-S141.

Refs: 47

ISSN: 0002-8703 CODEN: AHJOA2

CY United States

DT Journal; General Review

FS 018 Cardiovascular Diseases and Cardiovascular Surgery

SO Clinical Cardiology, (1999) Vol. 22, No. 1 SUPPL., pp. I10-I16.

Refs: 24

ISSN: 0160-9289 CODEN: CLCADC

CY United States

DT Journal; Conference Article

FS 018 Cardiovascular Diseases and Cardiovascular Surgery

037 Drug Literature Index

039 Pharmacy

LA English

SL English

ED Entered STN: 19990225

Last Updated on STN: 19990225

L5 ANSWER 169 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

AN 1998372756 EMBASE

TI Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience.

AU Goncalves L.M.

CS L.M. Goncalves, Cardiology Branch, National Heart, Lung/Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892-1518, United States. goncalvl@gwgate.nhlbi.nih.gov

SO Revista Portuguesa de Cardiologia, (1998) Vol. 17, No. SUPPL. 2, pp. 11-20.

Refs: 103

ISSN: 0304-4750 CODEN: RPCADZ

CY Portugal

DT Journal; General Review

FS 018 Cardiovascular Diseases and Cardiovascular Surgery

030 Pharmacology

037 Drug Literature Index

052 Toxicology

LA English

SL English; Portuguese

ED Entered STN: 19981130

CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
018 Cardiovascular Diseases and Cardiovascular Surgery
LA English
SL English
ED Entered STN: 960708
Last Updated on STN: 960708

L5 ANSWER 172 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 96035325 EMBASE
DN 1996035325
TI Antithrombin determinants of ***coronary*** ***artery***
disease in transplanted human hearts.
AU Labarrere C.A.; Faulk W.P.
CS Division of Experimental Pathology, Reprod./Transplant. Immunology Ctr.,
Methodist Hospital, 1701 N Senate Blvd, Indianapolis, IN 46202, United
States
SO Seminars in Hematology, (1995) Vol. 32, No. 4 SUPPL. 2, pp. 61-66.
ISSN: 0037-1963 CODEN: SEHEA3
CY United States
DT Journal; Conference Article
FS 009 Surgery
018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
LA English
SL English
ED Entered STN: 960212
Last Updated on STN: 960212

L5 ANSWER 173 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 91230395 EMBASE
DN 1991230395
TI Coronary atherosclerosis: Current therapeutic approaches and future

RESPONSE TO PDGF, EGF, FGF, AND ***VEGF*** ; ANTIARTHRITIC AGENTS;
ANTITUMOR AGENTS; CARDIOVASCULAR DISORDERS

IN Brown Paul A; Bursten Stuart L; Rice Glenn C; Singer Jack W
PA Cell Therapeutics Inc (32953)
PI US 5859018 A 19990112 (CITED IN 003 LATER PATENTS)
AI US 1995-485322 19950607
RLI US 1994-181947 19940114 DIVISION ABANDONED
FI US 5859018 19990112
DT Utility
FS CHEMICAL
GRANTED
CLMN 9
GI 30 Drawing Sheet(s), 36 Figure(s).

L5 ANSWER 176 OF 549 IFIPAT COPYRIGHT 2005 IFI on STN
AN 03026608 IFIPAT;IFIUDB;IFICDB
TI METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN
RESPONSE TO PDGF,EGF,FGF AND ***VEGF*** ; ANTITUMOR, ANTICANCER
AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS
IN Brown Paul A; Bursten Stuart L; Rice Glenn C; Singer Jack W
PA Cell Therapeutics Inc (32953)
PI US 5795898 A 19980818 (CITED IN 004 LATER PATENTS)
AI US 1995-485325 19950607
RLI US 1994-181947 19940114 DIVISION ABANDONED
FI US 5795898 19980818
DT Utility
FS CHEMICAL
GRANTED
CLMN 9
GI 30 Drawing Sheet(s), 36 Figure(s).

L5 ANSWER 177 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 2000:2695 IMSDRUGNEWS

TITLE: gene therapy, cardiovascular disease GenVec phase change
II, USA (peripheral vascular disease)

TITLE: trafermin Scios, Chiron, Orquest, Selective Genetics
licensing agreement
SOURCE: R&D Focus Drug News (***15 Nov 1999***).
WORD COUNT: 130

L5 ANSWER 183 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:3161 IMSDRUGNEWS
TITLE: ***VEGF*** 121-based therapy, Scios Scios licensing
offer, Worldwide
SOURCE: R&D Focus Drug News (***25 Oct 1999***).
WORD COUNT: 44

L5 ANSWER 184 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:577 IMSDRUGNEWS
TITLE: telbermin Genentech considers product future
SOURCE: R&D Focus Drug News (***1 Mar 1999***).
WORD COUNT: 78

L5 ANSWER 185 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:76 IMSDRUGNEWS
TITLE: gene therapy, ***VEGF*** -2, Vascular Genetics Vascular
Genetics IND allowed
SOURCE: R&D Focus Drug News (***11 Jan 1999***).
WORD COUNT: 81

L5 ANSWER 186 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:4062 IMSDRUGNEWS
TITLE: basic fibroblast growth factor Chiron phase change II, USA
SOURCE: R&D Focus Drug News (***16 Nov 1998***).
WORD COUNT: 166

L5 ANSWER 187 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

SOURCE: R&D Focus Drug News (***30 Mar 1998***).

WORD COUNT: 96

L5 ANSWER 192 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 97:2552 IMSDRUGNEWS

TITLE: telbermin Genentech phase change I, USA

SOURCE: R&D Focus Drug News (***18 Aug 1997***).

WORD COUNT: 26

L5 ANSWER 193 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 97:556 IMSDRUGNEWS

TITLE: trafermin Scios phase change II, USA (***coronary***
 artery ***disease***)

SOURCE: R&D Focus Drug News (***3 Mar 1997***).

WORD COUNT: 43

L5 ANSWER 194 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 96:3214 IMSDRUGNEWS

TITLE: trafermin Scios, Wyeth Ayerst licensing agreement

SOURCE: R&D Focus Drug News (***4 Nov 1996***).

WORD COUNT: 93

L5 ANSWER 195 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 96:1488 IMSDRUGNEWS

TITLE: gene therapy, cardiovascular disease GenVec, Scios
 licensing agreement

SOURCE: R&D Focus Drug News (***24 Jun 1996***).

WORD COUNT: 59

L5 ANSWER 196 OF 549 IMSRESEARCH COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:1157 IMSRESEARCH

-----+-----+-----
| Ludwig Institute | United States
| for Cancer |
| Research |

L5 ANSWER 198 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1011012836 JICST-EPlus
TI Gene Therapy Update in Cardiovascular Disease.
AU SYMES J F
CS Tufts Univ. School Of Medicine, Usa
SO Jpn Circ J, (2000) vol. 64, no. Satellite Seminar Abstracts, pp. 104-105.
Journal Code: F0908A
CODEN: NJUGAK; ISSN: 0047-1828
CY Japan
DT Journal; Preprint
LA English
STA New

L5 ANSWER 199 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1010449915 JICST-EPlus
TI Therapeutic Angiogenesis Induced by Hepatocyte Growth Factor: Potential
Gene Therapy for Ischemic diseases.
AU AOKI M; MORISHITA R; TANIYAMA Y; KANEDA Y; OGIIHARA T
CS Osaka Univ. Medical School, Osaka, Jpn
SO J Atheroscler Thromb, (2000) vol. 7, no. 2, pp. 71-76. Journal Code:
L2187A (Fig. 5, Ref. 29)
ISSN: 1340-3478
CY Japan
DT Journal; Preprint
LA English
STA New

L5 ANSWER 200 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1010355801 JICST-EPlus
TI Myocardial ischemia enhances the expression of acidic fibroblast growth

CS Todai Daigakuin'igakukeikenkyuka
Yamaguchi Univ., Sch. of Med.
SO Seibutsu Butsuri Kagaku (Japanese Journal of Electrophoresis), (2000) vol.
44, no. 4, pp. 257-259. Journal Code: G0565A (Ref. 13)
CODEN: SBBKA4; ISSN: 0031-9082
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L5 ANSWER 203 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000916109 JICST-EPlus
TI Transplantation and regenerative medicine - present situation of study and
prospect. Heart and blood vessel.
AU KOIKE HIROMI; MORISHITA RYUICHI; KANEDA YASUFUMI
CS Osaka Univ., Grad. Sch.
SO Karento Terapi (Current Therapy), (2000) vol. 18, no. 10, pp. 1847-1851.
Journal Code: G0171B (Fig. 1, Tbl. 1, Ref. 14)
ISSN: 0287-8445
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 204 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000846517 JICST-EPlus
TI Remodeling of Coronary Artery Lesions Due to Kawasaki Disease.
AU SUZUKI A
MIYAGAWA-TOMITA S; NAKAZAWA M
YUTANI C
CS Tokyo Teishin Hospital, Jpn
Tokyo Women's Medical Univ., Tokyo, Jpn
National Cardiovascular Center, Osaka, Jpn
SO Jpn Heart J, (2000) vol. 41, no. 3, pp. 245-256. Journal Code: Z0752A
(Fig. 4, Ref. 22)
ISSN: 0021-4868

TI Gene Therapy for Ischemic Disease.
AU KOIKE HIROMI; MORISHITA RYUICHI
CS Osaka Univ., Grad. Sch.
SO Saibo Kogaku (Cell Technology), (2000) vol. 19, no. 8, pp. 1166-1171.
Journal Code: Y0229A (Fig. 3, Ref. 8)
ISSN: 0287-3796
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 208 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000627035 JICST-EPlus
TI Pericardial Fluid From Patients With Ischemic Heart Disease Accelerates
the Growth of Human Vascular Smooth Muscle Cells.
AU YONEDA T; FUJITA M; KIHARA Y; HASEGAWA K; INANAMI M; NOHARA R; SASAYAMA S
SAWAMURA T
TANAKA T
CS Kyoto Univ., Kyoto, Jpn
National Cardiovasular Center Res. Inst., Osaka, Jpn
Takeda Hospital, Kyoto, Jpn
SO Jpn Circ J, (2000) vol. 64, no. 7, pp. 495-498. Journal Code: F0908A (Fig.
3, Ref. 13)
CODEN: NJUGAK; ISSN: 0047-1828
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 209 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000456471 JICST-EPlus
TI Basic Fibroblast Growth Factor Inhibits Lipopolysaccharide-induced
Apoptosis in Cardiac Myocytes.
AU IWAI-KANAI E; HASEGAWA K; ARAKI M; FUJITA M; KAKITA T; MORIMOTO T;
SASAYAMA S
CS Kyoto Univ., Kyoto, Jpn

TI Gene Therapy for ASO: Toward the clinical trial.
AU AOKI MOTOKUNI; MORISHITA RYUICHI
CS Osaka Univ., Grad. Sch.
SO Idenshi Igaku, (2000) vol. 4, no. 1, pp. 151-155. Journal Code: L3408A
(Fig. 6, Ref. 7)
ISSN: 1343-0971
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 213 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000256799 JICST-EPlus
TI ***VEGF*** and vasculoangiogenesis/vascular remodeling.
AU ITO HIROSHI; NAKAO KAZUWA
CS Kyoto Univ., Grad. Sch.
SO Nippon Rinsho (Japanese Journal of Clinical Medicine), (2000) vol. 58, pp.
200-205. Journal Code: Z0679A (Fig. 7, Ref. 20)
ISSN: 0047-1852
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 214 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189138 JICST-EPlus
TI Cytokines in pericardial fluid collected at open heart surgery.
AU TOMIZAWA YASUKO; ENDO MASAHIRO; NISHIDA HIROSHI; IMAI YASUHARU; ISHIZUKA
TSUTOMU; HAYASHI TETSUO; KOYANAGI HITOSHI
CS Tokyo Women's Medical College, Heart Inst. of Japan
SO Coronary, (1999) vol. 16, no. 4, pp. 288-292. Journal Code: Y0812A (Fig.
3, Ref. 13)
ISSN: 0910-3031
CY Japan
DT Journal; Article
LA Japanese

TI Gene therapy for cardiovascular diseases.
AU AOKI MOTOKUNI
MORISHITA RYUICHI
CS Osaka Univ., Med. Sch.
Osaka Univ., Grad. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000)
vol. 192, no. 3, pp. 205-208. Journal Code: Z0649A (Fig. 4, Ref. 3)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 218 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189066 JICST-EPlus
TI History and prospect of angiogenic therapy.
AU UCHIDA YASUMI; KANAI MASAHIKO
UCHIDA HARUKO
UCHIDA YUKO
OGAWA MUNEYUKI
CS Toho Univ. School of Medicine., Sakura Hospital
Univ. of Tokyo, Fac. of Med.
Chiba Univ., Sch. of Med.
Jikei Univ. School of Medicine
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000)
vol. 192, no. 1, pp. 128-133. Journal Code: Z0649A (Fig. 3, Ref. 16)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 219 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189064 JICST-EPlus
TI Gene therapy for restenosis.
AU AOKI MOTOKUNI; MORISHITA RYUICHI

L5 ANSWER 222 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000122237 JICST-EPlus
TI New Development of Genetic Medicine. Gene Therapy for Cardiovascular Diseases.
AU AOKI MOTOKUNI; MORISHITA RYUICHI; KANEDA YASUFUMI
CS Osaka Univ.
SO Saishin Igaku, (2000) vol. 55, no. 1, pp. 38-43. Journal Code: Z0358A
(Fig. 4, Ref. 7)
CODEN: SAIGAK; ISSN: 0370-8241
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 223 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000055956 JICST-EPlus
TI The Angiogenesis Therapy using ***VEGF*** .
AU TAKESHITA SATOSHI
CS Teikyo Univ., Sch. of Med.
SO Ther Res, (1999) vol. 20, no. 11, pp. 3035-3040. Journal Code: Y0681A
(Fig. 2, Ref. 22)
ISSN: 0289-8020
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 224 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000050410 JICST-EPlus
TI Vascular Medicine. Therapeutic angiogenesis.
AU ASAHARA TAKAYUKI; IWAGURO HIDEKI
CS St. Elizabeth's Medical Center Cardiovascular Res. And Medicine
SO Bio Clin, (1999) vol. 14, no. 14, pp. 1254-1260. Journal Code: L0059A
(Fig. 3, Ref. 19)
ISSN: 0919-8237

CS Osaka City Univ., Med. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1999)
vol. 191, no. 5, pp. 505-508. Journal Code: Z0649A (Fig. 3, Ref. 34)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 228 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990991097 JICST-EPlus
TI Elucidation of intracellular information transfer mechanism in the
myocardial ischemia reperfusion injury and the establishment of the
anti-adhesion molecule therapy.
AU SEKO YOSHINORI
CS Univ. of Tokyo, Fac. of Med.
SO Sankyo Seimei Kagaku Kenkyu Shinko Zaidan Kenkyu Hokokushu, (1999) vol.
14, pp. 99-109. Journal Code: L2409A (Fig. 7, Ref. 8)
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 229 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990985611 JICST-EPlus
TI Combination of Physiology and Molecular Biology in Cardiology. Ischemic
Myocardium Disorders and Treatment.
AU KITAKAZE MASAFUMI; KUZUYA TSUNEHIKO; HORI MASATSUGU
CS Osaka Univ., Grad. Sch.
SO Junkanki Senmon'i, (1999) vol. 7, no. 2, pp. 215-223. Journal Code: L1766A
(Fig. 6, Tbl. 3, Ref. 19)
ISSN: 0918-9599
CY Japan
DT Journal; Commentary
LA Japanese
STA New

SO Gekkan Soshiki Baiyo Kogaku (Tissue Culture Engineering), (1999) vol. 25,
no. 11, pp. 447-451. Journal Code: F0781B (Fig. 5, Ref. 9)

ISSN: 0386-1791

CY Japan

DT Journal; General Review

LA Japanese

STA New

L5 ANSWER 233 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 990880725 JICST-EPlus

TI Ischemic heart disease handbooks. Angina pectoris and asymptomatic myocardial ischemia. Present of gene therapy for the angina pectoris.

AU AOKI MOTOKUNI; MORISHITA RYUICHI

CS Osaka Univ., Grad. Sch.

SO Shindan to Chiryo (Diagnosis and Treatment), (1999) vol. 87, no. 9, pp.
1604-1609. Journal Code: Z0941A (Fig. 3, Tbl. 2, Ref. 6)

ISSN: 0370-999X

CY Japan

DT Journal; Commentary

LA Japanese

STA New

L5 ANSWER 234 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 990874402 JICST-EPlus

TI Co-localized expression of vascular endothelial growth factor(***VEGF***) and its receptor in atherectomy specimens mediates restenosis after coronary angioplasty.

AU SAKOMURA YASUNARI; YAMAGUCHI JUN'ICHI; TSURUMI YUKIO; KAWANA MASATOSHI;
KASANUKI HIROSHI

CS Tokyo Women's Medical College, Heart Inst. of Japan

SO Tokyo Joshi Ika Daigaku Sogo Kenkyujo Kiyo, (1998) vol. 19, pp. 72-73.
Journal Code: L0631A (Ref. 3)

ISSN: 0911-4491

CY Japan

DT Journal; Short Communication

LA Japanese

AN 990719527 JICST-EPlus
TI Rehabilitation of heart failure. Cure. 8-b. Exercise therapy for ischemic heart disease with complication. Exercise therapy for angina pectoris.
AU FUJITA MASATOSHI
CS Kyoto Univ., Coll. of Med. Technol.
SO Heart View, (1999) vol. 3, no. 8, pp. 867-870. Journal Code: L3359A (Fig. 3, Ref. 18)
ISSN: 1342-6591
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 238 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 990709417 JICST-EPlus
TI Recent topics on common diseases. Circulatory organ. Ischemic heart disease.
AU OGAWA HISAO
CS Kumamoto Univ., Med. Sch.
SO Gendai Iryo, (1999) vol. 31, no. 7, pp. 1637-1642. Journal Code: Z0273B (Fig. 2, Tbl. 1, Ref. 12)
ISSN: 0533-7259
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 239 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 990705297 JICST-EPlus
TI Heart failure carried over from childhood. 11. Blood vessel remodeling in distal stage of kawasaki disease coronary artery failure.
AU SUZUKI JUNKO
TOMITA SACHIKO; BOKU JINSAN; NAKAZAWA MAKOTO
CS Tokyo Posts. and Telecommun. Hosp.
Tokyo Women's Medical College, Heart Inst. of Japan

AN 990550807 JICST-EPlus
TI Gene therapy for atherosclerosis.
AU MORISHITA RYUICHI; OGIHARA TOSHIO; KANEDA YASUFUMI
CS Osaka Univ., Grad. Sch.
SO Idenshi Igaku, (1999) vol. 3, no. 2, pp. 326-331. Journal Code: L3408A
(Fig. 3, Tbl. 1, Ref. 25)
ISSN: 1343-0971
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 243 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990509421 JICST-EPlus
TI A Study to Determine if Basic Fibroblast Growth Factor(***bFGF***)
Reduces Myocardial Infarct Size in Acute Coronary Arterial Occlusion.
AU SASAME A; NAKAJIMA H; TAMURA K; MIYAGI M; RAKUE H; USUI M; KATOH T; NAITOH
Y; IBUKIYAMA C
CS Tokyo Medical Univ., Tokyo, Jpn
SO Jpn Heart J, (1999) vol. 40, no. 2, pp. 165-178. Journal Code: Z0752A
(Fig. 6, Ref. 35)
ISSN: 0021-4868
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 244 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990509187 JICST-EPlus
TI Therapeutic Angiogenesis for Ischemic Heart Disease.
AU TAKESHITA SATOSHI
CS Teikyo Univ., Sch. of Med.
SO Kokyu to Junkan (Respiration and Circulation), (1999) vol. 47, no. 5, pp.
449-453. Journal Code: Z0660A (Ref. 18)
ISSN: 0452-3458
CY Japan

CS Osaka City Univ., Med. Sch.
SO Ther Res, (1999) vol. 20, no. 3, pp. 587-595. Journal Code: Y0681A (Fig.
6, Ref. 19)
ISSN: 0289-8020
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 248 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990399674 JICST-EPlus
TI Elevated Circulating Levels of Basic Fibroblast Growth Factor and Vascular
Endothelial Growth Factor in Patients With Acute Myocardial Infarction.
AU TAMURA K; NAKAJIMA H; RAKUE H; SASAME A; NAITO Y; NAGAI Y; IBUKIYAMA C
CS Tokyo Medical Univ., Tokyo, Jpn
SO Jpn Circ J, (1999) vol. 63, no. 5, pp. 357-361. Journal Code: F0908A (Fig.
2, Ref. 40)
CODEN: NJUGAK; ISSN: 0047-1828

CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 249 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990371647 JICST-EPlus
TI Effect of Angiogenic Therapy with Vascular Endothelial Growth Factor for
Acute Myocardial Infarction.
AU HARA TAKESHI; NAITO YUICHI; NAKAJIMA HITOSHI; TAMURA KEN; IBUKIYAMA
CHIHARU
CS Tokyo Medical College
SO Nippon Rinsho Seiri Gakkai Zasshi (Japanese Journal of Applied
Physiology), (1999) vol. 29, no. 1, pp. 5-13. Journal Code: Y0689A (Fig.
7, Ref. 23)
ISSN: 0286-7052
CY Japan
DT Journal; Article

the kawasaki disease remoteness stage. The second report.

AU SUZUKI ATSUKO
TOMITA SACHIKO; NAKAZAWA MAKOTO; KOMATSU KEIKO

CS Tokyo Posts. and Telecommun. Hosp.
Tokyo Women's Medical Coll.

SO Prog Med, (1998) vol. 18, no. 7, pp. 1594-1599. Journal Code: F0664B (Fig. 5, Ref. 11)
ISSN: 0287-3648

CY Japan

DT Journal; Short Communication

LA Japanese

STA New

L5 ANSWER 253 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980640272 JICST-EPlus

TI Approach to the elucidation of disease state.By what reason multiple risk factor syndrome causes the arteriosclerosis. 3.Mechanism of crisis of arteriosclerosis in hyperlipidemia. Significance of arterialization factor ***VEGF*** .

AU ITO YUTAKA; NAKAO KAZUYASU

CS Kyoto Univ., Graduate School

SO Mebio, (1998) vol. 15, pp. 104-110. Journal Code: X0106A (Fig. 9, Tbl. 2, Ref. 7)
ISSN: 0910-0474

CY Japan

DT Journal; Commentary

LA Japanese

STA New

L5 ANSWER 254 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980612724 JICST-EPlus

TI Molecular-biological approach of cardiovascular disease.From the basic to the clinic.The control using the gene of the restenosis after the PTCA.

AU MATSUSHITA HIDETSUGU; MORISHITA RYUICHI; OGAWARA TOSHIO

CS Osaka Univ., Med. Sch.

SO Junkan Kagaku (Circulation Science), (1998) vol. 18, no. 6, pp. 536-539.

L5 ANSWER 257 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980325579 JICST-EPlus
TI Effects of Transient Coronary Occlusion on the Capillary Network in the Left Ventricle of Rat.
AU XIE Z; GAO M; KOYAMA T
CS Hokkaido Univ., Sapporo, JPN
SO Jpn J Physiol, (1997) vol. 47, no. 6, pp. 537-543. Journal Code: Z0753A (Fig. 5, Tbl. 1, Ref. 17)
CODEN: JJPHAM; ISSN: 0021-521X
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 258 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980264305 JICST-EPlus
TI Regulation and failure of coronary circulation. Coronary collateral circulation.
AU FUJITA MASATOSHI
CS Kyoto Univ., Coll. of Med. Technol.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1998) pp. 89-93. Journal Code: Z0649A (Fig. 4, Ref. 18)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 259 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 970989373 JICST-EPlus
TI Experimental study of effects of adenosine on angiogenesis in rat myocardial infarction.
AU KOBAYASHI MASAO; ABE GEN; SHIMIZU HIROSHI; OGAWA YASUHIKO; OMOTO NAOKI; MATSUOKA KAZUSHI; KAWAMURA KOICHI; MASUDA HIROTAKE; MIURA MAMORU
CS Akita Univ., Sch. of Med.
SO Shinkin no Kozo to Taisha (Cardiac Structure and Metabolism), (1997) vol.

TI Coronary collateral circulation.
AU FUJITA MASATOSHI
CS Kyoto Univ., Coll. of Med. Technol.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1996)
vol. 179, no. 10, pp. 835-839. Journal Code: Z0649A (Fig. 4, Ref. 18)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 263 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 970062755 JICST-EPlus
TI Vascular remodeling.
AU FUJIKAWA HIDEYUKI; SHIMADA KAZUYUKI
CS Jichi Med. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1996)
vol. 179, no. 10, pp. 809-814. Journal Code: Z0649A (Fig. 3, Tbl. 1, Ref.
24)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 264 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 970002451 JICST-EPlus
TI Ischemic heart disease. New development of treatment and prevention.
Gene therapy for post PTCA restenosis.
AU MORISHITA RYUICHI; HIGAKI TSUNEO; OGAWARA TOSHIO
CS Osaka Univ., Med. Sch.
SO Rinsho Kagaku (Journal of Clinical Science), (1996) vol. 32, no. 11, pp.
1419-1425. Journal Code: Z0350B (Fig. 5, Tbl. 3, Ref. 23)
ISSN: 0385-0323
CY Japan
DT Journal; Commentary

infarction.

AU SHINOHARA K; SHINOHARA T; MOCHIZUKI N; MOCHIZUKI Y; SAWA H; KOHYA T;
FUJITA M; FUJIOKA Y; NAGASHIMA K
CS Hokkaido Univ. School of Medicine, Sapporo, JPN
SO Heart Vessels, (1996) vol. 11, no. 3, pp. 113-122. Journal Code: X0101A
(Fig. 7, Tbl. 2, Ref. 33)
ISSN: 0910-8327
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 268 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960813551 JICST-EPlus
TI Roles of inflammatory cytokine/growth factor in coronary sclerosis and
crown twitch.
AU ITO AKIRA; SHIMOKAWA HIROAKI; FUKUMOTO YOSHIHIRO; KADOKAMI TOSHIAKI;
FURUZAI TOSHIYUKI; KUWATA KOICHI; YAMAWAKI TOORU; EGASHIRA KENSUKE;
TAKESHITA AKIRA
CS Kyushu Univ., Fac. of Med.
SO Ther Res, (1996) vol. 17, no. 8, pp. 3239-3247. Journal Code: Y0681A (Fig.
10, Ref. 4)
ISSN: 0289-8020
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 269 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960765728 JICST-EPlus
TI Therapeutic angiogenesis and its clinical applications.
AU TAKESHITA SATORU
CS Teikyo Univ., Sch. of Med.
SO Jikken Igaku (Experimental Medicine), (1996) vol. 14, no. 15, pp.
2160-2162. Journal Code: Y0568A (Fig. 2, Ref. 8)
ISSN: 0288-5514

TI Contralateral arterial bolus injection of 30 micrograms of basic fibroblast growth factor failed to augment myocardial blood flow in infarcted myocardium in dogs.

AU MIYATAKA M; ISHIKAWA K; OGAWA I; KOKA H; NAKAI S; KINO H; INAGAKI M; KIMURA A; KATORI R

CS Kinki Univ. School of Medicine, Osaka, JPN

SO Acta Med Kinki Univ, (1996) vol. 21, no. 1, pp. 53-58. Journal Code: S0990A (Tbl. 3, Ref. 22)

ISSN: 0386-6092

CY Japan

DT Journal; Article

LA English

STA New

L5 ANSWER 273 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 960220340 JICST-EPlus

TI ***Coronary*** ***artery*** ***disease*** of dialysis patient. Coronary circulation adjustment and disease state. (2). The control of vascular endothelial cell proliferation.

AU KUZUYA TSUNEHIKO; NISHIDA MASASHI; TADA MICHIHIKO

CS Osaka Univ., Med. Sch.

SO Rinsho Toseki (Japanese Journal of Clinical Dialysis), (1996) vol. 12, no. 2, pp. 171-174. Journal Code: X0146A (Fig. 1, Ref. 7)

ISSN: 0910-5808

CY Japan

DT Journal; General Review

LA Japanese

STA New

L5 ANSWER 274 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 960101131 JICST-EPlus

TI Elastase and cell matrix interactions in the pathobiology of vascular disease.

AU RABINOVITCH M

CS Univ. Toronto, Ontario, CAN

SO Acta Paediatr Jpn, (1995) vol. 37, no. 6, pp. 657-666. Journal Code:

STA New

L5 ANSWER 277 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950854178 JICST-EPlus
TI Effect of Basic Fibroblast Growth Factor(b-FGF) in Expansion and
Remodeling after Acute Myocardial Infarction.
AU WANG D Y; NAGAO KEN; WATANABE IKUYOSHI; KANMATSUSE KATSUO
CS Nihon Univ., Sch. of Med.
SO Nichidai Igaku Zasshi (Journal of Nihon University Medical Association),
(1995) vol. 54, no. 5, pp. 304-309. Journal Code: F0911A (Fig. 4, Tbl. 2,
Ref. 17)
CODEN: NICHAS; ISSN: 0029-0424
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 278 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950758711 JICST-EPlus
TI Recent view on coronal collateral circulation.
AU SHINOYAMA SHIGETAKE
CS Kyoto Univ., Fac. of Med.
SO Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine),
(1995) vol. 72, no. 8, pp. 2025-2035. Journal Code: Z0376B (Fig. 10, Ref.
35)
ISSN: 0021-4965
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 279 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950751806 JICST-EPlus
TI Q&A for acute myocardial infarction Therapeutic angiogenesis.
AU TAKESHITA SATOSHI; SATO TOMOHIDE
CS Teikyo Univ., Sch. of Med.

STA New

L5 ANSWER 282 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950365635 JICST-EPlus
TI Angiogenesis by ***bFGF*** .
AU UCHIDA YASUMI; MIWA ATSUKO
CS Univ. of Tokyo, Fac. of Med.
SO Coronary, (1995) vol. 12, no. 1, pp. 33-40. Journal Code: Y0812A (Fig. 9,
Ref. 26)
ISSN: 0910-3031
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 283 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950262206 JICST-EPlus
TI Coronary collateral vessels and fibroblast growth factor.
AU UCHIDA YASUMI; MIWA ATSUKO
CS Univ. of Tokyo, Fac. of Med.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1995)
vol. 172, no. 9, pp. 594-598. Journal Code: Z0649A (Fig. 4, Ref. 26)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 284 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950196851 JICST-EPlus
TI Current Perspectives on the Problem of Ischemic Heart Disease.
Angiogenesis and Coronary Collateral Development.
AU UCHIDA YASUMI; MIWA ATSUKO
CS Univ. of Tokyo, Fac. of Med.
SO Saishin Igaku, (1995) vol. 50, no. 2, pp. 218-226. Journal Code: Z0358A
(Fig. 9, Ref. 26)

DT Journal; Commentary

LA English

STA New

L5 ANSWER 287 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 940756922 JICST-EPlus

TI The Expression and the Role of Vascular Endothelial Growth Factor(***VEGF***) in Human Normal and Myocardial Infarcted Heart.

AU SHINOHARA KAHORU

CS Hokkaido Univ., Sch. of Med.

SO Hokkaido Igaku Zasshi (Hokkaido Journal of Medical Science), (1994) vol. 69, no. 4, pp. 978-989, 991, 993. Journal Code: Z0749A (Fig. 7, Tbl. 2, Ref. 20)

ISSN: 0367-6102

CY Japan

DT Journal; Article

LA Japanese

STA New

L5 ANSWER 288 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 940112450 JICST-EPlus

TI Angiogenic therapy by basic fibroblast growth factor for myocardial infarction.

AU MIWAVYANAGISAWA ATSUKO; UCHIDA YASUMI

ITO HIDEKI

CS Univ. of Tokyo, Faculty of Medicine

Tokyotorojin'iryosenta

SO Rinsho Men'eki (Clinical Immunology), (1994) vol. 26, no. 1, pp. 99-106. Journal Code: Z0528B (Fig. 5, Tbl. 2, Ref. 23)

ISSN: 0386-9695

CY Japan

DT Journal; General Review

LA Japanese

STA New

L5 ANSWER 289 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

HIDEAKI; SUGIMOTO TSUNEAKI
YOSHITAKE YOSHINO
ITO HIDEKI
KAJI KAZUHIKO

CS Univ. of Tokyo, Faculty of Medicine
Tokyotorojin'iryosenta
Tokyo Metrop. Inst. of Gerontology
Kanazawa Medical Univ.

SO Myakkangaku (Journal of Japanese College of Angiology), (1992) vol. 32,
no. 11, pp. 1229-1234. Journal Code: Z0216B (Fig. 8, Ref. 11)
ISSN: 0387-1126

CY Japan

DT Journal; Article

LA Japanese

STA New

L5 ANSWER 292 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930074736 JICST-EPlus
TI Hypoxia Induces the Alterations in Endothelial Cell Growth.
AU OGAWA SATOSHI; MATSUMOTO MASAYASU; MAEDA YUSUKE; KAMADA TAKENOB
KUWABARA KEISUKE; KOGA SHIN; KOGA YUKI; STERN D
CS Osaka Univ., Medical School
Koronbiadai
SO Myakkangaku (Journal of Japanese College of Angiology), (1992) vol. 32,
no. 11, pp. 1225-1228. Journal Code: Z0216B (Fig. 4, Ref. 8)
ISSN: 0387-1126

CY Japan

DT Journal; Article

LA Japanese

STA New

L5 ANSWER 293 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930074735 JICST-EPlus
TI The Role of Basic Fibroblast Growth Factor in the Developemtn of
Collateral Circulation.
AU CHIBA MICHIO; SUMIDA EMIKO; SUMIDA EIJI; TANAKA MASASHI; OKA NAOKI; KUWANO

ISSN: 0029-0203

--

CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 296 OF 549 MEDLINE on STN
AN 2003455187 MEDLINE
DN PubMed ID: 14517380
TI Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
AU Fujita M; Ikemoto M; Tanaka T; Tamaki S; Yamazato A; Sawamura T; Hasegawa K; Kihara Y; Nohara R; Sasayama S
CS College of Medical Technology, Kyoto University, Kyoto 606-01, Japan.
SO Angiogenesis, *** (1998) *** 2 (1) 105-8.
Journal code: 9814575. ISSN: 0969-6970.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; PUBMED-NOT-MEDLINE
EM 200310
ED Entered STN: 20031001
Last Updated on STN: 20031011
Entered Medline: 20031010

L5 ANSWER 297 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN
AN 2000-0358764 PASCAL
CP Copyright .COPYRGT. 2000 INIST-CNRS. All rights reserved.
TIEN Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris
AU UNGER E. F.; GONCALVES L.; EPSTEIN S. E.; CHEW E. Y.; TRAPNELL C. B.; CANNON R. O. III; QUYYUMI A. A.; STINE A.; LOSCALZO J.; STIBER J. A.
CS Cardiology Branch, National Heart, Lung, and Blood Institute, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United

L5 ANSWER 299 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS
RESERVED. on STN

AN 1998-0489871 PASCAL

CP Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.

TIEN Effects of ***coronary*** ***artery*** ***disease*** on
expression and microvascular response to ***VEGF***

AU METAIS C.; JIANYI LI; JIAN LI; SIMONS M.; SELLKE F. W.

CS Division of Cardiothoracic Surgery, Department of Surgery, of the Beth
Israel-Deaconess Medical Center and Harvard Medical School, Boston,
Massachusetts 02215, United States; Cardiovascular Division, Department
of Medicine of Beth Israel-Deaconess Medical Center and Harvard Medical
School, Boston, Massachusetts 02215, United States

SO American journal of physiology. Heart and circulatory physiology,
(1998) , 44(4), H1411-H1418, 48 refs.
ISSN: 0363-6135 CODEN: AJPPDI

DT Journal

BL Analytic

CY United States

LA English

AV INIST-670D, 354000070093100360

L5 ANSWER 300 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS
RESERVED. on STN

AN 1998-0161236 PASCAL

CP Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.

TIEN Growth factors as a potential new treatment for ischemic heart disease:
Endothelial dysfunction, the renin-angiotensin system, and nitric oxide:
impact on ***coronary*** ***artery*** ***disease*** and
therapeutic interventions

AU BAUTERS C.
PEPINE Carl J. (ed.)

CS Service de Cardiologie B et Hemodynamique, Hopital Cardiologique,
Universite de Lille, Lille, France
Division of Cardiovascular Medicine, University of Florida College of
Medicine, Gainesville, Florida, United States

L5 ANSWER 305 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1645746 PHARMAML
TI Genentech disappointed by Phase II rhVEGF165 data
SO Marketletter February 22, 1999
DT Newsletter
WC 503

L5 ANSWER 306 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1641161 PHARMAML
TI Genentech Starts Trials Of Recombinant ***VEGF***
SO Marketletter April 3, 1998
DT Newsletter
WC 750

L5 ANSWER 307 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1640985 PHARMAML
TI ***VEGF*** Gene Therapy For CAD/PAD
SO Marketletter March 25, 1998
DT Newsletter
WC 61

L5 ANSWER 308 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1639829 PHARMAML
TI First Patient Gets Gene Therapy For CAD
SO Marketletter January 8, 1998
DT Newsletter
WC 296

L5 ANSWER 309 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2001:138 PHIN
DN B00689884
DED 1 Dec 2000
TI Twisted Genes A passing fashion? By Tim Searle
SO Bioventure-View (***2000***) No. 1512 p5
DT Newsletter

DN C00663242
DED 8 May 2000
TI Phase II CAD (***coronary*** ***artery*** ***disease***) gene therapy trials begin
SO Clinica (***2000***) No. 907 p16
DT Newsletter
FS BRIEF

L5 ANSWER 314 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:7020 PHIN
DN B00659202
DED 1 Apr 2000
TI COMPANY SNAPSHOT - Human Genome Sciences Inc. Rockville, MD * Nasdaq: HGSI
SO Bioventure-View (***2000***) No. 1504 p12
DT Newsletter
FS FULL

L5 ANSWER 315 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:5904 PHIN
DN C00658114
DED 20 Mar 2000
TI Researches say gene therapy trials for heart disease show promising results, despite FDA "caution"
SO Clinica (***2000***) No. 900 p15
DT Newsletter
FS FULL

L5 ANSWER 316 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 1999:17149 PHIN
DN S00638962
DED 1 Oct 1999
TI Chiron poised for new growth opportunities
SO Scrip (***1999***) No. 2477 p9

DN S00600330
DED 30 Oct 1998
TI Preclinical research update
SO Scrip (***1998***) No. 2383 p23
DT Newsletter
FS FULL

L5 ANSWER 321 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 97:16345 PHIN
DN S00551440
DED 10 Sep 1997
TI Parke-Davis and GenVec partnership
SO Scrip (***1997***) No. 2267 p9
DT Newsletter
FS FULL

L5 ANSWER 322 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 97:13715 PHIN
DN S00546366
DED 3 Jul 1997
TI Genentech earnings down, sales flat
SO Scrip (***1997***) No. 2253 p12
DT Newsletter
FS FULL

L5 ANSWER 323 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 96:21681 PHIN
DN S00517376
DED 29 Nov 1996
TI Scios' Natrecor moves into Phase III
SO Scrip (***1996***) No. 2185 p13
DT Newsletter
FS FULL

SOURCE: Applied Genetics News, (***Dec 2000***) Vol. 21, No. 5.
ISSN: 0271-7107.

PUBLISHER: Business Communications Company, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 214

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 328 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1116652 PROMT

TITLE: Human Genome Sciences Forms Biotech Deals. (Brief Article)

AUTHOR(S): PAPANIKOLAW, JIM

SOURCE: Chemical Market Reporter, (***6 Mar 2000***) Vol. 257,
No. 10, pp. 22.

ISSN: ISSN: 1092-0110.

PUBLISHER: Schnell Publishing Company, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 525

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 329 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1077662 PROMT

TITLE: GENVEC RAISES \$38M IN IPO FOR ADENOVECTOR TECHNOLOGY. (Brief
Article)

AUTHOR(S): Osborne, Randall

SOURCE: BIOWORLD Today, (***13 Dec 2000***) Vol. 11, No. 240.

PUBLISHER: American Health Consultants, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 371

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 330 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:939684 PROMT

TITLE: Newly Published Preclinical Study Demonstrates Relaxin Selectively Stimulates ***VEGF*** and ***bFGF*** at Ischemic Sites.

SOURCE: PR Newswire, (***31 Oct 2000***) pp. 6454.

PUBLISHER: PR Newswire Association, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 604

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 334 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:869511 PROMT

TITLE: GENVEC TRIES AGAIN FOR IPO, SEEKS \$50M FOR GENE PRODUCTS.

AUTHOR(S): Huggett, Brady

SOURCE: BIOWORLD Today, (***9 Oct 2000***) Vol. 11, No. 195.

PUBLISHER: American Health Consultants, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 517

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 335 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:851873 PROMT

TITLE: Genzyme Surgical Products Initiates Second Cardiovascular Gene Therapy Clinical Trial.

SOURCE: PR Newswire, (***2 Oct 2000***) pp. 7025.

PUBLISHER: PR Newswire Association, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 1439

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

LANGUAGE: English

WORD COUNT: 656

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 339 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:665667 PROMT

TITLE: Collateral Announces Expanded Angiogenic Gene Research
Collaboration With New York University.

SOURCE: PR Newswire, (***2 Aug 2000***) .

PUBLISHER: PR Newswire Association, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 703

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 340 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:588546 PROMT

TITLE: Transgene Selects Two Novel Cardiovascular Genes From Human
Genome Sciences for Gene Therapy Development.

SOURCE: PR Newswire, (***12 Jul 2000***) pp. 6625.

PUBLISHER: PR Newswire Association, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 2145

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 341 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:527148 PROMT

TITLE: REPAIR INC. PURSUING ANGIOGENIC THERAPIES BASED ON
FGF - ***1*** , FIBRIN.(Brief Article)

AUTHOR(S) : Welch, Mary

SOURCE: BIOWORLD Today, (***21 Jun 2000***) Vol. 11, No. 120.

PUBLISHER: American Health Consultants, Inc.

ACCESSION NUMBER: 2000:390881 PROMT
TITLE: gene therapy, cardiovascular disease GenVec begins phase II trial.(Brief Article)
SOURCE: R & D Focus Drug News, (***8 May 2000***) .
ISSN: 1350-1135.
PUBLISHER: IMS World Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 142
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 345 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:369841 PROMT
TITLE: Collateral Therapeutics Appoints John F. Warner Ph.D. Vice President Of Technology.
SOURCE: PR Newswire, (***9 May 2000***) .
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 787
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 346 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:316730 PROMT
TITLE: Human Genome Sciences Inc. Rockville, MD * Nasdaq: HGSI.(Brief Article) (Statistical Data Included)
SOURCE: BioVenture View, (***April 2000***) Vol. 15, No. 4, pp. 12.
ISSN: 0892-1903.
PUBLISHER: BioVenture Publishing
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 660
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 350 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:230890 PROMT

TITLE: GENE THERAPY: Naked Gene Delivery Service.(Brief Article)

SOURCE: Applied Genetics News, (***March 2000***) Vol. 20, No. 8.

ISSN: 0271-7107.

PUBLISHER: Business Communications Company, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 269

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 351 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:193460 PROMT

TITLE: Chiron ***FGF*** - ***2*** study in CAD
disappoints.(Brief Article)

SOURCE: Marketletter, (***20 Mar 2000***) .

ISSN: 0951-3175.

PUBLISHER: Marketletter Publications Ltd.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 375

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 352 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:187473 PROMT

TITLE: AMERICAN COLLEGE OF CARDIOLOGY'S SCIENTIFIC SESSION

CHIRON'S ***FGF*** - ***2*** REDUCES ANGINA, BUT
FAILS WITH PRIMARY ENDPOINT.

AUTHOR(S) : Pihl; Carey, Karen

SOURCE: BIOWORLD Today, (***14 Mar 2000***) Vol. 11, No. 49.

PHARMA.

AUTHOR(S) : Pihl; Carey, Karen
SOURCE: BIOWORLD Today, (***28 Feb 2000***) Vol. 11, No. 37.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 662

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 356 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:133836 PROMT
TITLE: Vical, Human Genome Sciences and Vascular Genetics Enter Strategic Collaboration.
SOURCE: Business Wire, (***25 Feb 2000***) pp. 43.
PUBLISHER: Business Wire
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 765

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 357 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:111745 PROMT
TITLE: Collateral Therapeutics announces issuance of United States patent for angiogenic growth factor gene ***Vegf*** -145. (Brief Article)
SOURCE: BIOTECH Patent News, (***Jan 2000***) Vol. 14, No. 1.
ISSN: 0898-2813.
PUBLISHER: Biotech Patent News
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 511

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 358 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:727610 PROMT
TITLE: Collateral Therapeutics Creates First Combination FGF/
 VEGF Gene For Non-Surgical Cardiovascular
 Angiogenesis.
SOURCE: PR Newswire, (***8 Nov 1999***) pp. 8563.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 695
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 362 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:654487 PROMT
TITLE: Scios Announces 1999 Third Quarter Financial Results.
SOURCE: PR Newswire, (***8 Oct 1999***) pp. 2565.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1696
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 363 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:527351 PROMT
TITLE: COLLATERAL THERAPEUTICS RAISES \$33.9M IN PRIVATE PLACEMENT.
AUTHOR(S) : Seachrist, Lisa
SOURCE: BIOWORLD Today, (***13 Aug 1999***) Vol. 10, No. 156.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 562
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 364 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:376201 PROMT

TITLE: Biosense Webster Announces Collaboration with Vascular Genetics Inc. on Catheter Delivery of Gene Therapy to Treat Cardiac Disease.

SOURCE: PR Newswire, (***10 Jun 1999***) pp. 6525.

PUBLISHER: PR Newswire Association, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 448

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 1999:329291 PROMT

TITLE: Trimedyne Subsidiary Enters Gene Therapy Collaboration With Endovasc Ltd. Inc.

SOURCE: Business Wire, (***20 May 1999***) pp. 1125.

PUBLISHER: Business Wire

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 452

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 1999:273148 PROMT

TITLE: Megabios Acquires Angiogenesis Gene.

SOURCE: PR Newswire, (***27 Apr 1999***) pp. 3938.

PUBLISHER: PR Newswire Association, Inc.

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 764

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 1999:175526 PROMT
TITLE: Genentech disappointed by Phase II rhVEGF165 data.
SOURCE: Marketletter, (***1 Mar 1999***) .
ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 504
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 374 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:162782 PROMT
TITLE: Megabios and GeneMedicine Complete Merger.
SOURCE: PR Newswire, (***19 Mar 1999***) pp. 8437.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 636
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 375 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:145715 PROMT
TITLE: vascular endothelial growth factor Genentech considers
product future.
..
SOURCE: R & D Focus Drug News, (***3 Mar 1999***) .
ISSN: 1350-1135.
PUBLISHER: IMSWorld Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 90
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 376 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:40475 PROMT
TITLE: Genzyme General Forms Collaboration to Develop Cell Therapies for Cardiovascular Disease.
SOURCE: PR Newswire, (***21 Jan 1999***) pp. 8640.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2579
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 1999:21785 PROMT
TITLE: Gene therapy, ***VEGF*** -2, Vascular Genetics Vascular Genetics IND allowed.
SOURCE: R & D Focus Drug News, (***11 Jan 1999***) pp. NA(1).
ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 106
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 1998:687886 PROMT
TITLE: GENENTECH: Year-end results show growth plan on track
SOURCE: M2 Presswire, (***26 Jan 1998***) .
PUBLISHER: M2 Communications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1687
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

SOURCE: The Lancet, (***14 Nov 1998***) pp. 1603(1).

ISSN: 0099-5355.

LANGUAGE: English

WORD COUNT: 794

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 386 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:567527 PROMT

TITLE: Angiogenesis May Be Stimulated by EECP(R) Therapy.

SOURCE: PR Newswire, (***4 Nov 1998***) pp. 5638.

LANGUAGE: English

WORD COUNT: 221

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 387 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:553344 PROMT

TITLE: angiopoietin 1 Regeneron, Procter & Gamble preclinical data.

SOURCE: R & D Focus Drug News, (***2 Nov 1998***) pp. NA(1).

ISSN: 1350-1135.

LANGUAGE: English

WORD COUNT: 233

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 388 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:469943 PROMT

TITLE: Gene therapy, vascular endothelial growth factor B
Collateral Therapeutics, Ludwig Institute for Cancer Research, AMRAD licensing termination

SOURCE: R & D Focus Drug News, (***14 Sep 1998***) pp. N/A.

ISSN: 1350-1135.

LANGUAGE: English

WORD COUNT: 171

TITLE: COLLATERAL THERAPEUTICS WINS ANGIOGENESIS GENES PATENT By
Randall Osborne Staff Writer

SOURCE: BIOWORLD Today, (***12 Aug 1998***) pp. N/A.

LANGUAGE: English

WORD COUNT: 401

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 393 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:398071 PROMT

TITLE: GENVEC WITHDRAWS IPO; BLAMES UNSTABLE MARKET CONDITIONS

SOURCE: BIOWORLD Today, (***4 Aug 1998***) pp. N/A.

LANGUAGE: English

WORD COUNT: 463

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 394 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:232468 PROMT

TITLE: Research Study Indicates That TMR Using The Heart Laser System Enhances The Effectiveness Of Gene Therapy For Heart Disease

SOURCE: PR Newswire, (***8 May 1998***) pp. 508NEF003.

LANGUAGE: English

WORD COUNT: 574

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 395 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:175708 PROMT

TITLE: DEVELOPMENTS IN BIOTECHNOLOGY :GeneMedicine-Cationic Lipid Gene Delivery System In Two Phase II Gene Therapy Angioplasty Clinical Trials

SOURCE: BioAccess, (***1 Apr 1998***) pp. N/A.
ISSN: 1356-3432.

LANGUAGE: English

ACCESSION NUMBER: 1998:64791 PROMT
TITLE: gene therapy, FGF-4, gene therapy, heart disease,
Collateral Therapeutics Collateral Therapeutics IND
submission Schering AG IND submission Schering AG
Collateral Therapeutics
SOURCE: R & D Focus Drug News, (***19 Jan 1998***) pp. N/A.
ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 209
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 400 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:41293 PROMT
TITLE: Genentech's Year-End Results Show Growth Plan on Track:
Earnings Increase Nine Percent on Revenues Exceeding \$1
Billion.
SOURCE: Business Wire, (***22 Jan 1998***) pp. 01220134.
LANGUAGE: English
WORD COUNT: 2029
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 401 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:32445 PROMT
TITLE: First Patient Gets Gene Therapy For CAD
SOURCE: Marketletter, (***19 Jan 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 297
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 402 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:17434 PROMT
TITLE: Collateral Therapeutics Announces Details of First

WORD COUNT:

675

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 406 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:445891 PROMT

TITLE: vascular endothelial growth factor Genentech phase change
I, USA

Vascular endothelial growth factor for ***coronary***
artery ***disease*** enters Phase II trials

SOURCE: R & D Focus Drug News, (***18 Aug 1997***) pp. N/A.
ISSN: 1350-1135.

LANGUAGE: English

WORD COUNT: 40

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 407 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:283114 PROMT

TITLE: Companies aim novel therapeutic strategies at dual nature
of angiogenesis.

Novel therapeutic strategies are being developed by several
biotechnology companies, based on dual nature of
angiogenesis

AUTHOR(S): Liszewski, Kathy

SOURCE: Genetic Engineering News, (***1 May 1997***) pp. 6.
ISSN: 0270-6377.

LANGUAGE: English

L5 ANSWER 408 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:77299 PROMT

TITLE: The Long and the Short of Business Development

SOURCE: Genesis Report-Rx, (***1 Dec 1996***) pp. N/A.
ISSN: 1061-2270.

LANGUAGE: English

ACCESSION NUMBER: 96:557916 PROMT

TITLE: Scios and Wyeth-Ayerst Announce Agreement to Develop
FIBLAST for Neurological and Cardiovascular Disorders

SOURCE: PR Newswire, (***23 Oct 1996***) pp. 1023SFW050.

LANGUAGE: English

WORD COUNT: 952

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 96:554482 PROMT

TITLE: Industry News (Licensing) Human iNOS Gene Licensed for Gene
Transfer Pharmaceutical Applications

SOURCE: Blood Weekly, (***21 Oct 1996***) pp. N/A.

ISSN: 1065-6073.

LANGUAGE: English

WORD COUNT: 562

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 96:521824 PROMT

TITLE: GenVec, Inc. Licenses The Human iNOS Gene From The
University of Pittsburgh For All Gene Transfer
Pharmaceutical Applications

SOURCE: PR Newswire, (***9 Oct 1996***) pp. 1009NYW003.

LANGUAGE: English

WORD COUNT: 777

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 96:388705 PROMT

TITLE: EUROPEAN PATENT OFFICE RULES IN FAVOR OF SCIOS FOR FIBLAST

L5 ANSWER 419 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:285146 PROMT

TITLE: GENVEC INC. LICENSES GENE FROM SCIOS INC. FOR BIOBYPASS
PRODUCT IN HEART AND VASCULAR DISEASE

SOURCE: PR Newswire, (***4 Jun 1996***) pp. 0604NYTU010.

LANGUAGE: English

WORD COUNT: 535

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 420 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:282152 PROMT

TITLE: COMPANY DEVELOPMENTS-Product Developments: SCIOS INC

SOURCE: Bioventure View, (***Jun 1996***) pp. N/A.

ISSN: 0892-1903.

LANGUAGE: English

WORD COUNT: 36

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 421 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:270947 PROMT

TITLE: Scios to patent method of producing recombinant human basic
fibroblast growth factor

SOURCE: BIOTECH Patent News, (***1 May 1996***) pp. N/A.

ISSN: 0898-2813.

LANGUAGE: English

WORD COUNT: 454

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 422 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:240262 PROMT

TITLE: SCIOS RECEIVES U.S. PATENT FOR THE RECOMBINANT PRODUCTION

SO KARDIOLOGIYA, (***OCT-DEC 2000***) Vol. 40, No. 12, pp. 82-86.
Publisher: IZD VO MEDITSINA, PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA.
ISSN: 0022-9040.

DT General Review; Journal
LA Russian
REC Reference Count: 43

L5 ANSWER 425 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 2000:779094 SCISEARCH
GA The Genuine Article (R) Number: 361YH
TI Angiogenesis and vasculogenesis. Therapeutic approaches for stimulation of post-natal neovascularization
AU Kalka C (Reprint); Asahara T; Krone W; Isner J M
CS TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT MED CARDIOVASC RES, 736 CAMBRIDGE ST, BOSTON, MA 02135 (Reprint); UNIV COLOGNE, KLIN & POLIKLIN INNERE MED 2, D-5000 COLOGNE 41, GERMANY
CYA USA; GERMANY
SO HERZ, (***SEP 2000***) Vol. 25, No. 6, pp. 611-622.
Publisher: URBAN & VOGEL, C/O SPRINGER GMBH & CO AUSLIEFERUNGSGESELLSCHAFT KUNDENSERVICE ZEITSCHRIFTEN, D-69126 HABERSTRASBE 7, GERMANY.
ISSN: 0340-9937.

DT Article; Journal
FS CLIN
LA German
REC Reference Count: 90
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 426 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 2000:598823 SCISEARCH
GA The Genuine Article (R) Number: 339PB
TI Adenovirus-mediated ***VEGF*** (121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia
AU Gowdak L H W; Poliakova L; Wang X T; Kovacs I; Fishbein K W; Zacheo A;

AN 1999:982252 SCISEARCH
GA The Genuine Article (R) Number: 265KJ
TI Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia
AU Sumino H; Nakamura T (Reprint); Ichikawa S; Kanda T; Sakamaki T; Sato K; Kobayashi I; Nagai R
CS GUNMA UNIV, SCH MED, DEPT INTERNAL MED 2, 3-39-22 SHOWA, MAEBASHI, GUMMA 3718511, JAPAN (Reprint); GUNMA UNIV, SCH MED, DEPT INTERNAL MED 2, MAEBASHI, GUMMA 3718511, JAPAN; CARDIOVASC HOSP CENT JAPAN, GUNMA 3770061, JAPAN; GUNMA UNIV, SCH MED, DEPT LAB MED, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT MED INFORMAT & DESIC SCI, MAEBASHI, GUMMA 371, JAPAN
CYA JAPAN
SO ATHEROSCLEROSIS, (***JAN 2000***) Vol. 148, No. 1, pp. 189-195.
Publisher: ELSEVIER SCI IRELAND LTD, CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND.
ISSN: 0021-9150.
DT Article; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 25

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 429 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN
AN 1999:654157 SCISEARCH
GA The Genuine Article (R) Number: 227QN
TI Increased production of cytokines and growth factors by aortic allografts:
A possible explanation for myointimal hyperplasia formation
AU Sterpetti A V (Reprint); Cucina A; Randone B; Guglielmi M B; Fragale A;
Cavallaro A
CS UNIV ROMA LA SAPIENZA, IST CLIN CHIRURG 1, LAB CASTRO LAURENZIANO, VIA A
SCARPA 14, I-00161 ROME, ITALY (Reprint); UNIV ROMA LA SAPIENZA, IST ISTOL
& EMBRIOL, I-00161 ROME, ITALY
CYA ITALY
SO EUROPEAN SURGICAL RESEARCH, (***JUL-AUG 1999***) Vol. 31, No. 4, pp.

AN 1998:758407 SCISEARCH
GA The Genuine Article (R) Number: 124DT
TI Effects of ***coronary*** ***artery*** ***disease*** on expression and microvascular response to ***VEGF***
AU Metais C; Li J Y; Li J; Simons M; Sellke F W (Reprint)
CS BETH ISRAEL DEACONESS MED CTR, DEPT SURG, DIV CARDIOTHORAC SURG, EAST CAMPUS, DANA 905, BOSTON, MA 02215 (Reprint); BETH ISRAEL DEACONESS MED CTR, DEPT SURG, DIV CARDIOTHORAC SURG, BOSTON, MA 02215; BETH ISRAEL DEACONESS MED CTR, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02215; HARVARD UNIV, SCH MED, BOSTON, MA 02215
CYA USA
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, (***OCT: *** 1998***) Vol. 44, No. 4, pp. H1411-H1418.
Publisher: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.
ISSN: 0363-6135.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 48
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 432 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1998:300195 SCISEARCH
GA The Genuine Article (R) Number: ZG762
TI Gene therapy for restenosis
AU Steg P G (Reprint); Feldman L
CS HOP BICHAT, SERV CARDIOL, INSERM U460, 46 RUE HENRI HUCHARD, F-75877 PARIS 18, FRANCE (Reprint)
CYA FRANCE
SO PATHOLOGIE BIOLOGIE, (***MAR 1998***) Vol. 46, No. 3, pp. 201-204.
Publisher: EXPANSION SCI FRANCAISE, 31 BLVD LATOUR MAUBOURG, 75007 PARIS, FRANCE.
ISSN: 0369-8114.
DT Article; Journal

AU HARADA K; FRIEDMAN M; LOPEZ J J; WANG S Y; LI J; PRASAD P V; PEARLMAN J D; EDELMAN E R; SELLKE F W; SIMONS M (Reprint)

CS HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, CARDIOVASC DIV, HARVARD THORNDIKE LAB, BOSTON, MA, 02215 (Reprint); HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, CARDIOVASC DIV, HARVARD THORNDIKE LAB, BOSTON, MA, 02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT SURG, BOSTON, MA, 02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT RADIOL, BOSTON, MA, 02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, CHARLES A DANA RES INST, VASC BIOL UNIT, BOSTON, MA, 02215; MIT, PROGRAM HLTH SCI & TECHNOL, CAMBRIDGE, MA, 02139

CYA USA

SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, (***MAY:
*** 1996***) Vol. 39, No. 5, pp. H1791-H1802.

ISSN: 0363-6135.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 34

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 435 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 95:835524 SCISEARCH

GA The Genuine Article (R) Number: TG800

TI EFFECTS OF CYTOMEGALOVIRUS-INFECTION ON GROWTH-FACTOR PRODUCTION IN
ENDOTHELIAL-CELLS AND FIBROBLASTS

AU GARRETT J S; NARUS J C; BOHNSACK J F; CARLING D E; GRIEVES K G; WALDMAN W
J; SHADDY R E (Reprint)

CS PRIMARY CHILDRENS MED CTR, DIV CARDIOL, 100 N MED DR, SALT LAKE CITY, UT,
84113 (Reprint); UNIV UTAH, SCH MED, DEPT PEDIAT, SALT LAKE CITY, UT,
84132; OHIO STATE UNIV, DEPT PATHOL, COLUMBUS, OH, 43210

CYA USA

SO PEDIATRIC RESEARCH, (***DEC 1995***) Vol. 38, No. 6, pp. 1003-1008.
ISSN: 0031-3998.

DT Article; Journal

FS LIFE

VANDERBILT TRANSPLANT, DEPT MED, NASHVILLE, TN, 37232; VANDERBILT UNIV,
SCH MED, DEPT CARDIOTHORAC SURG, NASHVILLE, TN, 37232

CYA USA

SO TRANSPLANTATION, (***27 FEB 1995***) Vol. 59, No. 4, pp. 605-611.

ISSN: 0041-1337.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 48

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 438 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 94:580349 SCISEARCH

GA The Genuine Article (R) Number: PF354

TI MODIFICATION OF ALTERNATIVE MESSENGER-RNA SPLICING OF FIBROBLAST
GROWTH-FACTOR RECEPTORS IN HUMAN CARDIAC ALLOGRAFTS DURING REJECTION

AU ZHAO X M; FRIST W H; YEOH T K; MILLER G G (Reprint)

CS VANDERBILT UNIV, SCH MED, VANDERBILT TRANSPLANT CTR, A3310 MED CTR N,
NASHVILLE, TN, 37232 (Reprint); VANDERBILT UNIV, SCH MED, VANDERBILT
TRANSPLANT CTR, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT
THORAC SURG, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT MED,
NASHVILLE, TN, 37232

CYA USA

SO JOURNAL OF CLINICAL INVESTIGATION, (***SEP 1994***) Vol. 94, No. 3,
pp. 992-1003.

ISSN: 0021-9738.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 42

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 439 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 94:491287 SCISEARCH

L5 ANSWER 441 OF 549 USPATFULL on STN
AN 2004:301964 USPATFULL
TI Compositions and methods for modulating expression within smooth muscle cells
IN Owens, Gary K., Earlysville, VA, United States
Mack, Christopher, Chapel Hill, NC, United States
Blank, Randall, Charlottesville, VA, United States
PA Setagon, Inc., Charlottesville, VA, United States (U.S. corporation)
PI US 6825035 B1 20041130
WO 2000024254 20000504 <--
AI US 2001-807757 20010417 (9)
WO 1999-US24972 19991022
20010417 PCT 371 date
PRAI US 1998-105330P 19981023 (60)
DT Utility
FS GRANTED
LN.CNT 3217
INCL INCLM: 435/325.000
INCLS: 536/024.100; 435/320.100; 800/013.000
NCL NCLM: 435/325.000
NCLS: 435/320.100; 536/024.100; 800/013.000
IC [7]
ICM: C12N005-10
ICS: C12N015-63; C07H021-04; A01K067-00
EXF 536/24.1; 435/320.1; 435/325; 800/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 442 OF 549 USPATFULL on STN
AN 2004:78898 USPATFULL
TI Detecting genetic predisposition to sight-threatening diabetic retinopathy
IN Duff, Gordon W., South Yorkshire, UNITED KINGDOM
Richardson, Patrick R. S., Litton Nr. Buxton, UNITED KINGDOM
Rennie, Ian G., Newbold, UNITED KINGDOM
PA Interleukin Genetics, Inc., Waltham, MA, United States (U.S.)

INCLS: 514/002.000; 514/008.000; 514/012.000

NCL NCLM: 424/085.100

NCLS: 514/002.000; 514/008.000; 514/012.000

IC [7]

ICM: A61K038-19

EXF 424/85.1; 435/724; 514/12; 514/44; 514/2; 514/8

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 444 OF 549 USPATFULL on STN

AN 2002:340044 USPATFULL

TI Expandable space frame

IN Stevens, Walter J., Mountain View, CA, United States

Springer, George S., Stanford, CA, United States

PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)

PI US 6497724 B1 20021224

WO 9955257 19991104

<--

AI US 2000-674185 20001027 (9)

WO 1999-US9383 19990430

20001027 PCT 371 date

RLI Continuation-in-part of Ser. No. US 70476, now abandoned

DT Utility

FS GRANTED

LN.CNT 859

INCL INCLM: 623/001.150

INCLS: 623/001.160; 623/001.220

NCL NCLM: 623/001.150 ..

NCLS: 623/001.160; 623/001.220

IC [7]

ICM: A61F002-06

EXF 623/1.15; 623/1.16; 623/1.2; 623/1.22; 606/213

L5 ANSWER 445 OF 549 USPATFULL on STN

AN 2002:263279 USPATFULL

TI Electrically mediated angiogenesis

IN Conrad-Vlasak, Deena, Eden Prairie, MN, United States

FS GRANTED

LN.CNT 773

INCL INCLM: 604/103.020

NCL NCLM: 604/103.020

IC [7]

ICM: A61M029-00

EXF 606/108; 606/194; 606/192; 604/103.01; 604/103.02; 604/183; 604/191

L5 ANSWER 447 OF 549 USPATFULL on STN

AN 2001:33286 USPATFULL

TI Prevention and treatment of cardiovascular pathologies with tamoxifen analogues

IN Grainger, David J., Cambridge, United Kingdom

Metcalf, James C., Cambridge, United Kingdom

Kunz, Lawrence L., Redmond, WA, United States

Schroff, Robert W., Edmonds, WA, United States

PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

PI US 6197789 B1 20010306

WO 9640098 19961219

<--

AI US 1997-973570 19971205 (8)

WO 1996-US10211 19960607

19980908 PCT 371 date

19980908 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1995-478936, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-476735, filed on 7 Jun 1995, now patented, Pat. No. US 5595722 Continuation-in-part of Ser. No. US 1995-477393, filed on 7 Jun 1995 Continuation-in-part of Ser. No. US 1995-486334, filed on 7 Jun 1995, now patented, Pat. No. US 5770609

DT Utility

FS Granted

LN.CNT 4577

INCL INCLM: 514/319.000

INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000;
514/651.000; 514/866.000

NCL NCLM: 514/319.000

IN Nagler, Arnon, Jerusalem, Israel
Hazum, Eli, Rehovot, Israel
Geller, Ehud, Herzlia, Israel
Slavin, Shimon, Jerusalem, Israel
Vlodavsky, Israel, Mevaseret Zion, Israel
Pines, Mark, Rehovot, Israel
PA Agricultural Research Org. Ministry of Agriculture (Gov.), Israel
(non-U.S. government)
HadasitMedical Research Serv. & Devel. Ltd., Israel (non-U.S.
government)
PI US 6159488 20001212 <--
AI US 1999-325198 19990603 (9)
RLI Continuation-in-part of Ser. No. US 1999-180498, filed on 29 Mar 1999
which is a continuation of Ser. No. WO 1997-US15254, filed on 14 Aug
1997
DT Utility
FS Granted
LN.CNT 533
INCL INCLM: 424/423.000
INCLS: 424/422.000; 424/424.000; 424/473.000; 514/259.000
NCL NCLM: 424/423.000
NCLS: 424/422.000; 424/424.000; 424/473.000; 514/266.220
IC [7]
ICM: A61K031-505
EXF 424/422; 424/473; 424/423; 424/424; 514/259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 450 OF 549 USPATFULL on STN
AN 2000:167245 USPATFULL
TI Methods and apparatus for transvascular muscular revascularization and
drug delivery
IN Ruiz, Carlos, 1747 N. Country La., Pasadena, CA, United States 91107
PI US 6159196 20001212 <--
AI US 1998-37590 19980309 (9)
DT Utility
FS Granted

corporation)

PI US 6149641 20001121 <--
AI US 1998-220985 19981223 (9)
RLI Continuation of Ser. No. US 1997-916430, filed on 21 Aug 1997, now
patented, Pat. No. US 5866561
DT Utility
FS Granted
LN.CNT 250
INCL INCLM: 604/501.000
INCLS: 604/507.000; 604/103.010; 604/103.020; 623/001.000
NCL NCLM: 604/501.000
NCLS: 604/103.010; 604/103.020; 604/507.000
IC [7]
ICM: A61N001-30
EXF 623/1; 604/21; 604/506-510; 604/501; 604/103.01-103.02

L5 ANSWER 453 OF 549 USPATFULL on STN

AN 2000:145865 USPATFULL
TI Targeted contrast agents for diagnostic and therapeutic use
IN Unger, Evan C., Tucson, AZ, United States
Fritz, Thomas A., Tucson, AZ, United States
Gertz, Edward W., Paradise Valley, AZ, United States
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6139819 20001031 <--
AI US 1997-932273 19970917 (8)
RLI Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996,
now abandoned which is a continuation-in-part of Ser. No. US
1996-640464, filed on 1 May 1996, now abandoned which is a
continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995,
now abandoned And a continuation-in-part of Ser. No. US 1996-666129,
filed on 19 Jun 1996, now patented, Pat. No. US 6033645
DT Utility
FS Granted
LN.CNT 7523
INCL INCLM: 424/009.520
INCLS: 424/009.510; 424/450.000

AN 2000:138055 USPATFULL
TI Methods and compositions for diagnosis of hyperhomocysteinemia
IN Austin, Richard C., Ancaster, Canada
Hirsh, Jack, Hamilton, Canada
Weitz, Jeffrey I., Hamilton, Canada
PA Hamilton Civic Hospitals Research Development Inc., Canada (non-U.S.
corporation)

PI US 6132965 20001017 <--

AI US 1998-16540 19980130 (9)

RLI Continuation of Ser. No. US 1996-582261, filed on 3 Jan 1996

DT Utility

FS Granted

LN.CNT 2529

INCL INCLM: 435/006.000

INCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330

NCL NCLM: 435/006.000

NCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330

IC [7]

ICM: C07H021-04

ICS: C12Q001-68

EXF 435/6; 435/91.2; 536/23.1; 536/24.3; 536/24.33

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 456 OF 549 USPATFULL on STN

AN 2000:131591 USPATFULL

TI Nucleic acid ligands of tissue target

IN Stephens, Andrew, Boulder, CO, United States

Gold, Larry, Boulder, CO, United States

Speck, Ulrich, Berlin, Germany, Federal Republic of

PA NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S.
corporation)

PI US 6127119 20001003 <--

AI US 1997-976413 19971121 (8)

RLI Continuation-in-part of Ser. No. US 1995-433124, filed on 3 May 1995,
now patented, Pat. No. US 5750342 which is a continuation-in-part of
Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US

LN.CNT 5924

INCL INCLM: 530/350.000
INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100;
435/320.100; 435/325.000

NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000;
536/023.100; 536/023.500

IC [7]
ICM: C07K016-00
ICS: C12N015-00

EXF 536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/69.1; 435/7.1;
435/172.3; 435/320.1; 435/325; 935/32; 935/52; 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 458 OF 549 USPATFULL on STN
AN 2000:125551 USPATFULL
TI MRI imaging method and apparatus
IN Pearlman, Justin D., Brookline, MA, United States
PA Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States
(U.S. corporation)
PI US 6121775 20000919 <--
AI US 1998-98175 19980616 (9)
DT Utility
FS Granted
LN.CNT 857
INCL INCLM: 324/309.000
INCLS: 324/318.000; 324/300.000; 128/653.000 ..
NCL NCLM: 324/309.000
NCLS: 324/300.000; 324/318.000; 600/419.000
IC [7]
ICM: G01V003-00
EXF 324/309; 324/318; 324/300; 128/653; 600/410

L5 ANSWER 459 OF 549 USPATFULL on STN

AN 2000:125047 USPATFULL
TI Epoxide-containing compounds

US 1997-863877, filed on 27 May 1997, now patented, Pat. No. US 5910150
And a continuation-in-part of Ser. No. US 1997-863925, filed on 27 May
1997, now patented, Pat. No. US 5941839

DT Utility

FS Granted

LN.CNT 682

INCL INCLM: 606/170.000

INCLS: 606/159.000; 606/046.000

NCL NCLM: 606/170.000

NCLS: 606/046.000; 606/159.000

IC [7]

ICM: A61B017-00

EXF 606/1; 606/7; 606/14; 606/46; 606/159; 606/170

L5 ANSWER 461 OF 549 USPATFULL on STN

AN 2000:121539 USPATFULL

TI Methods for regulating transcription factors

IN Qabar, Maher N., Redmond, WA, United States

McMillan, Michael K., Bellevue, WA, United States

Kahn, Michael S., Kirkland, WA, United States

Tulinsky, John E., Seattle, WA, United States

Ogbu, Cyprian O., Bellevue, WA, United States

Mathew, Jessymol, Bellevue, WA, United States

PA Molecumetics Ltd., Bellevue, WA, United States (U.S. corporation)

PI US 6117896 20000912 <--

AI US 1998-22934 19980212 (9)

RLI Continuation-in-part of Ser. No. US 1997-797915, filed on 10 Feb 1997,
now abandoned And a continuation-in-part of Ser. No. US 692420

PRAI US 1997-47067P 19970519 (60)

DT Utility

FS Granted

LN.CNT 4501

INCL INCLM: 514/384.000

INCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400

NCL NCLM: 514/384.000

NCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400

TI Therapeutic compounds containing xanthinyl
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6100271 20000808 <--
AI US 1995-483871 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
now abandoned
DT Utility .
FS Granted
LN.CNT 1986
INCL INCLM: 514/263.000
INCLS: 514/265.000; 544/268.000; 544/269.000; 544/271.000
NCL NCLM: 514/263.200
NCLS: 514/210.210; 514/234.200; 514/263.220; 514/263.230; 514/263.240;
514/263.350; 544/268.000; 544/269.000; 544/271.000
IC [7]
ICM: A61K031-522
ICS: C07D473-10
EXF 544/271; 544/268; 544/269; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 464 OF 549 USPATFULL on STN
AN 2000:102275 USPATFULL
TI Gene therapies for enhancing cardiac function
IN Hammond, H. Kirk, La Jolla, CA, United States
Giordano, Frank J., Del Mar, CA, United States
Dillmann, Wolfgang H., Solana Beach, CA, United States4)
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6100242 20000808 <--
WO 9626742 19960906 <--
AI US 1997-722271 19971229 (8)
WO 1996-US2631 19960227

IC [7]

ICM: A61K031-16

ICS: A61K031-095; A61K031-105

EXF 514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909;
514/912

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 466 OF 549 USPATFULL on STN

AN 2000:91735 USPATFULL

TI Interferon responsive transcript (IRT-1)

IN Autieri, Michael V., Blue Bell, PA, United States

PA Temple University of the Commonwealth System of Higher Education,
Philadelphia, PA, United States (U.S. corporation)

PI US 6090580 20000718 <--

AI US 1998-4171 19980102 (9)

DT Utility

FS Granted

LN.CNT 1142

INCL INCLM: 435/069.100

INCLS: 435/252.330; 435/325.000; 435/320.100; 530/350.000; 536/023.100;
536/023.500

NCL NCLM: 435/069.100

NCLS: 435/252.330; 435/320.100; 435/325.000; 530/350.000; 536/023.100;
536/023.500

IC [7]

ICM: C12P021-06

ICS: C07H021-04

EXF 530/350; 536/23.5; 435/69.1; 435/252.3; 435/252.33; 435/320.1; 435/325

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 467 OF 549 USPATFULL on STN

AN 2000:37806 USPATFULL

TI Methods for using therapeutic compounds containing xanthinyl

IN Klein, J. Peter, Vashon, WA, United States

Leigh, Alistair J., Brier, WA, United States

Underiner, Gail E., Brier, WA, United States

INCLS: 435/007.100; 435/325.000; 435/243.000; 435/320.100; 536/023.510;
530/399.000

NCL NCLM: 435/069.400

NCLS: 435/007.100; 435/243.000; 435/320.100; 435/325.000; 530/399.000;
536/023.510

IC [7]

ICM: C12N015-18

ICS: C12N015-63; C12N001-21; C12N005-00

EXF 435/69.4; 435/320.1; 435/325; 435/243; 536/23.51; 530/399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 469 OF 549 USPATFULL on STN

AN 2000:12926 USPATFULL

TI Compositions and methods for the treatment and diagnosis of
cardiovascular disease using rchd523 as a target

IN Falb, Dean A., Wellesley, MA, United States

Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)

Brigham and Women's Hospital, Boston, MA, United States (U.S.
corporation)

PI US 6020463 20000201 <--

AI US 1997-944423 19971006 (8)

RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented,
Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US
1995-485573, filed on 7 Jun 1995, now patented, Pat. No. US 5968770
which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10
Feb 1995

DT Utility

FS Granted

LN.CNT 5972

INCL INCLM: 530/350.000

INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100

NCL NCLM: 530/350.000

NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100

IC [6]

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6020337 20000201 <--
AI US 1997-950810 19970916 (8)
RLI Continuation-in-part of Ser. No. US 1993-42946, filed on 5 Apr 1993, now
patented, Pat. No. US 5670506 And a continuation-in-part of Ser. No. US
1997-910579, filed on 26 Jul 1997
DT Utility
FS Granted
LN.CNT 1376
INCL INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCL NCLM: 514/263.340
NCLS: 514/210.210; 514/263.360; 544/267.000; 544/272.000; 544/277.000
IC [6]
ICM: A61K031-52
ICS: C07D473-00
EXF 514/258; 544/267; 544/272; 544/277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 472 OF 549 USPATFULL on STN
AN 2000:10014 USPATFULL
TI Compositions and methods for the treatment and diagnosis of
cardiovascular disease using rchd528 as a target
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation) ...
Brigham and Women's Hospital, Boston, MA, United States (U.S.
corporation)
PI US 6018025 20000125 <--
AI US 1997-944868 19971006 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented,
Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US
1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser.
No. US 1995-386844, filed on 10 Feb 1995
DT Utility

ICM: C07H021-04

ICS: C12N015-11; C12N015-63

EXF 514/44; 435/172.3; 435/320.1; 536/23.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 474 OF 549 USPATFULL on STN

AN 1999:159127 USPATFULL

TI Minimally invasive gene therapy delivery device and method

IN Rosengart, Todd K., Tenafly, NJ, United States

Crystal, Ronald G., Potomac, MD, United States

Hartman, Raymond A., Carlsbad, CA, United States

PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S.
corporation)

PI US 5997509 19991207 <--

AI US 1998-35892 19980306 (9)

DT Utility

FS Granted

LN.CNT 543

INCL INCLM: 604/164.000

INCLS: 604/116.000; 604/181.000; 604/187.000

NCL NCLM: 604/164.010

NCLS: 604/116.000; 604/181.000; 604/187.000

IC [6]

ICM: A61M005-178

ICS: A61M005-00

EXF 604/1; 604/95; 604/115; 604/116; 604/117; 604/181; 604/188; 604/187;
604/164; 604/207; 604/208; 604/211; 604/218; 604/246; 604/264;.. 604/272

L5 ANSWER 475 OF 549 USPATFULL on STN

AN 1999:151195 USPATFULL

TI GATA-6 transcription factor: compositions and methods

IN Walsh, Kenneth, Carlisle, MA, United States

PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S.
corporation)

PI US 5990092 19991123 <--

AI US 1997-927394 19970827 (8)

L5 ANSWER 477 OF 549 USPATFULL on STN

AN 1999:132529 USPATFULL

TI Fluorescence-based assays for measuring cell proliferation

IN Parandoosh, Zahra, San Diego, CA, United States

PA Irori, La Jolla, CA, United States (U.S. corporation)

PI US 5972639 19991026 <--

AI US 1997-901229 19970724 (8)

DT Utility

FS Granted

LN.CNT 1358

INCL INCLM: 435/029.000

NCL NCLM: 435/029.000

IC [6]

ICM: C12Q001-02

EXF 435/6; 435/7.1; 435/7.4; 435/7.72; 435/21; 435/29; 435/195; 435/196;
435/375; 935/66; 935/76

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 478 OF 549 USPATFULL on STN

AN 1999:124900 USPATFULL

TI Enantiomerically pure hydroxylated xanthine compounds

IN Bianco, James A., Seattle, WA, United States

Woodson, Paul, Bothell, WA, United States

Porubek, David, Edmonds, WA, United States

Singer, Jack, Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5965564 19991012 <--

AI US 1998-44976 19980320 (9)

RLI Continuation of Ser. No. US 1995-457703, filed on 1 Jun 1995, now patented, Pat. No. US 5739138 which is a division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now patented, Pat. No. US 5652243 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now patented, Pat. No. US 5648357 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US

angiogenesis

IN Kaplan, Aaron V., Los Altos, CA, United States
Simons, Michael, Chestnut Hill, MA, United States
PA Localmed, Inc., Palo Alto, CA, United States (U.S. corporation)
Beth Israel Deaconess Medical Center, Boston, MA, United States (U.S. corporation)
PI US 5941868 19990824 <--
AI US 1996-753224 19961122 (8)
PRAI US 1995-9086P 19951222 (60)
DT Utility
FS Granted
LN.CNT 544
INCL INCLM: 604/500.000
NCL NCLM: 604/500.000
IC [6]
ICM: A61M031-00
EXF 604/96; 604/101; 604/99; 604/265; 604/266; 604/890.1; 604/892.1; 604/52;
604/53; 606/192; 606/194

L5 ANSWER 481 OF 549 USPATFULL on STN

AN 1999:92656 USPATFULL

TI Compositions and methods for modulating growth of a tissue in a mammal
IN Weisz, Paul B., State College, PA, United States
PA Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

PI US 5935940 19990810 <--

AI US 1997-906500 19970805 (8) ..

RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 483 OF 549 USPATFULL on STN
AN 1999:56471 USPATFULL
TI Methods of modulating tissue growth and regeneration
IN Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5902799 19990511 <--
AI US 1997-906501 19970805 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809
DT Utility
FS Granted
LN.CNT 1703
INCL INCLM: 514/058.000
INCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
NCL NCLM: 514/058.000
NCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
IC [6]
ICM: A61K031-715
ICS: A61K031-735
EXF 514/58; 514/21; 514/56; 530/810; 530/812; 530/813; 530/817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 484 OF 549 USPATFULL on STN

AN 1999:43624 USPATFULL

RLI Continuation of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9 Nov 1992, now patented, Pat. No. US 5340813

DT Utility

FS Granted

LN.CNT 1351

INCL INCLM: 514/263.000
INCLS: 514/261.000; 544/267.000; 544/264.000; 544/265.000

NCL NCLM: 514/263.350
NCLS: 544/264.000; 544/265.000; 544/267.000

IC [6]
ICM: C07D473-00
ICS: A61K031-52

EXF 544/257; 544/267; 544/263; 544/285; 544/287; 514/263; 514/261

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 486 OF 549 USPATFULL on STN

AN 1999:40187 USPATFULL

TI Endothelial-cell specific promoter

IN Patterson, Winston Campbell, Brighton, MA, United States
Lee, Mu-En, Newton, MA, United States
Haber, Edgar, Salisbury, NH, United States

PA President and Fellows of Harvard College, Cambridge, MA, United States
(U.S. corporation)

PI US 5888765 19990330 <--

AI US 1995-494282 19950623 (8)

DT Utility .. --

FS Granted

LN.CNT 1003

INCL INCLM: 435/069.100
INCLS: 435/172.300; 435/320.100; 435/325.000; 536/024.100; 536/023.100

NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100; 536/024.100

IC [6]
ICM: C12N015-09
ICS: C12N015-11; C12N015-79; C12N015-85

PI US 5882914 19990316 <--

AI US 1995-480473 19950606 (8)

DT Utility

FS Granted

LN.CNT 2493

INCL INCLM: 435/252.300

INCLS: 435/320.100; 435/325.000; 536/023.500

NCL NCLM: 435/252.300

NCLS: 435/320.100; 435/325.000; 536/023.500

IC [6]

ICM: C12N001-20

ICS: C12N015-63; C12N005-00; C07H021-04

EXF 435/325; 435/252.3; 435/320.1; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 489 OF 549 USPATFULL on STN

AN 1999:27739 USPATFULL

TI Developmentally-regulated endothelial cell locus-1

IN Quertermous, Thomas, Nashville, TN, United States

Hogan, Brigid, Brentwood, TN, United States

Snodgrass, H. Ralph, Powell, OH, United States

Zupancic, Thomas Joel, Worthington, OH, United States

PA Progenitor, Inc., Menlo Park, CA, United States (U.S. corporation)

Vanderbilt University, Nashville, TN, United States (U.S. corporation)

PI US 5877281 19990302 <--

AI US 1996-659235 19960605 (8)

RLI Continuation-in-part of Ser. No. US 1995-480229, filed on 7 Jun 1995.

DT Utility

FS Granted

LN.CNT 2861

INCL INCLM: 530/350.000

INCLS: 530/402.000; 530/300.000; 530/383.000; 435/069.700; 536/023.100;

536/023.400; 536/023.500

NCL NCLM: 530/350.000

NCLS: 435/069.700; 530/300.000; 530/383.000; 530/402.000; 536/023.100;

536/023.400; 536/023.500

TI Compositions and methods for modulating growth of a tissue in a mammal
IN Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5874419 19990223 <--
AI US 1997-905612 19970804 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 20 -900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809, issued on 2 Feb 1993
DT Utility
FS Granted
LN.CNT 1482
INCL INCLM: 514/058.000
INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 514/769.000;
424/652.000; 424/682.000; 424/617.000; 536/103.000
NCL NCLM: 514/058.000
NCLS: 424/617.000; 424/652.000; 424/682.000; 514/021.000; 514/023.000;
514/054.000; 514/060.000; 514/769.000; 536/103.000
IC [6]
ICM: A61K031-735
ICS: A61K047-02; C08B037-16
EXF 514/21; 514/23; 514/54; 514/58; 514/60; 514/769; 536/103; 424/652;
424/682; 424/617

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 492 OF 549 USPATFULL ON STN
AN 1999:15930 USPATFULL
TI Epoxide-containing compounds

LN.CNT 229

INCL INCLM: 514/182.000

INCLS: 604/096.000

NCL NCLM: 514/182.000

NCLS: 604/096.010

IC [6]

ICM: A61K031-56

EXF 514/182

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 494 OF 549 USPATFULL on STN

AN 1999:4647 USPATFULL

TI Fas ligand compositions for treatment of proliferative disorders

IN Walsh, Kenneth, Carlisle, MA, United States

PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S.
corporation)

PI US 5858990 19990112 <--

AI US 1997-810453 19970304 (8)

DT Utility

FS Granted

LN.CNT 3038

INCL INCLM: 514/044.000

INCLS: 435/006.000; 435/172.100; 435/320.100; 435/069.100; 435/375.000;
435/377.000

NCL NCLM: 514/044.000

NCLS: 435/006.000; 435/069.100; 435/320.100; 435/375.000; 435/377.000

IC [6]

ICM: A61K048-00

ICS: C12N015-11

EXF 435/6; 435/172.1; 435/172.3; 435/320.1; 435/325; 435/69.1; 435/31.1;
435/375; 435/377; 536/23.1; 536/23.5; 514/2; 514/44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 495 OF 549 USPATFULL on STN

AN 1998:157185 USPATFULL

TI Compositions and methods for the treatment and diagnosis of

now abandoned

DT Utility

FS Granted

LN.CNT 2429

INCL INCLM: 514/651.000

INCLS: 514/824.000

NCL NCLM: 514/651.000

NCLS: 514/824.000

IC [6]

ICM: A61K031-135

EXF 514/56; 514/651; 514/824

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 497 OF 549 USPATFULL on STN

AN 1998:154038 USPATFULL

TI Methods of determining chemicals that modulate expression of genes associated with cardiovascular disease

IN Foulkes, J. Gordon, Huntington Station, NY, United States

Liechtfried, Franz E., Vienna, Austria

Pieler, Christian, Vienna, Austria

Stephenson, John R., Santa Cruz, CA, United States

Case, Casey C., Lynbrook, NY, United States

PA Oncogene Science, Inc., Uniondale, NY, United States (U.S. corporation)

PI US 5846720 19981208 <--

AI US 1996-700757 19960815 (8)

RLI Continuation of Ser. No. US 1992-832905, filed on 7 Feb 1992, now patented, Pat. No. US 5580722 which is a continuation-in-part of Ser. No. US 1990-555196, filed on 18 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-382712, filed on 18 Jul 1989, now abandoned

DT Utility

FS Granted

LN.CNT 3998

INCL INCLM: 435/006.000

INCLS: 435/069.800; 435/091.500; 435/320.100; 935/077.000; 935/078.000

NCL NCLM: 435/006.000

Klein, J. Peter, Vashon Island, WA, United States

Rice, Glenn C., Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5837703 19981117 <--

AI US 1993-152650 19931112 (8)

RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
now abandoned

DT Utility

FS Granted

LN.CNT 2596

INCL INCLM: 514/183.000

INCLS: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000;
514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;
514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;
548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000

NCL NCLM: 514/183.000

NCLS: 514/211.150; 514/228.800; 514/241.000; 514/242.000; 514/249.000;
514/256.000; 514/266.200; 514/266.300; 514/270.000; 514/274.000;
514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;
548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000

IC [6]

ICM: A61K031-55

ICS: A61K031-515; A61K031-445; A61K031-52

EXF 544/276; 544/272; 544/216; 544/257; 544/285; 544/286; 544/301; 544/311;
544/335; 514/263; 514/183; 514/211; 514/228.8; 514/241; 514/242;
514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315;
514/348; 514/357; 514/374; 514/400; 514/418; 514/425; 514/427; 540/467;
540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334;

RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878 , said Ser. No. US -152650 And Ser. No. US -164081 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned

DT Utility

FS Granted

LN.CNT 3136

INCL INCLM: 514/222.500

INCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800;
514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000;
514/249.000; 514/255.000; 514/258.000; 514/274.000; 514/301.000;
514/303.000; 514/311.000; 514/351.000; 514/360.000; 514/361.000;
514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000;
514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000;
514/378.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000;
514/415.000; 514/418.000; 514/424.000; 514/425.000; 514/433.000;
514/452.000; 514/432.000; 514/438.000; 346/113.000; 346/114.000;
346/164.000; 346/300.000; 549/014.000; 549/050.000; 549/075.000;
549/367.000; 549/368.000; 544/002.000; 544/003.000; 544/005.000;
544/008.000; 544/053.000; 544/063.000; 544/065.000; 544/066.000;
544/067.000; 544/090.000; 544/091.000; 544/127.000; 544/128.000;
544/162.000; 544/215.000; 544/219.000; 544/229.000; 544/235.000;
544/237.000; 544/255.000; 544/278.000; 544/311.000; 544/353.000;
544/385.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000;
548/143.000; 548/146.000; 548/153.000; 548/174.000; 548/207.000;
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000;
548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000;
548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000;
548/486.000; 548/543.000; 548/546.000

NCL NCLM: 514/222.500

NCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800;
514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000;
514/249.000; 514/255.020; 514/260.100; 514/274.000; 514/301.000;

L5 ANSWER 502 OF 549 USPATFULL on STN
AN 1998:128232 USPATFULL
TI Method of attenuating arterial stenosis
IN Abendschein, Dana R., St. Louis, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5824644 19981020 <--
AI US 1996-675122 19960703 (8)
RLI Continuation-in-part of Ser. No. US 1996-648777, filed on 16 May 1996,
now abandoned which is a continuation-in-part of Ser. No. US
1994-271930, filed on 7 Jul 1994, now abandoned
DT Utility
FS Granted
LN.CNT 679
INCL INCLM: 514/012.000
INCLS: 514/002.000; 514/021.000; 530/324.000; 530/350.000; 530/380.000;
424/422.000
NCL NCLM: 514/012.000
NCLS: 424/422.000; 514/002.000; 514/021.000; 530/324.000; 530/350.000;
530/380.000
IC [6]
ICM: A61K038-00
ICS: C07K014-00; A61F013-00
EXF 514/12; 514/2; 514/21; 530/350; 530/324; 530/380; 424/422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 503 OF 549 USPATFULL on STN
AN 1998:122413 USPATFULL
TI Substituted amino alkyl compounds
IN Klein, J. Peter, Vashon Island, WA, United States
Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5817662 19981006 <--
AI US 1995-468656 19950606 (8)
RLI Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned

935/6; 935/8; 935/17; 935/77; 935/78

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 505 OF 549 USPATFULL on STN
AN 1998:111942 USPATFULL
TI Therapeutic compounds containing pyrimidinyl moieties
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5807862 19980915 <--
AI US 1995-478112 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 2190
INCL INCLM: 514/269.000
INCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
NCL NCLM: 514/269.000
NCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
IC [6]
ICM: A61K031-505
ICS: C07D239-54
EXF 514/269; 514/274; 544/309; 544/310; 544/311; 544/312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 506 OF 549 USPATFULL on STN
AN 1998:111941 USPATFULL
TI Amine substituted xanthinyl compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Rice, Glenn C., Seattle, WA, United States

ICM: A61K038-18

ICS: C07K014-50; A61N001-18

EXF 514/12; 514/56; 424/548; 424/198.1; 530/399; 536/21; 607/3; 607/50

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 508 OF 549 USPATFULL on STN

AN 1998:108415 USPATFULL

TI Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms

IN Underiner, Gail E., Brier, WA, United States

Porubek, David, Seattle, WA, United States

Klein, J. Peter, Vashon Island, WA, United States

Woodson, Paul, Edmonds, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5804584 19980908 <--

AI US 1995-468659 19950606 (8)

RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070

DT Utility

FS Granted

LN.CNT 1554

INCL INCLM: 514/269.000

INCLS: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000

NCL NCLM: 514/269.000

NCLS: 514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000

IC [6]

ICM: C07D239-54

ICS: A61K031-52

EXF 514/242; 514/243; 514/269; 544/298; 544/299

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 509 OF 549 USPATFULL on STN

AN 1998:104752 USPATFULL

TI Amine substituted compounds

IN Klein, J. Peter, Vashon, WA, United States

LN.CNT 2822

INCL INCLM: 514/263.000
INCLS: 514/183.000; 514/249.000; 514/259.000; 514/274.000; 514/309.000;
514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000;
514/626.000; 514/668.000; 514/669.000

NCL NCLM: 514/263.350
NCLS: 514/183.000; 514/249.000; 514/266.300; 514/274.000; 514/309.000;
514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000;
514/626.000; 514/668.000; 514/669.000

IC [6]

ICM: A01N043-00

ICS: A01N043-90; A01N043-58; A01N043-42

EXF 514/263; 514/249; 514/259; 514/265; 514/274; 514/309; 514/315; 514/418;
514/425; 514/617; 514/619; 514/626; 514/668; 514/669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 511 OF 549 USPATFULL on STN

AN 1998:95545 USPATFULL

TI Enantiomerically pure hydroxylated xanthine compounds

IN Bianco, James A., Seattle, WA, United States

Woodson, Paul, Bothell, WA, United States

Porubek, David, Edmonds, WA, United States

Singer, Jack, Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5792772 19980811 <--

AI US 1995-458957 19950601 (8)

RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now patented,
Pat. No. US 5652243 which is a division of Ser. No. US 1994-307554,
filed on 16 Sep 1994, now patented, Pat. No. US 5648357 which is a
continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1992-926665,
filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned

DT Utility

FS Granted

LN.CNT 1734

-

IN Pratt, Richard E., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States

PA The Board of Trustees of the Leland Stanford Junior Univ., Palo Alto,
CA, United States (U.S. corporation)

PI US 5785965 19980728 <--

AI US 1996-647821 19960515 (8)

DT Utility

FS Granted

LN.CNT 905

INCL INCLM: 424/093.210
INCLS: 424/093.100; 424/093.200; 435/172.300; 435/325.000

NCL NCLM: 424/093.210
NCLS: 424/093.100; 424/093.200; 435/325.000; 435/455.000; 435/456.000

IC [6]
ICM: A01N063-00
ICS: C12N015-00

EXF 600/36; 623/1; 623/11; 623/12; 435/172.3; 435/240.2; 435/320.1; 435/325;
424/93.21; 424/93.1; 424/93.2; 514/44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 514 OF 549 USPATFULL on STN

AN 1998:82763 USPATFULL

TI Hydroxyl-containing xanthine compounds

IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States -

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5780476 19980714 <--

AI US 1995-468660 19950606 (8)

RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16
Nov 1992, now patented, Pat. No. US 5473070

DT Utility

FS Granted

LN.CNT 1672

EXF 544/267; 544/257; 544/285; 544/286; 544/287; 544/311; 546/141; 546/243;
546/246; 548/477; 548/546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 516 OF 549 USPATFULL on STN

AN 1998:79342 USPATFULL

TI Acetal-and ketal-substituted pyrimidine compounds

IN Leigh, Alistair, Brier, WA, United States

Underiner, Gail, Brier, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5777115 19980707 <--

AI US 1994-193331 19940207 (8)

RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now abandoned

DT Utility

FS Granted

LN.CNT 1632

INCL INCLM: 544/242.000

INCLS: 544/267.000; 514/269.000; 514/270.000; 514/256.000

NCL NCLM: 544/242.000

NCLS: 544/267.000

IC [6]

ICM: C07D239-26

ICS: A61K031-505

EXF 544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

..
L5 ANSWER 517 OF 549 USPATFULL on STN

AN 1998:72634 USPATFULL

TI Prevention and treatment of cardiovascular pathologies

IN Grainger, David J., Cambridge, England

Metcalfe, James C., Cambridge, England

Kunz, Lawrence L., Redmond, WA, United States

Schroff, Robert W., Edmonds, WA, United States

Weissberg, Peter L., Cambridge, England

PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

LN.CNT 2183

INCL INCLM: 514/263.000

INCLS: 544/271.000; 544/273.000

NCL NCLM: 514/263.350

NCLS: 514/151.000; 544/271.000; 544/273.000

IC [6]

ICM: M61K031-52

EXF 514/263; 544/271; 544/273

L5 ANSWER 519 OF 549 USPATFULL on STN

AN 1998:51651 USPATFULL

TI Substituted amino alcohol compounds

IN Klein, J. Peter, Vashon, WA, United States

Underiner, Gail E., Brier, WA, United States

Kumar, Anil M., Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5750575 19980512 <--

AI US 1995-475721 19950607 (8)

RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And a continuation-in-part of Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned

DT Utility

FS Granted

LN.CNT 3115

INCL INCLM: 514/617.000

INCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000

NCL NCLM: 514/617.000

NCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000

IC [6]

ICM: A61K031-165

ICS: A61K031-135; C07C233-35; C07C215-20

EXF 564/355; 564/182; 564/361; 514/617; 514/653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PA New England Medical Center Hospitals, Inc., Boston, MA, United States
(U.S. corporation)

PI US 5728534 19980317 <--

AI US 1996-684704 19960719 (8)

DT Utility

FS Granted

LN.CNT 1298

INCL INCLM: 435/007.100
INCLS: 435/007.800; 435/007.720; 435/244.000; 435/325.000; 435/375.000;
435/069.100

NCL NCLM: 435/007.100
NCLS: 435/007.720; 435/007.800; 435/069.100; 435/244.000; 435/325.000;
435/375.000

IC [6]
ICM: G01N033-53
ICS: G01N033-566; C12N015-09

EXF 435/325; 435/375; 435/7.1; 435/7.8; 435/244; 435/7.72; 435/7.2; 435/69.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 522 OF 549 USPATFULL on STN

AN 97:86614 USPATFULL

TI Halogen, isothiocyanate or azide substituted xanthines

IN Leigh, Alistair, Brier, WA, United States
Michnick, John, Seattle, WA, United States
Kumar, Anil, Seattle, WA, United States
Underiner, Gail, Brier, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5670506 19970923 <--

AI US 1993-42946 19930405 (8)

DT Utility

FS Granted

LN.CNT 1994

INCL INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000

NCL NCLM: 514/141.000
NCLS: 544/267.000; 544/272.000; 544/277.000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 524 OF 549 USPATFULL on STN
AN 97:66130 USPATFULL
TI Methods of using enantiomerically pure hydroxylated xanthine compounds
IN Bianco, James A., Seattle, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5652243 19970729 <--
AI US 1994-343810 19941122 (8)
RLI Division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1731
INCL INCLM: 514/263.000
INCLS: 514/262.000; 514/265.000; 514/814.000
NCL NCLM: 514/263.360
NCLS: 514/814.000
IC [6]
ICM: A61K031-52
EXF 514/262; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 525 OF 549 USPATFULL on STN
AN 97:61689 USPATFULL
TI Enantiomerically pure hydroxylated xanthine compounds
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5648357 19970715 <--
AI US 1994-307554 19940916 (8)

514/258.000; 514/259.000; 514/261.000; 514/262.000; 514/263.000;
514/270.000; 514/274.000; 514/297.000; 514/300.000; 514/301.000;
514/302.000; 514/303.000; 514/306.000; 514/307.000; 514/311.000;
514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000;
514/359.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000;
514/364.000; 514/365.000; 514/367.000; 514/369.000; 514/372.000;
514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000;
514/379.000; 514/380.000; 514/381.000; 514/383.000; 514/389.000;
514/394.000; 514/395.000; 514/398.000; 514/399.000; 514/401.000;
514/404.000; 514/406.000; 514/413.000; 514/415.000; 514/416.000;
514/418.000; 514/423.000; 514/424.000; 514/425.000; 514/427.000;
514/428.000; 544/001.000; 544/002.000; 544/003.000; 544/008.000;
544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000;
544/090.000; 544/091.000; 544/162.000; 544/215.000; 544/216.000;
544/219.000; 544/220.000; 544/224.000; 544/235.000; 544/239.000;
544/254.000; 544/255.000; 544/257.000; 544/262.000; 544/272.000;
544/277.000; 544/278.000; 544/280.000; 544/283.000; 544/286.000;
544/301.000; 544/311.000; 544/335.000; 544/336.000; 544/350.000;
544/353.000; 544/385.000; 544/401.000; 546/102.000; 546/113.000;
546/114.000; 546/115.000; 546/117.000; 546/118.000; 546/119.000;
546/122.000; 546/138.000; 546/139.000; 546/150.000; 546/153.000;
546/157.000; 546/164.000; 546/176.000; 546/178.000; 546/242.000;
546/243.000; 546/246.000; 546/264.000; 546/300.000; 546/334.000;
548/100.000; 548/123.000; 548/125.000; 548/127.000; 548/128.000;
548/131.000; 548/134.000; 548/146.000; 548/153.000; 548/179.000;
548/186.000; 548/207.000; 548/214.000; 548/215.000; 548/217.000;
548/221.000; 548/225.000; 548/228.000; 548/229.000; 548/235.000;
548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000;
548/252.000; 548/267.200; 548/267.800; 548/303.700; 548/306.400;
548/307.100; 548/309.700; 548/319.100; 548/323.500; 548/340.100;
548/348.100; 548/349.100; 548/356.100; 548/370.100; 548/375.100;
548/379.400; 548/452.000; 548/453.000; 548/470.000; 548/482.000;
548/485.000; 548/486.000; 548/491.000; 548/503.000; 548/532.000;
548/543.000; 548/546.000; 548/550.000; 548/565.000; 548/566.000

NCL NCLM: 514/263.350

NCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800;

548/550.000; 548/565.000; 548/566.000

IC [6]

ICM: A61K031-415

ICS: A61K031-42; A61K031-425; A61K031-52

EXF 544/272; 514/263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 527 OF 549 USPATFULL on STN

AN 97:51973 USPATFULL

TI Peptide mediated enhancement of thrombolysis methods and compositions

IN Lawrence, Daniel A., Ann Arbor, MI, United States

Ginsburg, David, Ann Arbor, MI, United States

Shore, Joseph D., Grosse Point Farms, MI, United States

Fay, William P., Ann Arbor, MI, United States

Olson, Steven T., Chicago, IL, United States

Francis-Chmura, Ann Marie, Warren, MI, United States

Eitzman, Daniel T., Ypsilanti, MI, United States

Paielli, Dell, Wyandotte, MI, United States

PA The Regents of the University of Michigan, Ann Arbor, MI, United States
(U.S. corporation)

Henry Ford Health System, Detroit, MI, United States (U.S. corporation)

PI US 5639726 19970617 <--

AI US 1994-315461 19940930 (8)

DT Utility

FS Granted

LN.CNT 4817

INCL INCLM: 514/012.000 ..-

INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/324.000;
530/325.000; 530/326.000; 530/327.000; 530/328.000

NCL NCLM: 514/012.000

NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/324.000;
530/325.000; 530/326.000; 530/327.000; 530/328.000

IC [6]

ICM: A61K038-00

ICS: A61K038-02; C07K005-00; C07K007-00

EXF 530/324; 530/325; 530/326; 530/327; 530/328; 514/12; 514/13; 514/14;

IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5621102 <--
AI US 1995-456897 19950601 (8)

RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
 now abandoned which is a continuation of Ser. No. US 1993-13977, filed
 on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No.
 US 1992-926665, filed on 7 Aug 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
 now abandoned

DT Utility

FS Granted

LN.CNT 1763

INCL INCLM: 544/267.000
 INCLS: 514/340.000

NCL NCLM: 544/267.000

IC [6]
 ICM: C07D473-06
 ICS: C07D473-08; C07D473-12

EXF 544/267

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 530 OF 549 USPATFULL on STN

AN 97:31706 USPATFULL

TI Enantiomerically pure hydroxylated xanthine compounds to treat
 inflammatory diseases

IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5620984 19970415 <--

FS Granted

LN.CNT 1725

INCL INCLM: 514/263.000

INCLS: 514/921.000

NCL NCLM: 514/263.360

NCLS: 514/921.000

IC [6]

ICM: A61K031-52

EXF 514/263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 532 OF 549 USPATFULL on STN

AN 97:5708 USPATFULL

TI Method for identifying an agent which increases TGF-beta levels

IN Grainger, David J., Cambridge, England

Metcalf, James C., Cambridge, England

PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

PI US 5595722 19970121 <--

AI US 1995-476735 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994
which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13
May 1993, now abandoned And Ser. No. US 1994-241844, filed on 12 May
1994 which is a continuation-in-part of Ser. No. US 1993-62451, filed on
13 May 1993, now abandoned which is a continuation-in-part of Ser. No.
US 1993-11669, filed on 28 Jan 1993, now abandoned

DT Utility

FS Granted

LN.CNT 4090

INCL INCLM: 424/009.200

NCL NCLM: 424/009.200

IC [6]

ICM: A61K049-00

EXF 424/9.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 533 OF 549 USPATFULL on STN

AI US 1995-456899 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1728
INCL INCLM: 514/263.000
NCL NCLM: 514/263.360
IC [6]
 ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 535 OF 549 USPATFULL on STN
AN 96:111313 USPATFULL
TI Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
IN Foulkes, J. Gordon, Huntington Station, NY, United States
 Liechtfried, Franz E., Vienna, Austria
 Pieler, Christian, Vienna, Austria
 Stephenson, John R., Santa Cruz, CA, United States
 Case, Casey C., Lynbrook, NY, United States
PA Oncogene Science, Inc., Uniondale, NY, United States (U.S. corporation)
PI US 5580722 19961203 <--
AI US 1992-832905 19920207 (7)
RLI Continuation-in-part of Ser. No. US 1990-555196, filed on 18 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-382712, filed on 18 Jul 1989, now abandoned
DT Utility
FS Granted
LN.CNT 4011
INCL INCLM: 435/006.000

L5 ANSWER 537 OF 549 USPATFULL on STN
AN 96:72817 USPATFULL
TI Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Weissberg, Peter L., Cambridge, United Kingdom
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5545569 19960813 <--
AI US 1995-450520 19950525 (8)
RLI Division of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2263
INCL INCLM: 436/518.000
NCL NCLM: 436/518.000
IC [6]
ICM: G01N033-543
EXF 436/518; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 538 OF 549 USPATFULL on STN
AN 95:105868 USPATFULL
TI Cell signaling inhibitors
IN Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5470878 19951128 <--
AI US 1993-164081 19931208 (8)
RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned

INCL INCLM: 514/396.000
INCLS: 514/399.000; 514/824.000

NCL NCLM: 514/396.000
NCLS: 514/399.000; 514/824.000

IC [5]
ICM: A61K031-415

EXF 514/396; 514/399; 514/824

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 540 OF 549 USPATFULL on STN

AN 91:84437 USPATFULL

TI Method for preventing tissue damage after an ischemic episode

IN Sheffield, Warren D., Lebanon, NJ, United States

PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)

PI US 5057494 19911015 <--

AI US 1988-227579 19880803 (7)

DT Utility

FS Granted

LN.CNT 487

INCL INCLM: 514/012.000
INCLS: 514/021.000

NCL NCLM: 514/012.000
NCLS: 514/021.000

IC [5]
ICM: A61K037-02
ICS: A61K037-36

EXF 514/12; 514/21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 541 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2001-025162 [03] WPIDS

CR 2001-041064 [05]

DNC C2001-007775

TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis,

AN 2000-619171 [59] WPIDS

CR 2000-619148 [58]

DNC C2000-185530

TI Enhancing collateral growth of collateral arteries and arteries from pre-existing arteriolar connections, using monocytes loaded with arteriogenic polypeptides, useful e.g. for treating cerebral occlusive and peripheral occlusive disease.

DC B04 D16 J04

IN BUSCHMANN, I; SCHAPER, W

PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN

CYC 90

PI WO 2000060054 A1 20001012 (200059)* EN 30 C12N005-10 <--

RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000045446 A 20001023 (200107) C12N005-10 <--

EP 1165754 A1 20020102 (200209) EN C12N005-10

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI

ADT WO 2000060054 A1 WO 2000-EP3087 20000406; AU 2000045446 A AU 2000-45446
20000406; EP 1165754 A1 EP 2000-926832 20000406, WO 2000-EP3087 20000406

FDT AU 2000045446 A Based on WO 2000060054; EP 1165754 A1 Based on WO
2000060054

PRAI EP 1999-106800 19990406

IC ICM C12N005-10

ICS A61K048-00; C12N005-06

L5 ANSWER 543 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-365394 [31] WPIDS

DNC C2000-110292

TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis.

DC B04 D16

L5 ANSWER 544 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-317840 [27] WPIDS
CR 2000-256860 [22]; 2002-608416 [65]; 2003-101732 [09]; 2003-174592 [17];
2003-746236 [70]
DNC C2000-096206
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury.
DC B04
IN KAVANAUGH, W M
PA (CHIR) CHIRON CORP; (WHIT-I) WHITEHOUSE M J
CYC 87
PI WO 2000021548 A2 20000420 (200027)* EN 66 A61K038-00 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG UZ VN YU ZA ZW
AU 9964111 A 20000501 (200036) <--
EP 1121141 A2 20010808 (200146) EN A61K038-18
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
JP 2002527401 W 20020827 (200271) 72 A61K038-22
ADT WO 2000021548 A2 WO 1999-US22936 19991013; AU 9964111 A AU 1999-64111
19991013; EP 1121141 A2 EP 1999-951728 19991013, WO 1999-US22936 19991013;
JP 2002527401 W WO 1999-US22936 19991013, JP 2000-575522 19991013
FDT AU 9964111 A Based on WO 2000021548; EP 1121141 A2 Based on WO 2000021548;
JP 2002527401 W Based on WO 2000021548
PRAI US 1998-104103P 19981013
IC ICM A61K038-00; A61K038-18; A61K038-22
ICS A61K031-726; A61P009-10
ICA C07K014-50

L5 ANSWER 546 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-246641 [21] WPIDS
CR 2000-038600 [03]
DNN N2000-184459 DNC C2000-074681
TI Implantable device, carrying cells which produce and release therapeutic agent locally at site, and a monitor to detect unfavorable physiological change and signal the cells before damage occurs, use, e.g., in ***coronary*** ***artery*** ***disease*** .
DC A96 B07 D16 D22 P31 P32
IN DONOVAN, M G; SOYHAN, O; SOYKAN, O
PA (MEDT) MEDTRONIC INC
CYC 20
PI WO 2000012028 A1 20000309 (200021)* EN 52 A61F002-06 <--
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
EP 1027014 A1 20000816 (200040) EN A61F002-06 <--
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 6206914 B1 20010327 (200119) A61F002-06
US 2001000802 A1 20010503 (200126) A61F002-06
EP 1426021 A1 20040609 (200438) EN A61F002-06
R: CH DE FR LI NL SE
EP 1027014 B1 20041124 (200477) EN A61F002-06
R: CH DE FR LI NL SE
US 6824561 B2 20041130 (200479) A61F002-06
DE 69922143 E 20041230 (200502) A61F002-06
ADT WO 2000012028 A1 WO 1999-US18719 19990823; EP 1027014 A1 EP 1999-942261 19990823, WO 1999-US18719 19990823; US 6206914 B1 CIP of US 1998-70480 19980430, US 1998-144420 19980831; US 2001000802 A1 CIP of US 1998-70480 19980430, Div ex US 1998-144420 19980831, US 2000-745144 20001220; EP 1426021 A1 Div ex EP 1999-942261 19990823, EP 2004-6105 19990823; EP 1027014 B1 EP 1999-942261 19990823, WO 1999-US18719 19990823, Related to EP 2004-6105 19990823; US 6824561 B2 CIP of US 1998-70480 19980430, Div ex US 1998-144420 19980831, US 2000-745144 20001220; DE 69922143 E DE 1999-622143 19990823, EP 1999-942261 19990823, WO 1999-US18719 19990823
FDT EP 1027014 A1 Based on WO 2000012028; EP 1426021 A1 Div ex EP 1027014; EP 1027014 B1 Related to EP 1426021, Based on WO 2000012028; US 6824561 B2 Div ex US 6206914; DE 69922143 E Based on EP 1027014, Based on WO

US 6261587 B1 CIP of US 1998-113437 19980710, US 1999-337959 19990622; US 2001007658 A1 CIP of US 1992-841973 19920224, CIP of US 1994-300429 19940902, CIP of US 1995-568482 19951207, Div ex US 1998-113437 19980710, US 2001-758676 20010111; US 2001010826 A1 CIP of US 1992-841973 19920224, CIP of US 1994-300429 19940902, CIP of US 1995-568482 19951207, CIP of US 1998-113437 19980710, Div ex US 1999-337959 19990622, US 2001-766330 20010119; AU 757968 B AU 1999-50952 19990709; US 6713079 B2 CIP of US 1992-841973 19920224, CIP of US 1994-300429 19940902, CIP of US 1995-568482 19951207, CIP of US 1998-113437 19980710, Div ex US 1999-337959 19990622, US 2001-766330 20010119; US 6730315 B2 CIP of US 1992-841973 19920224, CIP of US 1994-300429 19940902, Div ex US 1998-113437 19980710, CIP of US 1998-568482 19981207, US 2001-758676 20010111

FDT AU 9950952 A Based on WO 2000002596; EP 1094849 A1 Based on WO 2000002596; US 2001007658 A1 CIP of US 5834005, Div ex US 6231881; US 2001010826 A1 CIP of US 5834005, CIP of US 6231881; AU 757968 B Previous Publ. AU 9950952, Based on WO 2000002596; US 6713079 B2 CIP of US 5834005, CIP of US 6231881, Div ex US 6261587; US 6730315 B2 CIP of US 5834005

PRAI US 1999-337959 19990622; US 1998-113437 19980710;
US 1992-841973 19920224; US 1994-300429 19940902;
US 1995-568482 19951207; US 2001-758676 20010111;
US 2001-766330 20010119

IC ICM A61F002-00; A61F002-02; A61K009-06; A61L015-32; C12N005-00
ICS A61F013-00; A61K031-715; A61L015-44; A61L031-00; A61L033-00;
C12N005-02

L5 ANSWER 548 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-052684 [04] WPIDS

DNC C2000-013542

TI Use of angiogenic factors to stimulate angiogenesis for treatment of cardiovascular diseases.

DC A96 B04 D16

IN COLLEY, K J

PA (ANGI-N) ANGIOGENIX INC; (COLL-I) COLLEY K J

CYC 87

PI WO 9953943 A2 19991028 (200004)* EN 37 A61K038-18 <--

L5 ANSWER 549 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 1998-179057 [16] WPIDS
 DNC C1998-057496
 TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders.
 DC B04 D16
 IN ACHEN, M G; ALITALO, K; STACKER, S A; WILKS, A F
 PA (LUDW-N) LUDWIG INST CANCER RES; (UYHE-N) UNIV HELSINKI LICENSING LTD OY;
 (UYHE-N) UNIV HELSINKI LICENSING LTD
 CYC 79
 PI WO 9807832 A1 19980226 (199816)* EN 90 C12N001-21 <--
 RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT
 SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
 GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
 MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU
 ZW
 AU 9740796 A 19980306 (199830) C12N001-21 <--
 EP 956339 A1 19991117 (199953) EN C12N001-21 <--
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 AU 729880 B 20010215 (200115) C12N001-21
 US 6235713 B1 20010522 (200130) A61K038-18
 JP 2001517075 W 20011002 (200172) 112 C12N015-09
 EP 1283268 A2 20030212 (200312) EN C12N015-85
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 US 2003114658 A1 20030619 (200341) C07H021-04
 US 2003125537 A1 20030703 (200345) A61K038-18
 US 6689580 B1 20040210 (200413) C12N001-21
 US 2004175730 A1 20040909 (200459) C12Q001-68
 ADT WO 9807832 A1 WO 1997-US14696 19970821; AU 9740796 A AU 1997-40796
 19970821; EP 956339 A1 EP 1997-938486 19970821, WO 1997-US14696 19970821;
 AU 729880 B AU 1997-40796 19970821; US 6235713 B1 Provisional US
 1996-23751P 19960823, Provisional US 1996-31097P 19961114, Provisional US